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Summary of Thesis 
 
The human Ureaplasma species are among the smallest and simplest self-replicating 
bacteria known to date. These microbes cause infection in humans, particularly in the 
upper genital tract during pregnancy, leading to several adverse outcomes including 
preterm birth, chorioamnionitis, and respiratory diseases of neonates. Little is known 
about the pathogenesis of Ureaplasma and mechanisms by which they avoid recognition 
and killing by the complement system. In this thesis, some mechanisms underlying serum 
resistance of Ureaplasma spp. were investigated. This goal was achieved by creating 
serum-resistant models of serum-sensitive laboratory Ureaplasma strains and developing 
and using some proteomic and molecular biology methods to study the role of potential 
factors, which mediate serum resistance and play a role in pathogenesis of Ureaplasma. 
My original contribution to the knowledge in this work was the development of 
transposon mutagenesis method that can now be used to study virulence genes of 
Ureaplasma. This method will also allow genetic manipulation of Ureaplasma for future 
studies. Monitoring and investigating induced serum-resistant strains using immunoblot 
analysis and proteomics revealed significant changes in two candidate proteins coincident 
with serum resistance. The first was the elongation factor Tu protein that found to be 
immunogenic and had altered pI isoforms. The observed change in this protein was 
consistent in all serum-resistant strains, which suggests a possible role in mechanism of 
serum resistance, possibly as a mediator for binding complement regulators, such as 
factor H and C4BP, at the cell surface of Ureaplasma. The second candidate protein was 
a novel 41 kDa protein that was uniquely expressed in all induced serum-resistant strains. 
Expression of this protein in all resistant strains strongly indicates its involvement in 
mechanism(s) of serum resistance of Ureaplasma. The possible gene that encodes for this 
41 kDa protein has putatively been identified as UUR10_0137 in the genome of U. 
urealyticum serovar 10 (strain ATCC 33699) using the transposon mutagenesis method 
developed in this study. Although the gene product of UUR10_0137 gene is not known 
(hypothetical protein), this protein is now identified and proposed to have a role in serum 
resistance of Ureaplasma. The product of the UUR10_0137 gene could function as a 
complement regulator or inhibitor that prevents the activation of complement system, 
protecting Ureaplasma from the complement attack. The contribution of the multiple-
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banded antigen, MBA, was proven to be unimportant to serum resistance. Sole antigenic 
variations in this major surface antigen of Ureaplasma did not play any role in mediating 
serum resistance. Confirmation of a gene that mediates complement resistance would 
dramatically increase our understanding of Ureaplasma pathogenicity and provide a 
target for future human studies with preterm birth and Ureaplasma infection. 
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 1. Introduction 
1.1 Taxonomy and classification of Ureaplasma 
Ureaplasma spp. are a group of bacteria belonging to the class Mollicutes that contains 
four orders, five families, eight genera, and about 200 known species that are capable of 
infecting humans, vertebrate animals, arthropods, and plants (Razin et al., 1998; Waites 
et al., 2005). Ureaplasma spp. are recognised within the genus Ureaplasma that is 
taxonomically classified within the family Mycoplasmataceae, the order 
Mycoplasmatales, the class Mollicutes, and the phylum Firmicutes. Members of 
Mollicutes are believed to have evolved from Gram-positive bacterial ancestors, which 
had DNA with low G+C contents (Dybvig and Voelker, 1996). Ureaplasma can inhabit 
both human being and animal hosts, in which they can cause diseases (Razin et al., 1998). 
Ureaplasma spp. were first recognised as human pathogens in 1954, when isolated from 
men suffering from non-gonococcal urethritis (NGU) (Shepard, 1954). Ureaplasma spp., 
as well as all other members of the class Mollicutes, are phenotypically distinguished 
from other bacterial species by a total absence of a classical bacterial cell wall and small 
genome sizes (Razin et al., 1998).  Initially, human Ureaplasma spp. were described as 
T- strain mycoplasmas because of the tiny colonies they produce (ranging from 5 µm to 
20 µm) compared with those of other members of the same family (Shepard, 1956). 
However, due to their ability to hydrolyse urea and use it as a primary source of energy, 
they were proposed as a single genus, consisting of 14 serovars, based on metabolic 
inhibition tests and colony indirect epifluorescence assays, and designated as Ureaplasma 
(Robertson and Stemke, 1982; Shepard et al., 1974). From that time up until 2002, human 
Ureaplasma genus was believed to be comprised of only one single species, referred to as 
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Ureaplasma urealyticum, which was divided into two biovars: biovar parvo or biovar 1 
comprised of serovars (SVs) 1, 3, 6, and 14, and biovar T960 or biovar 2 included 
serovars (SVs) 2, 4, 5, 7, 8, 9, 10, 11, 12, and 13.  However, Robertson and co-workers 
(2002) reclassified the biovars of Ureaplasma urealyticum into two distinct human 
associated species: Ureaplasma parvum, previously biovar 1 and Ureaplasma 
urealyticum, previously biovar 2. The reclassification was based on similarity data 
obtained from phenotypic and genotypic methods that include DNA-DNA hybridisation 
homology (Christiansen et al., 1981), restriction endonuclease cleavage patterns (Razin et 
al., 1983) polyacrylamide gel electrophoresis of cellular proteins (Swenson et al., 1983), 
sequences of 16S rRNA, urease and multiple banded antigen genes (Knox et al., 1998; 
kong et al., 1999a) and genome size (Kakulphimp et al., 1991).  U. parvum has smaller 
genome size (0.75 - 0.77 Mb) than U. urealyticum (0.83 - 0.94 Mb) with the standard 
strains serovar 3 (strain 27) and serovar 8 (strain T960) as prototype strains for each 
species, respectively (Robertson et al., 2002).  
1.2 Description of Ureaplasma 
Ureaplasma are among the smallest and simplest self-replicating free-living prokaryotes 
known to date. They have a pleomorphic shape due to the absolute absence of a cell wall 
that maintains structural integrity of the cellular form for other types of bacteria (Figure 
1.1).  Instead of the cell wall, these micro-organisms are reported to have a triple layered 
membrane with micropili and an electron dense outer surface surrounding the cell (Black 
et al., 1972). As a result of the absence of a cell wall, Ureaplasma spp. are inherently 
resistant to many antimicrobial agents that interfere with cell wall synthesis, and are 
unstainable by Gram stain and very sensitive to dehydration (Waites et al., 2005). In fact, 
the lack of cell wall and the minute genome sizes make Ureaplasma unique amongst 
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prokaryotes. Mollicutes, to which Ureaplasma belongs, are believed to be evolved via a 
genomic reduction that has resulted in a significant loss of genes. The small genome size 
has limited the biosynthetic capability of Ureaplasma and rendered them fastidious 
microbes that necessitate a complex growth media for their culture. Ureaplasma spp. 
require sterols for their growth in vitro provided by an essential serum supplement added 
to growth media (Razin et al., 1998; Waites et al., 2005). Ureaplasma are very tiny 
bacteria with cells of approximately 0.2 µm, this small size allows them to pass through 
filters usually used to sterilise solutions (Robertson et al., 2002). Another unique 
characteristic of Ureaplasma, which is attributed to the genome reduction, is the lack the 
cell division FtsZ protein. This protein is required for forming a `Z` like ring between 
cells during cell division; therefore, the mechanism of their cell division is still elusive  
(Glass et al., 2000).  
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Figure 1.1 The Colony morphology of Ureaplasma.  (A) Tiny colonies of Ureaplasma 
spp. (bar=100m). (B) Electron micrograph shows pleomorphic small size cells of 
Ureaplasma cells (bar = 0.5m) (Robertson et al., 2002). 
 
(A) 
(B) 
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1.3 Genome structure and base composition 
Ureaplasma spp. possess a small circular chromosome that range in size from 0.75 - 0.77 
Mb for U. parvum and 0.83 - 0.94 Mb for U. urealyticum. The variability in genome sizes 
of mollicutes has been attributed to one of two factors; the first is the presence of 
repetitive elements, which are comprised of gene segments varying in size and number, 
and the second is variability in insertion sequence (IS) elements. In addition, it has been 
suggested that integration of viral sequences into the chromosome may result in 
differences in genome size within the same species (Razin et al., 1998).  The complete 
genome sequence of U. parvum serovar 3 (ATCC strain 700790) was published in 2000, 
which is available in the GenBank under accession no. NC_002162, (Glass et al., 2000). 
Furthermore, the full genome sequence of U. urealyticum serovar 10 (ATCC 33699 
strain) is also available on the GeneBank (accession no.  NC_011374); the genome size 
of this strain is 874,478 bp.  Analysis of gene content showed that that serovar 3 whole 
genome contained 751,719 bp with a G + C content of 25.5%.  A total of 613 predicted 
protein-encoding genes and 39 genes encoding RNAs, comprising 93% of the genome, 
were identified. The low G + C genome content is a distinctive feature of the Mollicutes, 
and the distribution of the G + C in the genome is believed to be irregular (Razin, 1985).  
In a current comparative genome analysis study, 538 genes were identified as the minimal 
functional core genes for U. parvum. Additionally, 175 genes (35% of the genome) were 
indicated to be unique to U. parvum, while 407 genes of the 613 U. parvum genes also 
existed in the U. urealyticum genome (Momynaliev et al., 2007). 
Another striking feature of Ureaplasma, which is a shared property among almost all 
mollicutes, is the unusual codon usage. The UGA codon in all other prokaryotes 
functions as a terminal stop codon (opal), whereas in Ureaplasma spp. UGA encodes for 
the amino acid tryptophan (Blanchard, 1990). It has been suggested that this unusual 
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codon usage was a consequence of the low G + C and the high A + T genome content of 
mollicutes; this is a bias towards A-T base pair during their evolution.  Using UGA codon 
as a tryptophan has resulted in deletion of the peptide chain release factor 2 (RF2) that 
recognises the stop codons UGA and UAA. However, the peptide chain release factor 1 
that recognises UAG and UAA was conserved (Razin et al., 1998). Therefore, it can be 
anticipated that Ureaplasma spp., as a member of mollicutes, uses only UAA and UAG 
as stop codons. The use of UGA as tryptophan codon makes the ability of expressing 
mollicute genes in Escherichia coli challenging, as E. coli recognises UGA as the opal 
stop codon. Consequently, cloned mollicute proteins expressed in E. coli are usually 
truncated. There have been attempts to overcome this problem by using E. coli strains 
with suppressed stop codon usage (Neyrolles et al., 1996; Renbaum et al., 1990; Smiley 
and Minion, 1993), but the efficiency of the expression was proven to be low.   
During their genome reduction process, Ureaplasma spp. has lost several essential genes, 
which are usually present in other prokaryotes. This, in fact, has limited their biosynthetic 
capabilities and required them to adopt a parasitic life style relying on in their host to 
survive. An example of gene loss limitations is the absolute dependence of Ureaplasma 
and all other mollicutes on the salvage pathway for synthesis of DNA precursors (purine 
and pyrimidine nucleotides). This pathway initiates via a thymidine kinase (TK) that 
helps the transfer of phosphates from nucleotides, e.g. ATP, to the 5’ hydroxyl group of 
pyrimidine deoxyribonucleoside (Carnrot et al., 2003).   
1.4 Ureaplasma virulence factors 
Although Ureaplasma spp. are usually found as commensal bacteria with a low virulence 
in the urogenital tract of both healthy men and women, it can occasionally cause invasive 
infections under specific circumstances (Waites et al., 2005). Several virulence factors of 
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Ureaplasma that may play a role in the pathogenesis have been proposed (Glass et al., 
2000; Momynaliev et al., 2007). These virulence factors include the following: 
1.4.1 The multiple banded antigen  
The multiple banded antigen (MBA) is a major surface antigen of Ureaplasma that was 
suggested to be one of the predominant antigens recognised during infection with 
Ureaplasma (Watson et al., 1990).  Watson and colleagues (1990) showed that human 
sera collected from patients infected with Ureaplasma were able to bind a 71 kDa band of 
Ureaplasma antigens. Further immunoblot analysis with monoclonal antibodies against 
the MBA (MAbs) has detected a unique laddering pattern (multiple banded) of this 
surface membrane protein, therefore this antigen was annotated the multiple banded 
antigen (Figure 1.2). 
Further investigations of Ureaplasma antigens showed high variations in the MBA size in 
vitro; it was also found that this antigen has both serovar-specific and cross-reactive 
epitopes, which indicates that both serovar-specific and cross-reactive monoclonal MBA 
antibodies (MAbs) can react with the MBA. Additionally, it was also demonstrated that 
Ureaplasma expressing MBA with altered size (in vivo) evolved from inoculating strains, 
and it was thought that the number of MBA variants may be associated with  
pathogenicity of Ureaplasma (Dando et al., 2012; Knox et al., 2010; Robinson et al., 
2013). The importance of this antigen in host defence was also addressed when it was 
shown that monoclonal antibodies (mAbs) against the MBA were able to inhibit 
Ureaplasma growth in vitro (Watson et al., 1990; Zheng et al., 1994; Zheng et al., 1992).  
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Figure 1.2 Size variation and unique laddering pattern of the multiple banded antigen. 
Immunoblot analysis of four clones of U. parvum SV3 (clones 2-4 were generated from a 
clinical isolate and clone 5 was clinical isolate from amniotic fluid) compared to SV3 
reference strain (Lane 1). The blot shows the MBA size variation detected by mAb. 
Adopted from: (Zheng et al., 1994). 
 
 
The MBA gene (mba) consists of two regions: the N-terminal region (5’ region) that 
contains a signal peptide and acylation site (a membrane lipoprotein lipid attachment site 
at a cysteine) and C-terminal region (3’ region), which is composed of multiple tandem 
repeat units (consisting of 18 nucleotides encode for six amino acids QPAGKE for U. 
parvum serovar 3). The C-terminal region (the variable part) was proven to be surface 
exposed, hydrophobic, antigenic and contains epitopes that are serovar-specific, and also 
it was determined that alterations in the copy number of the tandem repeats of this region 
was responsible for size variations in the MBA (Zheng et al., 1994; Zheng et al., 1995) . 
The N-terminal region of the MBA gene was shown to be conserved among all 14 
serovars of Ureaplasma (Zheng et al., 1995). The 5’ region of the MBA gene has been 
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used as a target for PCR methods of detection and speciation for Ureaplasma spp., 
because it contains species-specific nucleotide polymorphisms (Teng et al., 1994).  
As stated earlier, size variations in the MBA can occur in vitro as well as in vivo. In 
addition, the MBA, as a major surface antigen, was shown to undergo phase variation 
(silencing of gene expression through genomic rearrangement). This mechanism is a 
common strategy that has been well-documented in the closely related genus 
Mycoplasma, where several genes encoding for immunogenic membrane proteins have 
been found to undergo phase variation. Examples of such genes are vsp genes of 
Mycoplasma bovis, vsa genes of Mycoplasma pulmonis and vpma genes of Mycoplasma 
agalactiae (Bhugra and Dybvig, 1992; Bhugra et al., 1995; Chopra-Dewasthaly et al., 
2008; Citti et al., 2010; Glew et al., 2000; Lysnyansky et al., 2001). In general, phase 
variation is a well-known tactic used by most pathogenic bacteria to alter their surface-
exposed antigens to avoid recognition by the host immune system and to adapt to harsh 
environments (Salaun et al., 2003; van der Woude and Baumler, 2004). In Ureaplasma, 
phase variation has also been reported following a selection pressure with specific 
antibodies in vitro. In 2003, Monecke and colleagues  showed that putting Ureaplasma 
spp. under immunological pressure in vitro via passaging in a medium containing rabbit 
polyclonal anti-MBA antibodies resulted in emerging MBA-negative variants, which 
showed significant variations in the MBA gene when compared with the parental strains 
following PCR analysis and sequencing (Monecke et al., 2003). A phase variation (an 
ON/OFF switching) employed by Ureaplasmas, therefore, was suggested as a strategy for 
altering the expression of MBA to adapt to harsh environment and maintain survive; 
however the mechanism underlying that switch in expression of the MBA was not clear at 
that time. Another study by Zimmerman and co-workers (2009) has also shown that 
Ureaplasma is able to undergo phase switching in the MBA (locus UU375) expression 
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with an adjacent gene locus (UU376 gene) by inverting the MBA promoter to drive 
expression of the UU376. In this study, Ureaplasma was also subjected to immunological 
pressure through culturing and passaging in broth medium supplemented with antisera 
against either of the antigens. The authors of that study pointed out that the shift in the 
MBA expression to UU376 expression occurred as a result of a DNA inversion event 
(Figure 1.3).  The genes UU375 and UU376 face in the opposite orientation (only true for 
strain ATCC 27815, not ATCC 700970, and the authors predict an additional inversion 
event to explain this difference) and inversion of the intervening DNA sequence, which 
holds a single uni-directional promoter, determines which of these two genes was 
expressed. Therefore, the resulting change in antigenicity was proposed to be as a 
mechanism of immune evasion used by Ureaplasma to a void eradication by host 
immune defences (Zimmerman et al., 2009).  
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Figure 1.3   Schematic illustration of the possible DNA inversion events within the mba 
locus during phase variation based on published sequence information (a , b and c);  ir (a, 
b and c), intergenic regions; nr, nonrepetitive region of mba. Locus configurations of (a) 
U. parvum serovar 3 strain ATCC700970, (b) U. parvum serovar 3 type strain 
ATCC27815T, and (c) U. parvum serovar 3 expressing UU376. The upper number above 
the mba gene indicates the length of the region containing 40 repeat units, and the lower, 
the length of a region containing 7 repeat units. Black triangles indicate repeat regions 
that are putative recombination sites. Reproduced from: (Zimmerman et al., 2009), with 
permission from the publisher John Wiley and Sons. 
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Colonisation and establishment of an infection by a particular pathogen is somewhat 
attributed to its capability to attach to the mucosal surfaces of a susceptible host. 
Ureaplasma spp. are also found to adhere to different types of human cells such as 
spermatozoa (Busolo et al., 1984; Knox et al., 2003), erythrocytes (Saada et al., 1991), 
urethral epithelial cells (Razin et al., 1998) and human respiratory cells (Torres-
Morquecho et al., 2010). Although the receptors on host cells are believed to be sialyl 
residues and sulphated compounds, adhesin molecules that mediate Ureaplasma 
cytadherence have not been extensively defined. As a major surface antigen of 
Ureaplasma, MBA was proposed to be one of the possible adhesion molecules that 
facilitate the attachment of Ureaplasma cells to both erythrocytes and HeLa cells 
(Monecke et al., 2003). 
 Although the MBA has been suggested as one of the virulence factors for Ureaplasma 
spp., its precise role in Ureaplasma pathogenesis is still elusive. There have been some 
attempts to understand the role played by MBA in intra-amniotic infection and 
chorioamnionitis caused by Ureaplasma in pregnant sheep (Dando et al., 2012; Knox et 
al., 2010). Knox and colleagues (2010), for example, demonstrated size variations of the 
tandem repeat region of the MBA gene; and suggested that these variations in MBA 
expression in vivo could be a mechanism by which Ureaplasma escape recognition by 
host immune arsenals to mediate disease (Knox et al., 2010). 
1.4.2 Urease activity 
Ureases play an important role in the pathogenesis of several microorganisms via their 
enzyme activity. For example, urease activity is recognised as an important virulence 
factor for Proteus mirabilis, which causes urinary tract infections and Helicobacter pylori 
that causes gastritis and stomach cancer in human (Mobley et al., 1995; Olivera-Severo et 
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al., 2006). Ureaplasma spp. produces an abundant amount of urease that is used to 
hydrolyse urea to ammonia and release ATP, as a sole source of energy, the hydrolysis 
resection is as following: CO(NH2)2 + H2O → 2 NH3 + CO2.  Urease activity is also 
proposed as a significant virulence factor for these species (Mobley et al., 1995). 
Colonisation of the upper urinary tract leading to the formation of infective kidney stones 
by Ureaplasma is believed to be mediated by urease production (Hedelin et al., 1984; 
Reyes et al., 2006). Hydrolysis of urea via urease causes increased pH and ammonia 
toxicity. It was found that injecting viable Ureaplasma into mice led to death of these 
animals within 5 minutes; this outcome was prevented in another group of mice that were 
injected with bacteria pre-treated with a potent urease inhibitor (flurofamide). This 
indicated that urease activity and toxicity of ammonia was the inevitable cause of 
mortality in these animals. However the researchers argued that the bacterial dose used in 
their study was high and may not reflect the conditions in a naturally-occurring infection 
(Ligon and Kenny, 1991).  
1.4.3 Phospholipases 
Phospholipases (PLs) have been indicated as virulence factors in many bacterial 
pathogens (Songer, 1997).  In Ureaplasma, they have also been proposed as an important 
virulence factor (De Silva and Quinn, 1991).  Phospholipases have both 
phosphodiesterase and acyl hydrolase activity and are able to hydrolyze one or more ester 
bonds in phospholipids (Istivan and Coloe, 2006).  It has been suggested that 
phospholipases stimulate premature labor, which is often associated with Ureaplasma 
infection, via their action to hydrolyze phospholipids in the placental membrane. This 
process, consequentially, leads to release of arachidonic acid and formation of elevated 
levels of prostaglandins, which can trigger preterm birth (Bennett et al., 1987). Three 
types of PLs have been identified and localized in Ureaplasma spp., PLA1, PLA2 and 
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PLC. It has been found that the activity of these enzymes may vary among Ureaplasma 
serovars; for instance, it was demonstrated that the activity of PLA2 was 2-fold higher in 
serovar 8 membranes, whereas PLA1 was 2-fold higher in serovars 3 membranes (De 
Silva and Quinn, 1991). Furthermore, these authors found the activity of PLA2 in serovar 
8 to be 3-fold greater than that of SV3 and SV4. In spite of studying the activity of these 
enzymes, their putative orthologous sequences have not been identified in the fully 
sequenced genome of serovar 3 (Glass et al., 2000). This may be due to a sequence 
difference compared with that of other bacteria. Both PLA1 and PLA2 have been shown 
to have significant variations in their specific characteristics, indicating that they are 
unique enzymes for Ureaplasma relative to phospholipases from other prokaryotes (De 
Silva and Quinn, 1999).  Ureaplasmal PLA2 activity has also been suggested to inhibit 
pulmonary surfactant production and cause lung damage (Cultrera et al., 2006). This 
assumption is based on a study by Schrama and colleagues (2001) who demonstrated that 
PLA2 activity in meconium inhibits pulmonary surfactant in vitro (Romero et al., 2013; 
Schrama et al., 2001).  
1.4.4 Immunoglobulin A (IgA) protease  
IgA plays an important role in immune defence at mucosal membranes, as it is the most 
abundant immunoglobulin at these sites (Woof and Russell, 2011). However, many 
Gram-negative pathogenic bacteria, such as Neisseria gonorrhoeae, are capable of 
producing extracellular IgA proteases as a virulence factor that inhibit IgA function and 
allow them to colonise and invade host surfaces membranes (Klauser et al., 1993; Mistry 
and Stockley, 2006; Pohlner et al., 1987). Similarly, Ureaplasma spp. has also been 
found to produce IgA1 proteases, which are serine proteases (Kilian et al., 1984; 
Robertson et al., 1984; Spooner et al., 1992). Human Ureaplasma proteases were found 
to degrade human IgA1, but not IgA2, and were host specific as they could not cleave 
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murine, porcine, or canine IgA (Kapatais-Zoumbos et al., 1985). The inability of 
ureaplasmal IgA proteases to cleave IgA2 was suggested to be due to the omission of the 
specific region at which IgA is cleaved. Human IgA1 was found to be cleaved between 
proline and threonine residues located at positions 235 and 236, respectively (Spooner et 
al., 1992).  
1.4.5 Haemolysins  
Haemolysins are extracellular toxins produced by a number of Gram-positive and Gram- 
negative bacteria (e.g. Staphylococci aureus and E. coli) and play an important role as 
virulence factors (Bhakdi et al., 1988; Wiseman, 1975). In Ureaplasma, two haemolysins 
encoded by two genes hlyA and hlyC in the genome of U. parvum serovar 3  have been 
repored and shown to have an enzymatic activity (Glass et al., 2000).  Of these two 
haemolysin genes, hlyA has been suggested as the main haemolysin that may serve as a 
virulence factor for Ureaplasma spp. Such implication was made because this hemolysin 
has an orthologue with hemolytic and cytotoxic activity in some pathogenic bacteria, 
while hlyC gene is orthologous to M. pneumonia hemolysin which has its activity 
mediated by H2O2 (Glass et al., 2000).  
1.4.6 Pathogenicity islands (PAI) 
Pathogenicity islands (PAIs) are distinctive genetic elements found on the genomes of 
many bacterial pathogens and are absent from non-pathogenic strains of the same or 
closely related species. PAIs are believed to be acquired by horizontal gene transfer via 
transduction, conjugation and transformation. These genetic elements contain genes that 
encode numerous virulence factors (Schmidt and Hensel, 2004). A pathogenicity island 
of Ureaplasma was also proposed and characterised by Momynaliev and co-workers 
(2007), when they identified 4 regions of hypervariable plasticity on the chromosome of 
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U. parvum clinical isolates. Of these regions, the region containing genes annotated as 
UU145-UU170 in the genome of serovar 3 (ATCC 700970 strain) was proposed to be a 
pathogenicity island because of its genetic features: this region was not found in all 
investigated clinical isolates, it has a conserved length in the genomes that was found in, 
and its insertion site into the genome was directly linked to tRNA genes, which are well 
known as anchorage points for horizontally transferred genetic elements (Momynaliev et 
al., 2007). Supporting evidence for this includes the existence of genes encoding proteins 
essential for horizontal gene transfer such as the ripX integrase-recombinase enzyme and 
phage recombinase enzyme. Studying genes within the proposed PAI showed adhesin 
gene homologues that could be of importance to virulence. PAI normally have a skewed 
G + C content relative to the rest of the host genome, but in this case the G + C contents 
were very similar. Further comparative genomic analysis showed that tetranucleotides 
GCGC and CGCG were not present within the element, but abundant among other 
regions of the chromosome of Ureaplasma. The authors concluded that an association 
between this hypothetical PAI and the clinical outcome of U. parvum could happen 
(Momynaliev et al., 2007) , but no direct experimental evidence was provided.  
In a current study, similar insertion regions to that mentioned above were also identified 
through a comparative genome analysis of 19 U. parvum and U. urealyticum strains 
(Paralanov et al., 2012). Two gene insertion events were identified: the first one was as a 
result of a transposon insertion; and the DNA segment inserted contained 8 genes, 6 
encode hypothetical proteins, one hypothetical protein containing a subtilase domain, and 
one Type I specificity subunit of a restriction enzyme-like protein. The second insertion 
event is believed to be due to a phage insertion into the chromosome, as the insert has 
three phage genes,  The first gene encodes an integrase-recombinase protein that contains 
a phage integrase domain (UPA3_0153 [GenBank: YP_001752228]). A phage 
Aboklaish A.F.                                                                                                              Chapter 1: Introduction 
17 
 
recombination protein Bet (UPA3_0162 [GenBank: YP_001752237] is located further 
downstream of the integrase and the final gene in the insert is a phage terminase large 
subunit of the pbsx family (UPA3_0176 [GenBank: YP_001752251]. The fact that these 
insertions were found in some isolates of the same serovar and not in other isolates of the 
same serovar may indicate horizontal gene transfer of a group of foreign genes or a 
‘pathogenicity island’. 
1.5 Role of Ureaplasma in human diseases 
In spite of being common commensals in genitourinary tract of healthy individuals, 
Ureaplasma spp. are considered opportunistic human pathogens. In the early 1950s, these 
species were first linked to human diseases when isolated from urethral discharges from 
men with primary and recurrent non-gonococcal urethritis (NGC) (Shepard, 1954; 
Taylor-Robinson et al., 1977).  A few years later, an association between Ureaplasma 
and both adverse pregnancy outcomes and low birth weight in neonates was established 
(Cassell, 1986; Cassell et al., 1983). Currently, there is accumulating evidence that 
indicates the implication of human Ureaplasma in a broad range of medical 
complications in adult men and women as well as neonates. In adults, Ureaplasma have 
been associated with several diseases (genitourinary tract and non-genital infections) such 
as infertility, prostatitis, epididymitis, pyelonephritis, cystitis, suppurative arthritis, 
subcutaneous abscesses, osteomyelitis, urinary calculi, postpartum endometritis, 
chorioamnionitis, spontaneous abortion, premature birth, and stillbirth. Furthermore, it 
has been shown that Ureaplasma spp. are associated with diseases in premature babies 
such chronic lung disease of prematurity (CLD), pneumonia and meningitis (Viscardi, 
2010; Viscardi and Hasday, 2009; Waites et al., 2005; Waites et al., 2009).  
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It has been estimated that 40% - 80% of healthy adult women are asymptomatically 
colonised by Ureaplasma spp. in their cervix or vagina. Transmission of Ureaplasma 
infection occurs via venereal as well as vertical modes.  Colonised mothers are more 
likely to transfer the infection to their babies through vertical transmission either in utero 
or during delivery, with an infection rate reaching 90% (Waites et al., 2005). Ureaplasma 
spp. are a less common coloniser of the lower urogenital tract of men and the 
colonisation rate was estimated to be about 20% -29% (Kong et al., 2000a; Xiao et al., 
2010) U. parvum is more commonly detected than U. urealyticum in samples from 
urogenital tract of adults or respiratory tract of neonates (Waites et al., 2005); however, 
no significant difference in pathogenicity between the two species has been observed 
(Heggie et al., 1994; Katz et al., 2005; Sung et al., 2011). In contrast, it was noticed that 
premature babies colonised by U. urealyticum have a higher rate of broncho pulmonary 
dysplasia (BPD) compared with those colonised by U. parvum (Abele-Horn et al., 1997). 
Despite of all these considerable efforts to define which one of the two human 
Ureaplasma species is more virulent in several human infections, no consensus about this 
issue has been reached so far and investigations continue. It has been speculated that 
there may be variation in pathogenicity among the 14 serovars, indicating that differential 
virulence is more likely to be related to the serovars and even different isolates from the 
same serovar, rather than to species. Moreover, a current study has highlighted the issue 
of horizontal gene transfer among Ureaplasma clinical isolates, generating genetic hybrid 
forms from different serovars that cannot be assigned to any of the 14 known serovars 
using genetic methods (Xiao et al., 2011b). This phenomenon may also a play a role in 
variations in pathogenicity among Ureaplasma as some virulence genes could be 
acquired this way.  
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Interaction between Ureaplasma and the host immune system and the resultant 
inflammatory response has also been indicated to be an important contributor in 
ureaplasmal diseases, especially BPD in preterm babies. Ureaplasma spp. has been 
demonstrated to be recognised by the innate immune system via Toll-like receptors 
(TLRs) (Shimizu et al., 2008; Triantafilou et al., 2013). In the study by Shimizu and 
colleagues (2008), it was reported that U. parvum serovar 3 lipoproteins were able to 
initiate activation of nuclear factor-kappa B (NF-κB) in vitro through TLR1, TLR2, and 
TLR6 signalling. Triantafilou et. al., (2013) have also revealed the involvement of TLR2, 
TLR6 and TLR9 in the innate immune response against Ureaplasma serovars, and have 
shown activation with release of inflammatory cytokines tumour necrosis factor-α (TNF-
α), interleukin1β (IL-1β), IL-6 and IL-8 in human amniotic epithelial cells by 
Ureaplasma. A relationship between the activation of inflammatory cytokines (e.g. TNF-
α, IL1β, IL-8) triggered by Ureaplasma infection and the development of BPD in preterm 
babies has been reported by a number of studies of preterm babies (Viscardi, 2010; 
Viscardi and Hasday, 2009; Waites et al., 2005).  
 
1.6 The complement system overview 
In 1894, the complement system was first discovered by Jules Bordet as a heat-sensitive 
component in human serum that has anti-bacterial activity. The name complement was 
given because it was believed that this system has the ability to complement antibodies in 
opsonizing and killing bacteria. Although it was seen only as an effector support for the 
antibodies at that time, complement is now known to be able to activate in the absence of 
antibodies during early stages of infection via other pathways (Janeway et al., 2001). The 
complement system is an integral arm of the innate immune defenses against invading 
pathogens. Currently, the complement system is composed of more than 35 proteins and 
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glycoproteins circulating in plasma and expressed on human cell surfaces (Carroll and 
Sim, 2011). In humans, most of the complement components are produced in the liver 
(about 90%), the most notable exception is a critical component of the terminal pathway 
(C7) which is produced primarily in granulocytes. Although a normal range of circulating 
complement proteins is produced by hepatocytes, the majority of complement 
components are also acute phase reactants and synthesis can be induced locally in other 
cell types such as fibroblasts, endothelia, astrocytes during infection by primary acute 
cytokines such as IL-6, IL-1β and TNF-α (Carroll, 2004; Marsh et al., 2001; Wurzner et 
al., 1994). In general,  complement proteins function as enzymes, enzyme inhibitors, or 
enzyme cofactors, many of them circulate in plasma and body fluids in inactive forms 
(zymogenes), expressing their activity only after activation of the complement system. 
Besides, some of these proteins are bound to cell membranes and act as regulators of 
complement activation protecting host self-cells and tissues (Janeway et al., 2001). 
The complement system is activated via three different activation pathways in response to 
different initiators, the classical pathway, the alternative pathway, and the lectin pathway. 
Each single pathway depends on specific molecules (components) for its initiation. 
However, all these pathways converge at the hydrolysis of a central C3 component by 
their respective pathway C3 convertases to generate the same set of effector molecules 
(Figure 1.4). C3 convertases, in the absence of regulation, proceed to cleave 
enzymatically intact C3 components. C3 is cleaved to C3a that is released and C3b, 
which binds covalently to the activating surface. If the activation continues, proteins of 
terminal pathway generate the membrane attack complex (MAC) that forms pores and in 
sufficient numbers, directly lyses the target cells.  Surface bound C3b is an opsonin that 
interacts with phagocyte receptors and mediate killing of invading microbes via 
phagocytosis.  Furthermore, the complement system also participates in generation of 
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inflammatory response fragments, called chemotaxins and anaphylotoxins (Walport, 
2001a).  
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Figure 1.4 Activation and evasion of complement. a) Overview the human complement 
system activation cascade. The initial steps of the complement system activation occur 
via three different pathways (the classical, lectin and alternative pathways), which are 
triggered differently by their specific molecules (components) binding to an activating 
surfaces such as invading microbes. However, they all converge at the hydrolysis of a 
central C3 component by their respective pathway C3 convertases to generate the same 
set of complement effector molecules, which play role in opsonization, recruitment of 
host effector cells and direct killing of invading pathogens. b) Microorganisms have 
developed many ways to evade complement actions. Suppression of CP activation can be 
achieved by trapping endogenous C1 inhibitor (C1-INH) to the surface or by inactivating 
antibodies through the capture of their Fc regions. Whereas the recruitment of soluble 
regulators by capturing host proteins is a common strategy to impair downstream 
complement actions, certain viruses also produce structural mimics of these regulators. In 
addition, some microbial proteins have similar activities to CD59 in preventing MAC 
formation. Direct inhibition of C3, the C3 and C5 convertases, C5 or the C5a receptor 
(C5aR) is a prominent strategy of Staphylococcus aureus. Finally, a set of different 
microbial proteases can degrade many of the crucial components of the complement 
system. These proteases act directly or by capturing and activating a human protease.  
Reproduced from: (Lambris et al., 2008), with permission from the publisher Nature 
publishing group. 
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1.6.1 The classical pathway 
The classical pathway was the first complement activation pathway to be discovered. The 
first component of this pathway is the C1-complex, which consists of one molecule of the 
hexameric glycoprotein C1q and two molecules of  each of the serine protease 
proenzymes C1r and C1s (C1qr2s2) and depends on  Ca
++  
for its assembly (Busby and 
Ingham, 1990). C1q plays an integral role as it bridges the gap between the innate and the 
adaptive immune response by binding antibodies (Fc-regions of IgG or IgM) attached to 
antigens such as bacteria, viruses or cell debris (Walport, 2001a).  The C1q component is 
also able to bind directly to the surface of some pathogens such as lipopolysaccharides 
(LPS), nucleic acids, immune complexes, some viruses and C-reactive protein (CPS) in 
the absence of antibodies and activate the classical pathway of the complement system 
(Kishore and Reid, 2000; Loos and Clas, 1987; McGrath et al., 2006). C1q belongs to a 
protein family called the collectins, and requires calcium for achieving maximum binding 
(Roumenina et al., 2005). A single molecule of C1q component consists of 3 combined 
polypeptide chains, which in turn combine in a complex of 6 collagen-like triple helical 
arms each with a globular head domain. Each globular head domain is a binding site for 
C1q that binds to Fc region of aggregated or antigen-bound IgG (IgG1 or IgG3) or IgM 
antibodies found on a target surface such as invading microorganisms (Kishore and Reid, 
2000). Binding of C1q to antibodies needs at least two molecules of IgG attached close 
enough to each other on a target surface to engage 2 globular  heads of C1q; this means 
that a relatively high surface density of IgG is required for the activation of the classical 
pathway. In contrast, only one pentameric molecule of IgM bound to a target antigen can 
activate the classical pathway, as each molecule has five separate domains that could 
work as C1q binding sites; Free IgM (not bound to antigen) cannot bind to C1q and 
initiate complement activation in the circulation because it is in the form of a planar 
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molecule, but once bound to an immune complex, a conformational change in IgM occurs 
(from a planar to bent form) allowing tight binding to C1q(Schumaker et al., 1987).  
Binding of C1q causes a conformational change in the C1-complex that leads to 
stimulation of an autocatalytic enzyme activity in C1r, the active form of C1r, which in 
turn, cleaves and activates C1s. The active form of C1s is an active serine protease that 
functions on two zymogens (substrates): the components C4 and C2.  The component C4 
is activated upon enzymatic cleavage by C1s into a small fragment C4a and large 
fragment C4b. C4b fragment binds covalently to the surface target in the area of C1, 
while C4a fragment, which is a soluble weak anaphylatoxin (Gorski et al., 1979), is 
released. C1s also cleaves C2 into C2a and C2b fragments; C2b is released and C2a binds 
to C4b, which is bound to the activating surface, in the presence of Mg
++
 to generate the 
C4b2a complex (Xu et al., 2001). The resulting C4b2a complex is called the classical C3 
convertase that cleaves C3 into C3a that is released and C3b, which is an opsonin that 
covalently binds to activating surfaces such as microbial surfaces. C3a is anaphylatoxins 
and chemoattractants that attracts and activates immune effector cells (basophils, mast 
cells, neutrophils and macrophages), and has also been reported to act directly as an 
antimicrobial and antifungal agent (Nordahl et al., 2004).   
 
1.6.2 The lectin pathway 
The lectin pathway was the latest defined complement activation pathway, as it was 
discovered in the 1980’s (Ikeda et al., 1987).  The lectin pathway is initiated upon 
binding of soluble pattern recognition molecules (PRM) (types of lectins): mannan 
binding lectin  and ficolins (M-ficolins, L-ficolins and H-ficolins) that are structurally 
similar to C1q, to  certain carbohydrate structures characteristic of non-self surfaces, e.g. 
microbial sugars (Holmskov et al., 2003; Runza et al., 2008).  MBL and ficolins activate 
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the lectin pathway in association with serine proteases called MBL-associated serine 
proteases (MASPs):  MASP-1, MASP-2, MASP-3 and a MBL-associated protein 19 
(MAp19), which are functionally similar to the proteases of the classical pathway C1 
complex (C1r and C1s)(Schwaeble et al., 2002; Thiel, 2007). Following binding of 
MBL/MASP-2 complex to microbial surface through recognition of prokaryotic 
carbohydrate motifs such as mannose, MASP subsequently cleaves the complement 
components C4 (to C4a and C4b) and C2 (to C2a and C2b) resulting in the formation of 
the C3 convertase, the C4bC2a complex, as above. The C4bC2a activates C3 by cleavage 
into C3a and C3b. C3a is an anaphylatoxin released away and C3b an opsonin binds to 
activating surfaces (e.g. microbes) (Turner, 1996; Sorensen et al., 2005).  
 
1.6.3 The alternative pathway 
Unlike the classical and lectin pathways, the alternative pathway is independent of 
activation by antigen-antibody complexes or pattern recognition. The activation of the 
alternative pathway requires four serum proteins: C3, factor B, factor D and properdin 
and uses its own C3 and C5 convertases. The initiation of alternative pathway activation 
occurs via slow spontaneous hydrolysis of an unstable internal thioester bond in C3 to 
generate C3(H2O) that is a C3b-like molecule; this mode of initiating the activation of 
alternative pathway is also called ‘tick-over’. In the presence of Mg2+, C3(H2O) molecule 
binds to factor B, which is a single chain plasma glycoprotein structurally homologous to 
C2 (Bentley, 1986). Binding C3(H2O) to factor B makes it unstable and exposes a site on 
factor B that serves as a substrate for factor D, which subsequently cleaves factor B into 
Ba and Bb fragments. Ba molecule is a smaller fragment that is released, while Bb 
fragment remains bound to C3(H2O) and forms C3(H2O)Bb complex, which is an 
unstable fluid-phase C3 convertase that, at this stage, still unbound in plasma. The free 
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C3 convertase promptly cleaves a few C3 molecules into C3b and C3a fragments, which 
are rapidly degraded in the absence of binding to activating surfaces of foreign cells or 
are quickly inactivated by regulators on the surface of host cells. However, C3b 
molecules, in presence of an infection, covalently bind to microbial surfaces via their 
thioester linkages and remain active for a longer time (Le Friec and Kemper, 2009). 
Surface-bound C3b, in the presence of Mg
2+
, binds factor B, which is in turn cleaved by 
factor D to form the C3bBb complex or the alternative C3 convertase, which is similar to 
C4b2a complex of the classical pathway.  C3 convertase activity of C3bBb complex is 
unstable at this point and needs to bind to properdin (a plasma protein also called factor 
P) to form stabilized C3bBbP complex or the active alternative pathway C3 convertase. 
Subsequently the surface-bound C3 convertases of alternative pathway cleave more C3 
and generate enormous aggregates of C3b molecules on microbial surfaces, which in turn, 
bind to factor B enabling its cleavage and activation by factor D and causing an intense 
spontaneous amplification. Properdin has also been reported to recognize and bind to 
surfaces of certain pathogens such as E. coli, Neisseria and yeasts and facilitates 
complement activation; therefore, it has been suggested to function as a pattern 
recognition receptor (PRR) to aid the initiation of the alternative pathway activation 
(Hourcade, 2006; Kemper and Hourcade, 2008; Le Friec and Kemper, 2009; Spitzer et 
al., 2007). The active surface-bound C3b fragment, which is required to initiate the 
alternative pathway cascade, can also be generated from the other cascades (the classical 
and lectin pathways), providing an amplification feed-back loop mechanism linking the 
all complement activation pathways. It is important to note that surface bound C3b on 
host cells is rapidly inactivated by the regulatory enzyme factor I (FI) into iC3b in the 
presence of host co-factors membrane cofactor protein (MCP,CD46) or factor H (FH). 
The iC3b is unable to bind to factor B and cannot form the C3 convertase. Therefore, the 
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alternative pathway on its own is only really effective for surfaces that lack the ability to 
regulate C3b (Zipfel and Skerka, 2009). The C3 convertase activity of C3bBb generates 
the C3bBb3b complex, or the alternative C5 convertase (equivalent to the classical and 
lectin pathways C5 convertases, C4b2a3b complex), which then cleaves C5 into C5a and 
C5b (Kinoshita et al., 1988). C5a is another potent anaphylatoxin diffuses way to the 
nearby environment, while C5b associates non-covalently to the activating surface and 
then recruits binding of C6 to initiate the common terminal pathway that leads to 
formation of the terminal complement complex (TCC), also known as the membrane 
attack complex (MAC), which form pores in the targets surface membrane, such as 
microbes and causes cell lysis (Pangburn and Rawal, 2002).  
 
1.6.4 The terminal pathway 
The final result of activation of all three complement pathways is the formation of C5 
convertase (composed of C4b2a3b complex for both the classical and lectin pathways and 
C3BbC3b complex for the alternative pathway) and initiation of the terminal pathway. C5 
is the first component in the terminal pathway, which is cleaved by C5 convertases into 
C5a and C5b as mentioned above. Active C5b molecule has affinity for binding 
sequentially and non-covalently to C6, C7, C8 and C9. Binding of activated C5b to C6 
has to happen rapidly, because the C5b molecule is unstable and prone to conformational 
change that could inactivate it and prevent C6 binding. But once bound to C6, C5b 
molecule becomes stable (DiScipio et al., 1999). Sequentially, the formed complex C5b6 
binds to C7 to form a hydrophobic complex (C5b67) that undergoes conformational 
change, which results in exposure of hydrophobic binding regions, and attaches itself to 
the surface membrane of the target pathogen. These hydrophobic binding regions in the 
complex are believed to facilitate the insertion of the C5b67 complex into the 
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phospholipid bilayer following attachment to microbial membranes (Muller-Eberhard, 
1986). If the location of that reaction was on an immune complex or other non-cellular 
activating surfaces, the hydrophobic binding sites cannot attach to the immune complexes 
and then the C5b67 complex will be released. Free C5b67 complexes can bind to and 
deposit on the membranes of nearby host cells resulting in cell lysis, however, such lysis 
is controlled by the complement regulator CD59 in normal situations (Podack et al., 
1979). Binding C8 to C7 in the C5b67 complex causes a conformational change in C8 
that exposes its hydrophobic domain, allowing the insertion into the interior of 
phospholipid membranes. In absence of C9, the C5b678 complex is capable of forming a 
small pore that can induce lysis of red blood cells and some nucleated cells (Gee et al., 
1980; Sodetz, 1989). The last step of in the terminal pathway and formation of the MAC 
is the binding and polymerization of 12- 18 molecules of C9 to the C5b678 complex 
(Muller-Eberhard, 1986). After binding to the complex, C9 also undergoes 
conformational changes that allow its insertion into the membrane. Composed of C5b678 
complex surrounded by a poly-C9 complex (C5b6-9 complex), the final complete MAC 
complex is now able to insert into and form large circular pore in the target cell 
membranes resulting in an osmotic cell lysis (Bhakdi et al., 1978).   
 
1.6.5 The regulation of complement activation 
The main function of complement system as an arm of the innate immunity is to aid the 
elimination of invading pathogens and the clearance of modified self-cells such as 
apoptotic cells. However, uncontrolled amplified complement activation can lead to 
several adverse effects on host self-cells. Therefore, the complement activation, under 
normal conditions, is firmly controlled and regulated to prevent any potential destruction 
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of self-cells and tissues. The complement activation cascades are regulated by a number 
of membrane-bound and circulating proteins called regulators of complement activation 
(RCA) (Zipfel and Skerka, 2009). These regulators act at all stages of complement 
activation and can be divided into two distinct groups: Fluid phase regulators and surface-
bound regulators.  
1.6.5.1 Fluid phase complement regulators 
Fluid phase regulators are soluble proteins present and circulating in plasma and body 
fluids (e.g. the synovial and vitreous). These regulators include the following: 
1.6.5.1.1 C1 inhibitor (C1INH) 
C1 inhibitor (C1INH) is one of the soluble regulators that control the activation of both 
the classical and the lectin pathways (Davis et al., 2008). C1INH is a member of proteins 
called serine protease inhibitors, and it regulates the classical pathway by either binding 
the active site of serine proteases C1r and C1s and dissociating them from the C1q-
complex or via blocking the antibody-independent C1q activation, thus preventing the 
subsequent activation of C4 or C2 (Ziccardi, 1982; Ziccardi and Cooper, 1979). C1INH is 
the only protease inhibitor that controls both the classical and lectin pathways (Davis et 
al., 2008). C1INH is also regulates the lectin pathway by inhibiting the proteolytic 
activities of both MASP-1 and MASP-2 by binding to them and forming a stable 
equimolar complexes (Kerr et al., 2008; Matsushita et al., 2000). Moreover, it can 
regulate the alternative pathway via inhibiting C3b and preventing the binding of factor B 
(Jiang et al., 2001)  
Inherited or acquired C1INH deficiency in humans can cause a lethal disease known as 
hereditary angioedema (HAE), which is characterized by edema in the skin and the 
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mucus membranes of both the gastrointestinal tract and the upper respiratory tract 
(Carugati et al., 2001).  
1.6.5.1.2 C4 binding protein (C4BP) 
C4 binding protein (C4BP) is a major fluid phase regulator that controls the activation of 
both the classical and the lectin pathways. It is a glycoprotein composed of 7 identical 
long α-chains (75 kDa) and one short β-chain (40kDa) linked together by disulphide 
bonds. Structurally, the chains of C4BP consist of short consensus repeats (SCRs); each 
α-chain has eight SCRs, while the β-chain has only three SCRs (Blom et al., 2004a, b). 
C4BP regulates the classical and lectin pathways by binding the C4b molecule and 
preventing the assembly of the C3 convertase C4b2a (Fujita and Nussenzweig, 1979). 
C4BP has the capacity to act as a cofactor to FI in cleaving the membrane-bound C4b 
into two inactive fragments (C4c and C4d), C4c diffuses away and C4d fragment remains 
bound to the target surface, hence blocking the formation as well as the reassembly of the 
C4b2a complex (Fujita and Tamura, 1983; Seya et al., 1995). It can also prevent the 
formation of the classical and lectin C3 convertases by binding nascent C4b fragments 
(Gigli et al., 1979). Additionally, C4BP can accelerate the decay of the C4b2a complex 
by separating C2a from C4b2a complex and preventing the re-assembly again (Gigli et 
al., 1979).  It is also believed that C4BP could act as cofactor to FI in mediating the 
degradation of soluble C3b, thus additionally accelerating the decay of the alternative 
C3bBb complex (Blom et al., 2003).  
Beyond complement regulation, C4BP has also additional activities such as binding to the 
vitamin K-dependent regulator protein S, which is one of the regulators of the coagulation 
system. While such binding does not interfere with regulatory action of C4BP, as it is the 
-chain that is responsible for this activity, it affects the cofactor role of protein S for 
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anticoagulant activated protein C (APC) activity (Dahlback and Hildebrand, 1983; van de 
Poel et al., 1999).  
1.6.5.1.3 Factor H (FH) 
While C4BP is a major regulator of the classical pathway, factor H (FH) is considered to 
be a major fluid phase regulator for the alternative pathway. FH is an abundant plasma 
glycoprotein of approximately 155 kDa in size (previously described as β1H-globulin) 
that is composed of 20 SCRs, which function as binding domains for FI, C3b and host 
cell surfaces (Nilsson and Mueller-Eberhard, 1965; Whaley and Ruddy, 1976). FH 
controls the activation of the complement cascade at the C3 level and is able to inactivate 
both soluble C3b and membrane-bound C3b. Binding and regulating the membrane-
attached C3b by FH is influenced by several membrane structural components of the host 
cell surfaces such as sialic acids, polyanionic substances (e.g. glycosaminoglycans) or 
sulphated polysaccharides (e.g. heparin) (Fearon, 1978). The FH regulatory action occurs 
via three ways: i) it acts as a main cofactor for the serine protease FI in the degradation of 
C3b into inactive form, iC3b; thus preventing the formation of the alternative C3 
convertase (C3bBb), ii) it prevents the assembly of the C3bBb complex by binding C3b 
and blocking the attachment of factor B, and iii) it functions as a decay accelerating factor 
for C3bBb complex by dissociating Bb from the C3bBb complex (Pangburn et al., 1977; 
Weiler et al., 1976; Whaley and Ruddy, 1976). In the absence of FH, a spontaneous, 
amplified activation of complement occurs, resulting in consumption of the C3 and factor 
B complement components (Schreiber et al., 1978).  
Beyond the control of the complement activation, FH is also a multifunctional protein 
that has further activities such as mediating cell attachment and acting as an adhesin 
(DiScipio et al., 1998; Nabil et al., 1997). It has also been shown that FH is able to 
interact with and bind to heparin, adrenomedullin (AM) and a 52-amino acid peptide 
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belonging to the calcitonin gene peptide superfamily, and it is anticipated that this 
interaction modulates the biological activities of these proteins (Pangburn et al., 1991; 
Pio et al., 2001). 
FH deficiency or dysfunction are associated with several diseases in humans such 
atypical haemolytic uremic syndrome (aHUS), membranoproliferative glomerulonephritis 
type II (MPGN-II) and recurrent microbial infections and chronic inflammation and 
immune evasion of tumour cells (Zipfel et al., 2006). This, in fact, indicates the 
importance of FH as an effective regulator of complement activation. 
FH has closely related glycoproteins that share common features and are encoded by 
genes located in the FH family gene cluster on chromosome 1q32 ; these family members 
are factor H-like protein 1 (FHL-1) and five factor H-related proteins (FHR1, FHR-2, 
FHR-3, FHR-4 and FHR-5) (Skerka et al., 2013; Zipfel et al., 2002). 
FHL-1 is an alternative spliced product of a 42 kDa of the gene that encodes for FH. This 
protein has 7 SCRs which are homologous to the N-terminal SCRs of FH and a four 
amino acid tail at the C-terminus that are FHL-1 specific; FHL-1 has a similar 
complement regulatory function to that of FH, as it can act as a cofactor for FI mediating 
the cleavage of C3b (Misasi et al., 1989). An additional role in complement control as a 
decay accelerating factor for C3 and C5 convertases has also been reported (Kuhn and 
Zipfel, 1996). FHL-1 has also been proposed to facilitate cell adhesion to the fibroactin 
matrix (Hellwage et al., 1997). 
FHRs are closely related proteins homologous to FH encoded by separate genes that are 
located on the same chromosome downstream the FH gene within the RCA (Regulation 
of Complement Activation) gene cluster (Diaz-Guillen et al., 1999). Like FH, all FHR 
proteins, with exception of FHR-4 are composed of SCRs and are able to identify self 
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from non-self-cell surfaces; These proteins can be divided into two main groups based on 
their covered domains: Group I composed of FHR-1, FHR-2 and FHR-5 and group II 
includes FHR-3 and FHR-4 (Skerka et al., 2013). Similar to FH, all five FHR proteins 
have been shown to play a role in complement regulation as well as other functions 
beyond complement, however, the defined mechanism of complement control of some of 
them is still not clear (Skerka et al., 2013). FHR-1 prevents the cleavage of C5 by binding 
and inhibiting the C3b component of the C5 convertase, but the exact mechanism still not 
fully defined. In addition, it has been shown to regulate the terminal pathway via 
preventing the assembly of the MAC complex (Heinen et al., 2009). FHR-2 has been 
shown to regulate the complement activation via inhibiting the alternative C3 convertase 
activity as well as preventing the formation of the terminal pathway complex (Eberhardt 
et al., 2013). Although the defined mechanism in complement regulation is still not 
understood, FHR-3 and FHR-4 have been shown to bind to C3b, C3d and heparin 
(Hellwage et al., 1999). FHR-5, in high concentrations, has been found to act as a 
cofactor for the serine protease FI as well as a decay accelerating factor, additionally, it 
can bind to C3b and heparin (McRae et al., 2005). With the exception of FHR-2, the 
majority of FHRs have been found to compete with factor H for binding to C3b 
(Goicoechea de Jorge et al., 2013).   
1.6.5.1.4 Clusterin 
Clusterin is a fluid phase complement regulator that has been described by several 
different names based on its multifunctional activities such as SP-40-40, Apo-J, 
complement lysis inhibitor (CLI) and sulphated glycoprotein 2 (SGP2) (Jenne and 
Tschopp, 1992). This soluble regulator consists of two chains (α-chain and β-chain) 
connected together by a disulphide bond and has an affinity to bind to aggregated cells 
such as erythrocytes and Sertoi cells.  It has also been demonstrated within soluble C5b-9 
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complexes in human glomeruli (Rosenberg and Silkensen, 1995). Clusterin regulates the 
terminal complement pathway by binding to the TCC complexes (C5b67 complex, C7, 
C8 and C9) and forming soluble complexes that are unable of insert into cell membranes 
and cause cell lysis (Tschopp et al., 1993). In addition, clusterin is also thought to play a 
role in some other biological activities such as the clearance of cellular debris and 
regulation of lipid transport (Jenne and Tschopp, 1992). 
1.6.5.1.5 Vitronectin  
Vitronectin, also known as S-protein, is a multifunctional glycoprotein that is involved in 
several other activities besides complement regulation (Preissner, 1991). Vitronectin is 
one of the regulators of the terminal complement pathway that inhibits the assembly of 
MAC complex. It does that by binding to C5b67, C5b6-8 and C5b6-9 complexes and 
prevents their attachment to host cell membranes and the formation of lytic pores (Podack 
and Muller-Eberhard, 1979).  S-protein is also able to inhibit the polymerization of C9 
and assembly of MAC complex on cell surfaces (Podack et al., 1984). As stated earlier, 
vitronectin has also other functions such as mediating both cellular adhesion and invasion 
as well as playing a role in the regulation of coagulation (Hayman et al., 1985; Singh et 
al., 2010). 
1.6.5.1.6 Carboxypeptidase N (CPN) 
Carboxypeptidase N is an enzyme (a plasma zinc metalloprotease) produced by 
hepatocytes that acts to remove carboxy-terminal arginines and lysines from peptides 
(e.g. kinins, creatine kinase MM-skeletal muscle and complement anaphylatoxins (C3a 
and C5a)) that circulate in bloodstream (Matthews et al., 2004). CPN was shown to 
inactivate the anaphylatoxins C3a and C5a as well as anaphylatoxins derived from 
bradykinin. Carboxypeptidase N inactivates C3a and C5a by cleaving terminal arginine 
and forming C3a(desArg) and C5a(desArg), which are markedly reduced in their ability 
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to bind their receptors (C3aR and C5aR, respectively) and  induce signalling (Bokisch 
and Muller-Eberhard, 1970). By functioning this way, Carboxypeptidase N protects the 
human body from unnecessary accumulation of possibly harmful peptides that have either 
local autocrine or paracrine activity (Skidgel and Erdos, 2007).     
  
1.6.5.2 Membrane bound complement regulators 
The membrane bound complement regulators are present on the surface of host cells and 
their main role is to mark host cells as self-cells and prevent the complement attack upon 
activation (Kim and Song, 2006). Several surface attached complement regulators have 
been characterized and defined such as complement receptor 1(CR1, CD35), decay 
accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46). 
1.6.5.2.1 Complement receptor 1 (CR1, CD35) 
Complement receptor 1 is a glycoprotein expressed on the surface of a number of 
circulating host cells such as erythrocytes, T lymphocytes, B lymphocytes, neutrophils, 
monocytes and eosinophils but not on platelets (Fearon, 1980). Expression of CR1on the 
surface of other human cells, including follicular dendritic cells, peripheral nerve fibers 
and glomerular podocytes, has also been demonstrated (Appay et al., 1990; Reynes et al., 
1985; Vedeler and Matre, 1990). CR1 regulates both the classical and alternative pathway 
as it acts as a cofactor for FI degradation of C3b and C4b as well as cleavage of iC3b into 
C3c and C3dg fragments (Medof et al., 1982). It also accelerates the decay of the 
classical and alternative C3 and C5 convertases that are assembled either intrinsically on 
the same cell or extrinsically on nearby cells (Krych-Goldberg et al., 1999). Furthermore, 
CR1 expressed on erythrocytes plays an exceptional role in mediating the delivery of 
Aboklaish A.F.                                                                                                              Chapter 1: Introduction 
36 
 
immune complexes bound to C3b from the circulation to the reticuloendothelial system 
for further processing (Medof et al., 1982). 
1.6.5.2.2 Decay accelerating factor (DAF, CD55) 
Decay accelerating factor (DAF) is a glycosylphosphatidylinositol (GPI) linked 
glycoprotein  (70 kDa) that is extensively expressed on a variety of human cells including 
circulating blood cells, endothelial cells and epithelial cells as well as being present in a 
soluble form in different body fluids (e.g. in plasma, synovial, and cerebrospinal fluids) 
(Medof et al., 1987).This complement regulator functions on and controls the activation 
of both the alternative and classical complement pathways via accelerating the decay of 
their respective C3 convertases (C3bBb and C4b2a, respectively) (Nicholson-Weller et 
al., 1983). DAF is able to bind to and remove C2a from C4b2a complex and Bb from 
C3bBb complex and prevents the assembly of these C3 convertases (Fujita et al., 1987).  
1.6.5.2.3 Membrane cofactor protein (MCP, CD46)  
Membrane cofactor protein (MCP or CD46) is an integral glycoprotein (a type I 
transmembrane protein) that is expressed on almost all surfaces of human cells and 
peripheral blood cells except erythrocytes (McNearney et al., 1989; Seya and Atkinson, 
1989). MCP is able to regulate the complement activation and protect autologous host 
cells from complement attack by binding to C3b and acting as a cofactor for FI in 
mediating the cleavage of C3b, and also, with a weak cofactor activity, facilitating the 
cleavage of C4b (Seya and Atkinson, 1989). Furthermore, MCP has been shown to work 
as a receptor for some microorganisms such as measles virus (MV), N. gonorrhoeae and 
Neisseria meningitides mediating their adherence to epithelial cells and entry to nucleated 
cells (Lindahl et al., 2000). 
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1.6.5.2.4 Protectin (CD59) 
CD59 is another complement regulator that is known by a number of different names, due 
to its initial description by different research groups, such as protein p18, membrane 
attack complex inhibitory factor (MACIP), homologous restriction factor 20 (HRF20), 
membrane inhibitor of reactive lysis (MIRL) (Holguin et al., 1989; Meri et al., 1990; 
Okada et al., 1989; Sugita et al., 1988).  Protectin is a glycoprotein that is ubiquitously 
expressed on the surfaces of human cells and tissues. CD59 is found on the surfaces of 
endothelial cells, epithelial cells, circulating blood cells, spermatozoa as well as neural 
tissues (Meri et al., 1991). Similar to DAF, CD59 has a GPI anchor and both its free 
circulating and membrane- bound forms can be found in the human body (Hakulinen and 
Meri, 1995; Rooney and Morgan, 1992; Vakeva et al., 1994)   CD59 is a regulator of the 
terminal pathway as it specifically inhibits the final steps of the MAC formation via 
binding to the C5b-8 complex and blocking the assembly of polymeric C9 complex 
thereby protects self-cell from the complement-mediated cell lysis (Meri et al., 1990). 
Combined deficiency in both CD59 and DAF is associated with a rare acquired 
haemolytic disorder called paroxysmal nocturnal haemoglobinuria (PNH) that is 
characterised by excessive lysis of red blood cells and leukocytes in a pattern earlier than 
normal (Risitano, 2013). 
 
1.7 Evasion of complement by pathogenic bacteria  
Despite the important role played by the complement system in the clearance of the 
invading microorganism, microbial pathogens, during their evolution, have developed 
many sophisticated tactics to avoid recognition and destruction by the complement 
system. These mechanisms either directly target and inactivate complement proteins or 
indirectly manipulate and modulate the complement activation by exploiting the 
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complement regulators, therefore, mimicking host self-cells and tissues (Figure 1.4). 
Microbial interference with complement activation occurs at any level of complement 
activation: at the initial stages of activation, at the C3 convertase generation or at the final 
stage of MAC formation. Microbial mechanisms and strategies of evading the 
complement system are comprehensively reviewed in a number of good reviews (Blom et 
al., 2009; Kraiczy and Wurzner, 2006; Lambris et al., 2008; Zipfel et al., 2013; Zipfel et 
al., 2007).  
1.7.1 Blocking the initial stages of complement activation  
Evading the initial levels of activation can happen by different ways. Some Gram-
positive bacteria, for example, express surface proteins that are able to bind the Fc region 
of immunoglobulins (IgG) and interfere with C1q binding thereby inhibiting the 
activation of the classical pathway. Staphylococcal protein A (SPA) and protein G of both 
S. aureus and Streptococci are good examples (Atkins et al., 2008; Nitsche-Schmitz et 
al., 2007). Moreover, some microbes are able to cleave immunoglobulins and C3/C3b 
and block the complement activation either directly with their own endogenous proteases 
or indirectly by acquiring and using human proteases. Examples of these are two cysteine 
proteinases of Streptococcus pyogenes: IgG degrading enzyme of S. pyogenes (IdeS) and 
streptococcal endotoxin B (SpeB) are able to bind to and dissociate the Fc region of 
membrane-bound IgG hence disrupt complement activation (von Pawel-Rammingen and 
Bjorck, 2003). S. aureus is also able to achieve the same outcome in an indirect way by 
binding and activating human plasminogen to plasmin, using its secreted enzyme 
staphylokinase (SAK).  Activated plasmin then binds to bacterial membranes and cleaves 
both IgG and C3b (Rooijakkers et al., 2005). Blocking the early stages of complement 
activation can also be achieved via recruiting the complement regulator C1INH, 
therefore, preventing the activation of classical pathway. Examples of pathogenic bacteria 
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that bind to C1 INH, which functions on and inhibits the activation of both the classical 
and lectin pathways, are E. coli O175:H7 and Bordetella pertussis (Lathem et al., 2004; 
Marr et al., 2007).   
1.7.2 Interfering with the formation of the C3 convertases   
Invading microorganisms have also evolved strategies to elude complement attack at the 
C3 convertases level. For example, S. aureus produces a secreted protein called 
staphylococcal complement inhibitor (SCI) that is able to bind to C3 convertases of both 
the classical and lectin pathways, hindering their activity to cleave the complement 
component C3 as well as preventing the formation of new C3 convertases (Rooijakkers et 
al., 2005). Moreover, Group A Streptococci, in order to protect itself from C3b deposition 
and phagocytosis, uses its cysteine protease SpeB to cleave properdin, which is required 
for the assembly of C3bBb complex.  Therefore, SpeB inhibits the formation of the C3 
convertase of the alternative pathway and blocking further cleavage of C3 (Tsao et al., 
2006). On the other hand, a number of pathogenic microbes are also able to mimic 
complement regulators that act as cofactors for factor I-mediated cleavage of C3b 
fragments. An example of such modulation is used by vaccinia virus, which has a protein 
known as vaccinia virus complement control protein (VCP) that has homology to C4BP 
and acts by functioning both as a decay accelerating factor for the C3 convertases, as well 
as being able to bind C4b and prevent the formation of the C4b2a complex (Kotwal et al., 
1990). Other microbes can indirectly interfere with the C3 convertase formation by 
binding to regulators of complement activation (RCA) that control complement activation 
at this level. Three fluid phase complement regulators (FH, FHL-1 and C4BP) that 
regulate the complement activation have been shown to be exploited by different 
pathogens to protect themselves from the complement activity. For example, S. pyogenes 
have been shown to used their M proteins to bind to FH, FHL-1 and C4BP and inactivate 
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C3 convertases of the alternative and lectin pathways and thereby avoiding the 
subsequent phagocytosis (Horstmann et al., 1988; Johnsson et al., 1996; Kotarsky et al., 
1998). Another example of bacterial binding to complement regulators is N. gonorrhoeae, 
which expresses outer membrane proteins called porins that are able to bind both FH (via 
por1A) and C4BP (via por1B) and inhibit activation of both the alternative and classical 
pathways (Ngampasutadol et al., 2005; Ngampasutadol et al., 2008; Ram et al., 1998). 
Further examples are reviewed in detail by (Blom et al., 2009).  
1.7.3 Evading the late stages of activation 
Even at the final stages of complement activation that lead to the formation of the 
cytolytic MAC, microbial pathogens have developed mechanisms to interfere with and 
prevent the activation of the terminal pathway of complement. Gram-positive bacteria are 
inherently resistant to direct lysis by complement attack due to the specific structure of 
their cell wall (which contains a thick peptidoglycan layer) that provides a physical 
barrier to block the insertion of the C5b-9 complex into the bacterial inner membrane 
(Joiner et al., 1983). Furthermore, the polysaccharide capsule produced by some bacteria 
such as S. pneumoniae act as a mechanical block that prevents both the direct killing by 
the complement and impedes the opsonophagocytic killing by professional phagocytes 
(Hyams et al., 2010). Many Gram negative bacteria can be directly lysed and killed by 
the complement activity (Fierer et al., 1972); however, it was found that the presence of 
long O-polysaccharide side chains of LPS in the cell wall of some serum resistant strains 
of the Gram negative bacteria, E. coli, provide a protective shield against the 
complement-mediated serum killing (Porat et al., 1987). The role of long O-
polysaccharide side chains of LPS in avoiding direct complement killing was also 
demonstrated among Salmonella Minnesota strains, as it was found to provide a physical 
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barrier preventing the insertion of the C5b-9 complex into the membrane of bacterial 
cells, thereby inhibiting the MAC-mediated cell lysis (Joiner et al., 1986).  
Moreover, some bacterial pathogens can directly modulate the late stages of complement 
activation (the terminal pathway) using their secreted proteins that have ability to inhibit 
the activation of the terminal pathway. S. aureus, for example, produces a family of 11 
proteins called staphylococcal superantigen-like (SSLs) that have a variety of biological 
functions; of these proteins, SSL7 has been found to bind to C5 preventing its cleavage 
into C5b and C5a fragments and thereby blocks the formation of the MAC and the 
complement-mediated cytolysis (Langley et al., 2005). Another example, the 
streptococcal inhibitor of complement (SIC) that is expressed by Group A streptococci 
can bind to the soluble C5b-7 complex and blocks its insertion into the cellular 
membranes (Fernie-King et al., 2001). Borrelia burgdorferi is another pathogen that is 
able to avoid the complement attack by producing a protein known as a CD59-like 
protein, which has a homology with the human membrane-bound complement regulator 
CD59; this protein is able to interfere with the final stage of the MAC formation by 
preventing the polymerisation of C9, hence inhibits the cell lysis (Pausa et al., 2003).  
On the other hand, other bacteria can indirectly inhibit the activation of the terminal 
pathway by acquiring and exploiting its regulators. A number of pathogenic bacteria, 
have been reported to recruit and bind the fluid phase complement regulator vitronectin 
that inhibits the MAC formation, examples include: H. influenzae, Moraxella catarrhalis, 
Pseudomonas aeruginosa, S. aureus, Streptococcus pneumoniae, and S. pyogenes (Singh 
et al., 2010). 
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1.7.4 Modulating the anaphylatoxins, C3a and C5a 
C3a and C5a are the small fragments that are cleaved and released from both the 
components C3 and C5, respectively, upon activation. These molecules are 
anaphylatoxins that act as chemoattractants to mediate effector cell migration and 
activation thereby triggering an inflammatory response. C5a particularly is able to recruit 
neutrophils and macrophages to phagocyte opsonized foreign cells such as pathogens or 
apoptotic cells. C5a interacts with its receptor C5aR that is widely expressed on many 
host cells, including inflammatory cells such as neutrophils, resulting in their stimulation 
to release their metabolic granules which intensify the immune response. Besides their 
activity as chemoattractants, C3a and C5a also have reported to have direct antimicrobial 
activity (Gavrilyuk et al., 2005; Hugli, 1986). Microbial pathogens have also developed 
ways to inactivate these anaphylatoxins and avoid their action. For example, S. aureus 
produces protein called chemotaxis inhibitory protein of S. aureus (CHIPS) that was 
shown to interfere with C5a signalling to neutrophil and monocyte via binding to C5aR 
on the surfaces of these inflammatory cells thereby blocking C5a binding (de Haas et al., 
2004; Postma et al., 2004). 
 
1.8 The complement system and Ureaplasma  
The complement activity against U. parvum has previously been investigated (Beeton et 
al., 2012). In that comprehensive study, the authors have found that complement 
mediated killing of this cell wall-less bacteria occurs by the activation of the classical 
complement pathway, with no involvement of the alternative and lectin pathways. 
Furthermore, the results revealed significant variations in susceptibility to complement-
mediated killing among the investigated serovars and clinical isolates of U. parvum, as 
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some were highly sensitive to complement-mediated serum killing, even in the absence of 
detectable anti-Ureaplasma antibodies suggesting direct C1q binding to Ureaplasma 
membranes, while others were resistant. As mentioned above, bacterial resistance to 
complement mediated killing is not uncommon phenomenon among bacterial pathogens; 
as this phenotypic trait renders resistant strains more virulent and enables them to cause 
systematic infections compared with sensitive strains (McCabe et al., 1978; Porat et al., 
1987). While several mechanisms responsible for complement resistance among 
pathogenic bacteria have been defined, strategies used by Ureaplasma to elude the 
complement system and avoid clearance have yet to be elucidated.   
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1.9 Hypothesis 
Resistance to complement mediated killing of Ureaplasma is key to its pathogenic 
potential, and induced serum resistance of laboratory strains of Ureaplasma will result in 
identifiable phenotypic and genotypic alterations that can be correlated to pathogenicity 
in future studies. Transposon mutagenesis can be used as a tool to identify serum resistant 
genes through removing resistance by gene disruption or delivering resistance genes to 
susceptible strains under control of strong exogenous high-expression promoters.  
 
1.10 Aims 
The objectives of this research work were: 
 To examine the association between serum resistance and MBA type and MBA 
size in U. urealyticum. 
  To generate serum-resistant Ureaplasma strains, through repeated sublytic 
challenge with NHuS, and identify proteins that are induced or cease to be 
expressed coincident with induction of serum resistance.  
 To use proteomics to identify proteins with altered size or pI isoforms co-incident 
with induction of Ureaplasma serum resistance.  
 To develop successful transposon mutagenesis for Ureaplasma, and characterise 
disrupted genes in strains with altered complement susceptibility or any other 
alteration in phenotype. 
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 To utilise red fluorescent protein gene expression as a measurable delivered 
foreign gene to determine the optimal promoter, codon usage and copy number to 
facilitate future expression and testing of any identified serum resistance genes.  
 Achieving these goals will definitely enhance our understanding of immune-
escape mechanisms of Ureaplasma. In addition, identification of virulence factors 
that mediate Ureaplasma infection will be of a great importance as it will provide 
new insights towards developing novel vaccines and therapeutics. 
  
 
Chapter 2 
Materials and methods 
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2. Materials and Methods 
2.1 Ureaplasma spp. serovars and clinical isolates 
All of the original characterised prototype serovars for all known 14 serovars (Robertson 
and Stemke, 1982) and several clinical isolates from both groups of Ureaplasma spp. (U. 
parvum and U. urealyticum) were investigated in this thesis. Selection of some 
representative serovars or identified clinical isolates for some experiments was performed 
to determine variations between groups and among serovars from the same group. 
 
2.1.1 Source of Ureaplasma spp.  
Ureaplasma spp. serovars (SV) and clinical isolates were kindly provided by Dr. Victoria 
Chalker from the Health Protection Agency (HPA) (Colindale, London; now known as 
Health Protection England (HPE)). Hence, the prefix HPA represents samples obtained 
from that source. While the HPA provided all representative samples for each serovar, all 
reference strains were originally received from either the Institute of Medical 
Microbiology, University of Aarhus, Denmark or Prof. Janet Robertson (University of 
Calgary, Canada).  All isolates were frozen and stored as stocks at -80 ˚C in my host 
laboratory.  U. parvum was represented by serovars 1, 3, 6 and 14, and U. urealyticum by 
serovars 2, 4, 5, 7, 8, 9, 10, 11, 12, and 13. In addition, several clinical U. urealyticum 
isolates were also provided by the HPA. During the tenure of this studentship, weekly 
samples were also received (following appropriate consent by collecting physician) from 
Dr. Nicola Maxwell at Deriford Hospital in Plymouth U.K.  Samples were anonymised 
and coded sequentially from 101, where each subsequent sample was given a sequential 
letter (i.e. sample Ply144C, corresponds to the 44
th
 recruited preterm neonate from 
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Plymouth and this sample represents the 3
rd
 consecutive collected sample from that 
baby). The results of these samples were not fed back to the collecting Neonatal Intensive 
Care Unit until the breaking of the codes for retrospective analysis.  In contrast, samples 
submitted to the laboratory from the University Hospital of Wales (UHW) NICU (7 in 
total) were positive samples submitted for diagnostic evaluation and were anonymised 
prior to being given to me.  A series of U. urealyticum clinical isolates from Prof. Cecile 
Bebear (University of Bordeaux, France) were also provided and include samples (UUf1 
& UUg1) that were from sexual partners (Beeton et al., 2009a). A list of isolates used in 
this study is presented in Table (2.1). 
 
Table 2.1 Ureaplasma serovars and clinical isolates used in this study 
Isolate Species Serovar 
DKF-1 Ureaplasma parvum SV1 
HPA5 Ureaplasma parvum SV3 
HPA2 Ureaplasma parvum SV6 
HPA32 Ureaplasma parvum SV14 
M0063/92 (T23) Ureaplasma urealyticum SV2 
M0089/92 (DFK-4) Ureaplasma urealyticum SV4 
SV5 (Western) Ureaplasma urealyticum SV5 
SV7 (KDF-7) Ureaplasma urealyticum SV7 
SV8 / T960 (CX8) Ureaplasma urealyticum SV8 
SV9 (Vancouver strain) Ureaplasma urealyticum SV9 
SV10 (Western) Ureaplasma urealyticum SV10 
Continued  
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Table 2.1 (continued)  
SV11 (K2) Ureaplasma urealyticum SV11 
SV12 (U24) Ureaplasma urealyticum SV12 
SV13 (U38) Ureaplasma urealyticum SV13 
HPA3 Ureaplasma urealyticum SV9/SV7/SV11 
I 
HPA4 Ureaplasma urealyticum SV4/SV12/SV13 
I 
HPA6 Ureaplasma urealyticum SV4/SV12/SV13
 I
 
HPA7 Ureaplasma parvum SV3 
HPA8 Ureaplasma parvum SV3 
HPA9 Ureaplasma parvum SV3 
HPA12 Ureaplasma urealyticum SV4/SV12/SV13
 I
 
HPA17 Ureaplasma urealyticum SV2/SV12
 I
 
HPA20 Ureaplasma urealyticum SV4/SV12/SV13
 I
 
HPA24 Ureaplasma urealyticum SV10
 I
 
HPA31 Ureaplasma urealyticum SV10
 I
 
HPA43 Ureaplasma urealyticum SV9
 I
 
HPA44 Ureaplasma urealyticum SV10
 I
 
HPA56 Ureaplasma parvum SV3 
HPA57 Ureaplasma parvum SV3 
HPA60 Ureaplasma parvum SV3 
HPA78 Ureaplasma parvum SV1 
W11 Ureaplasma urealyticum SV12
 I
 
U6 Ureaplasma parvum SV3 
UHW5 Ureaplasma parvum SV3 
UHW6 Ureaplasma parvum SV3 
I
 U. urealyticum clinical isolates identified and assigned in this study, HPA: isolates obtained from the 
Health Protection Agency (now known as Health Protection England, HPE); UHW: isolates obtained from 
the University Hospital of Wales.  
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2.1.2 Culturing of Ureaplasma spp. 
Ureaplasma spp., either from clinical samples or frozen stocks, was cultured in 
Ureaplasma Selective Medium (USM), unless stated otherwise. This medium was 
purchased from Mycoplasma Experience Ltd, Surrey, UK. While the exact formula is 
proprietary, the medium is thought to consist of a simple broth base medium 
supplemented with yeast extract 2.5 g/L, Urea   1 g/L , and 10% heat-inactivated porcine 
serum, with a pH indicator (phenol red), medium pH= 6.65, and 2.5 µg/ml Amphotericin 
B and 0.25 mg/ml Ampicillin. Cultures were done in flat-bottom 96-well plates and 
sealed with adhesive sealing tape (Elkay, Basingstoke) and incubated in a humidified 
tissue culture incubator set at 37 °C with atmospheric CO2 concentration.  
Culturing of Ureaplasma spp. on USM-Agar medium (Mycoplasma Experience Ltd, 
Surrey, UK) was done by inoculating and spreading 1 µl of Ureaplasma growth (~10
4
-
10
5
 CCU) in USM on the agar surface. The plates were incubated at 37 °C with 
atmospheric CO2 concentration for 24-48 h. Colonies were viewed under X4 and X10 
objective microscope lenses (Eclipse TS100 Inverted Routine Microscope, Nikon 
Instruments Europe B.V., UK). While colonies were viewed under the microscope, 
picking single colonies was also performed using sterile disposable loops. Single colonies 
were then transferred and inoculated into USM medium, where they were titrated out 
(1:10) and incubated as previously mentioned.  
 
2.1.2.1 Culturing Ureaplasma spp. from clinical samples and frozen stocks 
All clinical samples collected from Plymouth or Cardiff patients arrived at the laboratory 
as endotracheal aspirate samples. Upon receiving a sample, it was homogenised with a 1 
ml sterile pipette tip, and then 20 µl cultured by titration (1:10) in USM in a single 
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column (8 wells) of flat-bottom 96-well plate: 20 µl of well-mix sample was taken and 
inoculated in 180 µl USM in the first well and then serially diluted to 10
7
 (7
th
 well) in 
USM, and last well (8
th
 well) was left uninoculated as a negative control.  Each sample 
was cultured in triplicate. Plates were sealed with air tight clear adhesive seals. Cultures 
were then incubated at 37°C for 24 h.  Plates negative at 24h were re-examined at 48h to 
confirm the negative result. Positive cultures were indicated as a change in the colour of 
USM from yellow to red as the sole carbon source for Ureaplasma is urea which is 
converted to ammonium ions increasing the pH of the medium to >10. Ureaplasma 
isolates from positive cultures were collected and frozen as 20 µl stock aliquots at -80 °C 
until needed. When Ureaplasma clinical isolates were needed for an experiment, a 20 µl 
frozen aliquot was thawed on ice and then cultured by titration (1:10) in USM, as 
previously stated. This method usually provides a bacterial growth of about 10
4
- 10
5
 
CCU/ml after 24 h incubation. If a poor growth was obtained, i.e. < 10
4 
CCU, re-
subculture was done by diluting the final well that was starting to show colour change by 
1:10 serial dilution into USM to provide adequate growth for an experiment. Samples 
were subsequently prepared by a method according to whether they were to be used in 
complement studies, proteomic studies or genomic and transformation studies. 
 
2.1.2.2 Quantification of Ureaplasma spp. growth 
The standard unit used to quantify Ureaplasma numbers in broth media is colour 
changing units (CCU). To estimate the number of CCU of Ureaplasma in a sample or 
culture, the sample has to be serially diluted 1:10, as mentioned above: 180 µl of USM 
was added to each well of a single column (8 wells) of a 96 well plate. Then 20 µl of 
sample was inoculated into the first well to give an initial 1:10 dilution, and then from the 
initial inoculum the sample was serially diluted down to 10
7
, with the last well remained 
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as a negative control. After incubation for 48 h., plates were checked for colour change, 
and the last red well was designated as 1 CCU, which, in theory, contained between 1-9 
viable organisms and is, therefore, directly related to a Colony Forming Unit (CFU) (the 
standard unit used to quantify the number of other kind of bacteria) if it had been cultured 
on an agar plate. Therefore, the number of CCU of Ureaplasma in original sample can be 
calculated.  
 
2.2 Complement studies 
2.2.1 Serum source and preparation  
The human sera used in the complement studies were collected from healthy volunteers. 
The Normal human serum (NHuS) was collected from volunteer healthy females 
(designated ‘Vx’ for volunteer then ‘F’ followed by the number collected; therefore VxF4 
is the fourth female volunteer) and males (VxM#). NHuS was collected from previously 
characterised volunteers (Beeton et al., 2012) where presence or absence of anti-
Ureaplasma IgG antibodies had been determined using western blot probing of prototype 
strains. Seropositive sera yielded specific immunoreactive bands whereas seronegative 
sera did not show immunoreactive bands.  Blood from both sources was collected into 20 
ml glass universal bottles and allowed to coagulate at room temperature for 1 h. Then the 
clot was released from the wall of the bottle and re-incubated again on ice for another an 
hour to allow the clot to contract further.  The bottles were then centrifuged at 1000 x g 
for 10 min. The clear yellow supernatant (serum) was carefully transferred to clean 
universal bottles and aseptically dispensed in 400 µl aliquots in sterile microcentrifuge 
tubes and stored at – 80 °C until needed.  
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To prepare heat-inactivated serum (HI-NHuS), serum aliquots were incubated at 56°C for 
30 min. This heat treatment inactivates C2 of the complement system, which is required 
for both the classical and lectin pathways, and inactivates factor B that is required for the 
alternative pathway.  Sera was diluted to 50% (heat-inactivated or normal) for 
complement studies by mixing with an equal volume (1:1 v/v) of sterile veronal buffered 
saline, VBS, commercially available as Complement Fixation Buffer (Oxoid plc, 
Basingstoke, UK). 
 
2.2.2 Complement killing assay 
Complement killing assay was done according to the protocol described by Beeton et al. 
(2012). Log-phase growth Ureaplasma cultures were prepared as stated above (section 
2.1.2.1). 200 µl of bacterial growth was transferred, in duplicate, into the wells of a V-
bottom 96-well plate, the plate was sealed with clear adhesive film and centrifuged at 
3600 g for 10 min, and the supernatant then carefully removed by pipetting. One of each 
matching pair of bacterial pellets was re-suspended in 200 l of 50% NHuS diluted in 
VBS, and the other was re-suspended in a 50% heat-inactivated matched serum control 
(HI-NHuS), which was run in parallel as a direct comparison for later calculation and 
interpretation of killing. Plates then were incubated at 37° C for 1 hour, prior to 
centrifugation as above and removal of diluted serum. Pellets were then re-suspended in 
200 l USM and transferred to a flat-bottom 96-well plate. Surviving bacteria was 
quantified by titration in USM: both the test (NHuS exposed) and control (HI-NHuS 
exposed) were titrated out in 1:10 for 3 dilutions (1000-fold) and then 1:2 for 8 dilutions; 
this provided a dilution gradient to 2.56 x 10
5
. Plates were sealed and surviving bacteria 
were measured after 48 hour incubation at 37°C to enable maximum growth. Killing was 
determined as the relative decrease in bacterial titre relative to incubation with heat-
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inactivated serum (56°C, 30 min) as a control (Figure 2.1). All killing assays were 
performed in triplicate and repeated on at least three separate days with a range of 
characterised seropositive and seronegative human sera.  
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Figure 2.1 Schematic diagrams of the 96-well plate set up of complement killing assay.  
Four representative Ureaplasma isolates (A - D) were incubated under two conditions: 
50% heat inactivated normal human serum (HI-NHuS) and 50% normal human serum 
(NHuS).  Following complement attack Ureaplasma cells were titrated out as set out in 
the plate, initially 1:10 dilutions followed by 1:1 dilutions, to determine the fold reduction 
of colour changing units between HI-NHuS and NHuS (Plates I&II).  
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2.2.3 Complement-induced resistance assay 
The complement killing assay was performed as above, but with a sublytic dilution of 
NHuS serum (although often the first 1-2 wells show survival following challenge with 
seropositive serum) and the surviving bacteria is used as the source for the subsequent 
serial challenge. In the primary challenge, Ureaplasma was incubated with 200l of 50%, 
25%, 12.5% or 6.25% NHuS (seropositive or seronegative) diluted in sterile VBS at 37° 
C for 1 h, and along the side, the tested cells were also incubated with the same dilutions 
of the matched HI-NHuS in a similar way as previously described in the complement 
killing assay. Surviving Ureaplasma from the highest concentration of serum (even if 
only the first well) was used at 24 h post-challenge (to ensure log-phase growth of 
bacteria for the subsequent challenge).  The plates were then further incubated for 48 h to 
allow the assay to completely develop prior to recording killing results for each assay, 
however. The sublytic challenge process was repeated until a serum resistant strain 
emerged, generally requiring 5-6 serial challenges. After each challenge, 20 l of the 
surviving bacteria were collected and frozen at -80° C for further investigations. 
Confirmation of induced serum resistance was done by performing complement killing 
assay, in triplicates, on all serum-induced resistant strain compared to the sensitive parent 
strain. The serum-induced strains were stored as 20l aliquots at -80° C till needed for an 
experiment.  
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2.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
2.3.1 Sample preparation  
Ureaplasma total cell protein samples were prepared by centrifuging a scaled up 5 ml 
culture of bacterial growth (usually allowed to incubate for 48 h at 37
o
C before harvest) 
at 16000 x g for 10 min in a refrigerated bench top microfuge. The supernatant was 
discarded and the remaining bacterial pellet was washed three times in 1X sterile 
phosphate buffered saline, PBS (160 mM NaCl, 3 mM KCl, 8 mM Na2HPO4, and 1 mM 
K2HPO4, pH 7.4). The washed pellets were then re-suspended in 25 l 1X PBS and 25 l 
lithium dodecyl sulphate (LDS) sample loading buffer (Invitrogen, Paisley, UK). Samples 
were then heated at 95 ºC for 10 min to solubilise whole cell proteins and stored at -20° C 
till needed. For Western blot analysis, 7-10 l of each sample was resolved on by SDS-
PAGE.  
2.3.2 Gel preparation  
A gel casting system, Mini-PROTEAN 3 cell, was assembled as described by the 
manufacturer (Bio-Rad, Hertfordshire, UK). Separating (Resolving) gel was prepared 
according to the percentage of gel desired for depending on the mass of the proteins to be 
resolved.  As indicated in table 2.1.; in this study, both 7.5 % and 12.5% polyacrylamide 
gels were used. After the resolving gel set, stacking gel (4%) was prepared as shown in 
Table 2.2 and poured on top, and a gel comb was inserted.  
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Table 2.2 Ingredients required for preparing resolving and stacking gels 
 Stacking gel 4%  Resolving gel 7.5% 12.5% 
40% bis/acrylamide  1.012 ml  40% acrylamide  1.93 ml 3 ml 
dH2O 6.4 ml dH2O 5.470 ml 4.3 ml 
Upper buffer
* 
2.4 ml  Lower bufferˠ 2.5 ml 2.5 ml 
10% APS w/v 100 l  10% APS w/v 100 l 100 l 
TEMED 40l  TEMED 10 l 10 l 
Total volume 9.9 ml    Total volume 10 ml 10 ml 
* Upper buffer: 0.5M tris-HCl (pH 6.8), and 0.4% SDS,; ˠ Lower buffer: 1.5M tris-HCl (pH 8.8), 
and 0.4% SDS. 
 
2.3.3 Sample loading and electrophoresis 
For Western blot analysis, 5 l of MagicMark™ XP Western Protein Standard 
(Invitrogen, Paisley) and EZ-Run PreStained Rec Protein Ladder (Invitrogen, Paisley) 
was loaded on each gel. Proteins were resolved using 1x running buffer (25 mM Tris, 192 
mM glycine and 0.1% SDS at pH 8.3) at constant 150 V and approximately 120 mA for 
about 1 hour or until the dye front reached the bottom of the gel. Following gel 
electrophoresis, gels with separated proteins were processed according to next 
experiment, i.e. Western blot analysis or protein gel staining with dyes. 
 
2.4 Western blotting 
Following separation by electrophoresis, proteins were transferred from gels to 0.22 m 
nitrocellulose membranes using the Mini Trans-Blot® Electrophoretic Transfer Cell 
system, according to the manufacturer guidelines (Bio-Rad, Hertfordshire, UK). Gels, 
nitrocellulose membranes, sponge pads, and filter papers were initially submerged in 1X 
transfer buffer (14.4 g/L glycine, 3.03 g/L Tris base, 20 % methanol) and then arranged 
into transfer cassettes (gel sandwich) as recommended by the manufacturer. Gel sandwich 
was then assembled in the transfer tank, which was filled with transfer buffer. A cooling 
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unit (an ice pack) to keep the transfer buffer cool and a magnetic stir bar to circulate 
buffer were also added into the tank. Transfers were run at 100 V constant for 1 hour.  
After the electrophoretic transfer, the nitrocellulose membranes containing transferred 
proteins (the blots) were placed within a 50 ml falcon tube (Elkay, Basingstoke) and 
blocked for 1 hour with 25 ml blocking buffer (5% w/v non-fat milk in 1% PBS with 
0.05% Tween-20, PBST) on a roller.  Membranes were firstly probed with primary 
antibodies or NHuS diluted in blocking buffer, as shown in Table 2.3, overnight. 
Membranes were then washed in 1% PBST for 10 min (three times) followed by wash in 
1% PBS for 10 min (two times).  To detect the probing primary antibodies, blots were 
probed with an appropriate peroxidise-conjugated secondary antibody diluted in blocking 
buffer for 1 h (Table 2.3). Membranes were again washed three times in PBST and 
subsequently two times in PBS before detected with Pierce® ECL Western Blotting 
Substrate (Thermo scientific, Loughborough). The immunoreactions were visualised on 
FUJI Super RX X-ray films (Fujifilm, Tokyo, Japan), and immunoreactive bands on X-
ray films were then scanned and images were stored as TIFF files. 
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Table 2.3 Human sera and primary and secondary antibodies used in this study 
Serum or Primary 
Antibody   
Dilution Source Secondary Antibody Dilution Source 
NHuS  
(VxF1, F7, F9, M11, M12& 
M18) 
 
1:400 Normal Human 
Volunteers 
(Beeton et al., 
2012) 
Peroxidase-conjugated affiniPure F 
(ab) Fragment Donkey Anti-Human 
IgG (H+L) 
1:10000 Jackson 
ImmunoResearch 
Anti-mCherry polyclonal 
antibody 
1:1000 BioVision Peroxidase-conjugated AffiniPure 
Donkey Anti-Rabbit  IgG (H+L) 
1:10000 Jackson 
ImmunoResearch 
Anti-elongation factor Tu 
(EF-Tu) monoclonal 
antibody 
1:100 
(2DE=1:400) 
 
Hycult biotech Peroxidase-conjugated AffiniPure 
Goat Anti-Mouse IgG (H+L) 
1:10000 Jackson 
ImmunoResearch 
Anti-His tag 1:5000 BioLegend Peroxidase-conjugated AffiniPure 
Goat Anti-Mouse IgG (H+L) 
1:10000 Jackson 
ImmunoResearch 
Anti-MBA monoclonal 
antibodies 
1:1000  (Watson et al., 
1990) 
 
Peroxidase-conjugated AffiniPure 
Goat Anti-Mouse IgG (H+L) 
1:10000 Jackson 
ImmunoResearch 
Anti-UU280 polyclonal 
antibody 
1:200 This study 
(Genosphere-
Biotech, Paris, 
France) 
Peroxidase-conjugated AffiniPure 
Donkey Anti-Rabbit  IgG (H+L) 
1:10000 Jackson 
ImmunoResearch 
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 Table 2.4 Monoclonal anti-MBA antibodies used in this study 
 
Antibody Ureaplasma serovar  Reference or Source 
MAb 10C6.6 SV3  (Watson et al., 1990) 
MAb 8A1.2 SV10  “ 
MAb 5B1.1 SVs 3&14 “ 
2G9 SVs 1 & 6 “ 
6522 All Ureaplasma spp. SVs Virostat plc (Portland, ME) 
6523 SV3 & 14 “ 
6525 All Ureaplasma parvum “ 
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2.5 Proteomic studies  
The proteomic workflow used was as follows: Ureaplasma cell pellets were subjected to 
SDS protein extraction followed by protein assay, proteins separation by electrophoresis 
(2-D electrophoresis and/or 1-D electrophoresis), Colloidal Coomassie blue staining, spot 
picking, trypsin digestion and tandem mass spectrometry (MS/MS) analysis, a service 
provided by Cardiff University Central Biotechnology Services (CBS). In some 
occasions, two identical electrophoresis gels were prepared, one was stained with 
Colloidal Coomassie blue and the other was investigated by western blotting analysis to 
identify particular proteins to be picked from the other gel, which was stained with 
Colloidal Coomassie blue stain. 
 
2.5.1 Preparation of 10B Urea Broth (Shepard’s media) 
Urea broth medium was used to scale-up the growth of Ureaplasma to 100 ml cultures.  
One litre stocks were prepared by adding 14g of Mycoplasma broth base without crystal 
violet, pH 7.8: beef heart, infusion 6 g, peptone 10 g, sodium chloride 5 g  (Becton, 
Dickinson, France), 1 ml of 1% phenol red  and 0.2g herring sperm DNA (Sigma, UK) to 
688ml distilled water. Following adjustment of the pH to 5.5 with 2 N HCL, the media 
was autoclaved for 15 min at 121 °C; The following heat-labile supplements were then 
prepared and filter sterilised separately and added to the autoclaved base after cooling: 
200 ml of horse serum, 4 ml of 10% urea (Sigma, UK), 2.5 of 4% L-cysteine (prepared 
fresh on day of use), 100 ml of 25% yeast extract (Fisher-Scientific, UK), 5 ml of BD 
BBL
TM
  IsoVitaleX  Enrichment (Becton, Dickinson, France), 1 ml ampicillin (100 
mg/ml) (Sigma, UK), and 10 ml amphotericin B (250 µg/ml) ( Sigma, UK). The pH of 
media was adjusted again to 6.0 with 2 N HCL and then stored at 4 °C until needed.  
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2.5.2 Growing Ureaplasma spp. in 10B urea broth (scale up) 
Ureaplasma isolates were initially cultured by titration in USM (two columns of 8 wells) 
as described above; the last four wells that showed growth (colour change) after 24 h 
incubation were pooled together and directly transferred to 250 ml of media. The 
inoculated media was incubated at 37 °C for 48 h. After maximum colour change in the 
bottles, the bacterial growth was then pelleted at 10,000 xg for 30 min. The supernatant 
removed and the pellet was washed with 1X sterile PBS and centrifuged at 10,000 xg for 
10 min (washing was repeated 3 times). After washing, the bacterial pellet was ready for 
protein extraction and sample preparation for proteomic studies. This amount of growth 
was optimised to give a sufficient amount of protein from Ureaplasma cells for 
proteomic studies. 
 
2.5.3 Protein extraction  
Protein extraction was done using the cell lysis buffer (1% (w/v) SDS in Tri-ethyl 
ammonium Bicarbonate (TEAB)). The bacterial cell pellets were re-suspended in 100µl 
1% (w/v) SDS and incubating for 30 min at room temperature. The mixture was then 
boiled for 10 min and centrifuged at 13,000 rpm (15890 x g) for 5 min at 4 ˚C to clarify. 
The clear supernatant containing fully solubilised protein was removed, and protein 
concentration was quantified using the bicinchoninic acid (BCA) protein assay kit 
(Sigma-Aldrich, UK). 
 
2.5.4 Quantification of protein using BCA assay  
Quantification of protein concentration was done using the BCA assay or the Smith assay 
(Smith et al., 1985). The assay was performed in a 96-well plate and a standard curve 
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using a dilution series of bovine serum albumin, BSA (1 mg/ml) (Sigma) was used. 
Dilutions of BSA were prepared in plate column 12 using 200 µl of BSA solution in well 
H12 and 100 µl of distilled water in wells B12 to G12. 100 µl of solution from H12 was 
added to G12 and mixed, and then 100 µl was taken from G12 to F12 and so on until B-
12 (i.e. two-fold dilution series). A12 was left blank. From each diluted standard, 25 µl 
was taken and put in corresponding wells 1, 2, 3 of same row (triplicate); this comprised 
the standard curve. 25 µl of each test sample for protein quantification was added in 
duplicate in columns 4 and 5. BSA working reagent was prepared by mixing 5 ml reagent 
A and 100 µl reagent B. 200 µl of dilute BSA working reagent was added to each well 
(Figure 2.2). The plate was then covered with clear adhesive sealing film and incubated 
for 30 min. at 37º C. After colour was developed, the readings were then taken on a 
Dynex MRX TC Revelation 96-well microplate reader (Dynex Technologies, Chantilly, 
VA) at 570 nm. If any sample readings were out of range, it was diluted and repeated 
again. The protein concentration of samples was calculated using MRX software intrinsic 
to the plate reader.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Schematic diagram of a 96-well plate illustrating the BCA protein assay 
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2.5.6 One Dimensional Electrophoresis (1-DE) 
One dimensional electrophoresis was run using the XCell SureLock
™
 mini-cell 
electrophoresis system (Novex
® 
Life technology). The electrophoresis unit was 
assembled as described by the manufacturer. Sample preparation was also done according 
the gel manufacturer recommendations (Invitrogen) (Table 2.5).  
 
     Table 2.5 Sample preparation for 1-DE (Mini Gels) 
Reagent Reduced Sample Non-reduced sample 
Sample x µl x µl 
NuPAGE LDS sample buffer (4X) 2.5 µl 2.5 µl 
NuPAGE Reducing Agent 1 µl _ 
Deionized water To 6.5 µl To 7.5 µl 
Total volume 10 µl 10 µl 
      Samples were heated at 70º C for 10 min before loading. 
 
Gel cassettes were prepared by removing the NuPAGE gel from the pouch and rinsing in 
deionized water. The tape from the bottom of the cassette was then peeled off and the 
comb was gently removed, in one smooth motion, from the cassette. The sample wells 
were then rinsed with 1X NuPAGE SDS running buffer, 3-(N-morpholino) 
propanesulfonic acid (MOBS), and then inverted to remove the buffer.   The two cassette 
gels were assembled in the XCell SureLock mini cell tank such that the notched well side 
of the cassette faced inwards toward the buffer core. In case of using one cassette gel, a 
buffer dam was used to occupy the other place of the second cassette gel.  10 µl of each 
sample (15 µg protein) and 15 µl of unstained marker (Mark 12™ unstained standard, 
Invitrogen) were then loaded into the gel wells. Proteins were separated at 200V (120 
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mA, 25.0 W) for about 55 min or until the dye front reached the ridge at the bottom of the 
gel. Gels were then processed for Colloidal Coomassie blue staining or western blotting.   
 
2.5.7 Two-dimensional electrophoresis (2-DE) 
Two-dimensional electrophoresis of proteins was developed in 1975 as a powerful 
technique for separating proteins based on two parameters: isoelectric point and 
molecular weight (O'Farrell, 1975). This method has been widely used in proteomics. 
 
2.5.7.1 Protein precipitation using the 2D Clean-Up kit 
Before separating proteins by 2-DE, protein samples were subjected to protein 
precipitation and clean-up process using a 2D Clean-up kit as described by the 
manufacturer (GE Healthcare, Amersham, UK). This process removed contaminating 
substances such as excess salts, charged detergent, lipids, phenolics, and nucleic acids 
from proteins, which may interfere with isoelectric focusing (IEF) and mass 
spectrophotometry (MS) analysis. In this procedure, 65 µg (1-100 µl) of whole cell 
protein sample was transferred to a 1.5 ml microcentrifuge tube, and then 300 µl of 
precipitant (a solution that renders proteins insoluble) was added and briefly vortex 
mixed. The tube was centrifuged at 12000 xg for 5 min and supernatant was discarded. 
Centrifugation was repeated again to bring any remaining supernatant to the bottom of 
tube, and the supernatant was then carefully aspirated from the sample using 
micropipette. Without disturbing the pellet, 40 µl of co-precipitant (a solution contains 
reagents that co-precipitate with proteins and enhances their removal from solution) was 
added on top of the pellet and the tube was incubated on ice for 5 min. Another 
centrifugation at 12000 xg for 5 min was performed and any remaining supernatant 
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removed and discarded.  25 µl of deionised water was added to the pellet and mixed by 
vortex for 5-10 sec to disperse the pellet, but not to dissolve it. 1 ml of chilled wash 
buffer (a solution that is used to remove non-protein contaminants from the protein 
precipitate) (kept at -20º C) and 5 µl of wash additive (this solution contains a reagent 
that promotes rapid and complete re-suspension of the sample proteins) was then added 
and the tube was incubated in -20º C freezer for 30 min with brief vortex mix for 20-30 
sec every 10 min. The tube was spun at 12000 xg for 5 min and the supernatant was 
removed and discarded. Pellet was allowed to dry for no more than 5 min. The cleaned-
up protein pellet was then re-suspended in 116 µl of the rehydration/ lysis buffer (7 M 
Urea, 2M Thiourea, 2% CHAPS) as described below in the isoelectric focusing (IEF).  
 
2.5.7.3 Isoelectric Focusing (IEF) 
The first step in 2DE is the IEF, in which proteins are first separated by their pI and then 
further separated according to molecular weight through SDS-PAGE. The principle of the 
method was according to that described by (Mathew et al., 1975). IEF (the first 
dimension) was performed using isoelectric focussing strip (IPG), a 7 cm Immobiline 
Drystrip pH 3-10 NL (nonlinear) (GE Healthcare, Amersham, UK). 116 µl of protein 
sample prepared in the rehydration buffer was transferred into a 1.5 ml microcentrifuge 
tube and 1 µl of 1% Bromophenol Blue, 2 µl of Isoelectric focussing buffer (IPG buffer) 
(GE Healthcare, Amersham, UK) and 6.25 µl of 50 mM Dithiothreitol (DTT) were 
added. The total volume sample mixture was adjusted to be 125 µl using the rehydration 
buffer and all the sample was carefully pipetted into the strip holder (coffin) and 
distributed evenly over the 7 cm well.  Using tweezers, to hold the anode (+ ve) end of 
the IPG strip, the cover foil was pulled starting from the anode side of the IPG strip. The 
strip was then layered (the anode end of the strip towards the pointed end of the strip 
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holder, gel side down, avoiding bubble formation) on the sample-rehydration solution 
carefully to avoid getting any of the solution on top of the strip. A note of the strip 
number was taken for each specific sample. The sample and IPG strip was covered with 
0.5 ml of DryStrip cover fluid and then placed on an isoelectric focusing unit (IPGphor 
Isoelectric Focusing System, GE Healthcare, Amersham, UK) for first dimension 
electrophoresis. The system was switched on and set on protocol for a mini gel (7 cm) 
and the number of strips was altered accordingly. The protocol settings were as follows:  
Rehydration: 12 hours at 20º C and IEF parameters: 50 µA/strip, 20º C (Step 1: step and 
hold 500 V 1 hour; Step 2: Gradient 1000 V 2 hours; Step 3: step and hold 1000 V 1 
hour; Step 4: Gradient 8000 V 2 hours; Step 5: Step and hold 8000 V 8 hours). After 
inputting the conditions, the IEF was allowed to run to completion (total running time 26 
hours). When IEF was completed, the strips were taken from the coffin, and the strip was 
gently placed sideways on tissue to blot off excess liquid. Care was taken to avoid 
damaging the gel side of the strip. The IPG strips were then subjected to an equilibration 
process.   Each strip was first put in a 15 ml Falcon tube containing 5 ml of reducing 
solution (0.5 ml of 10X NuPAGE Sample Reducing agent (Invitrogen) and 4.5 ml of 1X 
NuPAGE LDS sample buffer (Invitrogen)), with the gel side of the strip up, and 
incubated for 15 min. on a rocker. The reducing solution was then decanted and the strip 
was carefully taken from the tube, using tweezers, and any excess liquid was removed by 
blotting. The strip was then transferred into another 15 ml Falcon tube containing 5 ml 
alkylating solution (116 mg of iodoacetamide in 5 ml of 1X NuPAGE LDS sample 
buffer) and incubated for 15 min on a rocker. In parallel, SDS-PAGE running buffer (1X 
MOPS: 40 ml 20X MOPS and 760 ml deionised water) was prepared.  
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2.5.7.4 Second dimension electrophoresis  
Second dimension electrophoresis was run using the XCell SureLock
™
 mini cell 
electrophoresis system according to manufacturer instructions as described in section 
2.5.6. The NuPAGE 4-12 Bis-Tris Zoom Gel (1 mm x IPG well) was removed from the 
pouch and the gel cassette was rinsed with deionised water.  Tape was removed from the 
bottom of the cassette and the comb removed from the cassette and sample wells were 
rinsed with 1X NuPAGE SDS running buffer. The cassette gels were assembled in the 
XCell SureLock mini cell tank and 1X MOBS running buffer added until the level of 
buffer reached above the strip and marker wells. The IPG strip was then taken carefully 
from the alkylating solution and blotted gently. The ends of the strip that have no gel 
were removed; the IPG strip was then transferred to the IPG well of NuPAGE 4-12% Bis-
Tris Zoom gel with the +ve end placed on the left next to the marker well containing 5 µl 
of unstained marker (Mark 12™ unstained standard, Invitrogen) (for western blot 3 µl of 
1:1 v/v mixture of Magic and pre-stained markers used). SDS-PAGE was then run at 
200V (120 mA, 25.0 W) for about 50 min. or until the dye front reached the ridge at the 
bottom of the gel. Gels were removed from the gel cassettes as described in 1-DE and 
processed according to the next experiment, i.e. Colloidal Coomassie blue staining or 
western blotting.  
 
2.5.8 Colloidal Coomassie blue staining 
Proteins in polyacrylamide gels were stained using Colloidal Coomassie blue stain kit 
according to manufacturer guidance (Invitrogen, UK). The staining method of this kit is 
based on the modified and enhanced protocol by (Neuhoff et al., 1985). Staining was 
done manually and solutions were prepared based on the number of gels to be stained 
(e.g. for one gel: the fixing solution was prepared by mixing 40 ml deionised water, 50 ml 
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methanol, and 10 ml acetic acid; and the staining solution was prepared by mixing 55 ml 
deionised, 20 ml methanol, 20 ml stainer A, and 5 ml of stainer B that was added in the 
second step of staining). After the end of electrophoresis, gels (7.5% SDS gels, NuPAGE 
Novex 4-12% Bis-Tris mini gels, or NuPAGE 4-12% Bis-Tris Zoom mini gels) were 
transfer to a weighing boat and soaked in the fixing solution for 10 min. at room 
temperature.  The fixing solution was then removed and the staining solution without 
stainer B was added on top of gels. Gels were soaked in this solution for 10 min at room 
temperature before adding stainer B to the existing staining solution. Gels were soaked in 
the staining solution with stainer B for about 12 h at room temperature. The staining 
solution was then decanted and replaced with 200 ml deionised water per gel. The gels 
were left to gently rock in water for at least 7 h until gels had a clear background. Gels 
were then scanned using an Image Scanner with MagicScan software (Amersham 
Biosciences) to record electronic image. The stained gels were stored submerged in 1% 
acetic acid (or 20% ammonium sulphate solution for long storage) at 4º C till needed for 
spot picking. 
 
2.5.9 Gel-based protein identification 
Gel-based protein identification was done by Cardiff University Central Biotechnology 
Services (CBS). After separating proteins by electrophoresis and staining with Colloidal 
Coomassie blue stain, gel plugs (1.5 mm diameter) were manually excised and placed in a 
96-well plate. Peptides were then recovered following trypsin digestion using a slightly 
modified version of the (Shevchenko et al., 1996) method. Sequencing grade modified 
trypsin (Promega, UK ) was used at 6.25 ng/l in 25 mM NH4HCO3 and incubated at 37º 
C for 3 hours. Finally the dried peptides were re-suspended in 50% (v/v) acetonitrile in 
0.1% (v/v) trifluoroacetic acid (TFA; 5l) for mass spectrometry (MS) analysis. An 
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aliquot corresponding to 10% of the material (0.5l) was spotted onto a 384-well MS 
plate. The samples were then allowed to dry and then overlaid with -cyano-4-
hydroxycinnamic acid (CHCA, Sigma, Dorset, UK); 0.5 l prepared by mixing 5 mg 
matrix with 1 ml of 50% (v/v) acetonitrile in 0.1% (v/v) TFA).  
 
Mass spectrometry was performed using a matrix- assisted laser desorption ionization 
time-of-flight (MALDI TOF/TOF) mass spectrometer (Applied Biosystems 4800 
MALDI TOF/TOF Analyzer; Foster City, CA, USA) with a 200 Hz solid state laser 
operating at a wavelength of 355nm (Bienvenut et al., 2002; Brennan et al., 2009; 
Gluckmann et al., 2007; Medzihradszky et al., 2000). MALDI mass spectra and 
subsequent MS/MS spectra of the 8 most abundant MALDI peaks were obtained 
following routine calibration. Common trypsin autolysis peaks and matrix ion signals and 
precursors within 300 resolution of each other were excluded from the selection and the 
peaks were analyzed with the strongest peak first. For positive-ion reflector mode spectra 
800 laser shots were averaged (mass range 700-4000 Da; focus mass 2000). In MS/MS 
positive ion mode 4000 spectra were averaged with 1 kV collision energy (collision gas 
was air at a pressure of 1.6 x 10-6 Torr) and default calibration.  
Combined protein mass fingerprint (PMF) and tandem mass spectrometry (MS/MS) 
queries were performed using the MASCOT Database search engine v2.1 (Matrix 
Science Ltd, London, UK) (Perkins et al., 1999) embedded into Global Proteome Server 
(GPS) Explorer software v3.6 (Applied Biosystems) on the Swiss-Prot database 
(download date 01/08/2008), and the secured database for Ureaplasma spp. from The J. 
Craig Venter Institute (JCVI), USA. Searches were restricted to the Ureaplasma spp.: U. 
parvum serovar 3 (strain ATCC 2715/ 27/ NCTC 11736), U. parvum serovar 1 (strain 
ATCC 27813) and U. parvum serovar 6 (strain ATCC 27818) taxonomy with trypsin 
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specificity (one missed cleavage allowed), the tolerances set for peptide identification 
searches at 50 ppm for MS and 0.3 Da for MS/MS. Cysteine modification by 
iodoacetamide was employed as a fixed modification with methionine oxidation as a 
variable modification. Search results were evaluated by manual inspection and conclusive 
identification confirmed if there was high quality tandem MS (good y-ion) data for ≥2 
peptides (E value p < 0.05 for each peptide; overall p < 0.0025) or one peptide (only if E 
value was p < 0.0001). 
 
2.5.10 Glycoprotein staining 
Glycoprotein staining was used to determine the presence of any glycosylation of proteins 
obtained for Ureaplasma whole lysate. Glycoprotein staining was performed by using a 
glycoprotein staining kit (Biosciences, USA) to detect glycoprotein carbohydrates in a gel 
electrophoresis matrix. The Glycoprotein staining kit is based on a modification of the 
Periodic Acid-Schiff (PAS) method (Zacharius et al., 1969). In this study, the SDS- 
PAGE gel was placed in a clean weighing tray containing 100 ml of 50% ethanol and 
rinsed on a shaker for 30 min. The solution was discarded and 100 ml of 3% acetic acid 
was added and the gel was rinsed on a rocking platform for 10 min. The solution was 
discarded and this wash step was repeated again. After fixing the gels, 25 ml of Glyco-
Oxidising Reagent was added and gently agitated for 15 min. The gel was then washed 
with 100 ml of 3% acetic acid for 5 min, and the solution was discarded and the washing 
step was repeated twice. 25 ml of Glyco-Stain was added and gently agitated on a shaker 
for 15 min. The gel was then washed three times with 100 ml 3% acetic acid for 10 min 
and rinsed with deionised water. The gel was scanned and an electronic image was saved. 
The results were seen as a cluster of magenta bands (glycoprotein positive control gave 
magenta bands at around 40-80 kDa). The gel was subsequently stained with RAPIDstain 
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(provided with the kit) to view the non-glycosylated proteins and to enhance glycoprotein 
staining. The gel was initially washed three times in deionised water for 10 min each and 
then was developed with 25 ml RAPID stain for 30-40 min. Staining was monitored and 
when a suitable level of staining was seen, the gel was removed and washed in deionised 
water for 30 min on a shaker. The gel was again scanned and electronic image saved. 
Stained gels were stored in 3% acetic acid.  
 
2.6 Molecular biology studies 
2.6.1 DNA extraction 
Genomic DNA of Ureaplasma was extracted using GenElute Bacterial Genomic DNA 
Kit (Sigma-Aldrich). Gram-negative bacterial preparation procedure was followed and 
performed as per manufacturer recommendations. Bacterial cell pellet was obtained from 
100 or 200 ml growth in USM by centrifuging for 1 hr. at 10,000 x g, and then removing 
and discarding the culture medium completely. The pellet was suspended thoroughly in 
180 µl of lysis solution and 20 µl of RNase A solution was added and mixed. The mixture 
was incubated for 2 min at room temperature; and then 20 µl of the proteinase K solution 
was added the sample and mixed before incubating again for 30 min at 55ºC.  A 200 µl of 
lysis solution C was added and mixed well by vortex for about 15 sec. to homogenise the 
mixture, and then re-incubated again for 10 min at 55ºC. The pre-assembled GenElute 
miniprep binding column was prepared by adding 500 µl of the column preparation 
solution to it and centrifuged at 12,000 x g for 1 min;  and elute was discarded.  200 µl of 
ethanol (100%) was added to the lysate mixture and mixed thoroughly by vortexing for 
10 sec to homogenise the mixture. The mixture was then transferred into the binding 
column using a wide bore pipette to avoid DNA shearing and centrifuged for 1 min at 
6500 x g. The collection tube was discarded and replaced with a new 2 ml collection tube. 
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500 µl of washing solution 1 was added to the column and centrifuged at 6500 x g for 1 
min. the elute was discarded and 500 µl of washing solution was added to the column and 
centrifuged for 3 min at 16,000 x g to dry the column.  Elution was discarded and an 
additional centrifugation for 1 min at 16,000 x g was done to remove any residual ethanol 
from the column before eluting the DNA.  The collection tube was discarded and 
replaced with a new 2 ml collection tube. DNA was eluted by adding 200 µl of the 
Elution solution directly onto the centre of the column and incubated for 5 min at room 
temperature before centrifuging at 6500 x g for 1 min. DNA yield was determined using 
spectrophotometer at 260 nm.  DNA samples were stored at -20º C until needed. 
DNA that was used for standard PCR experiments was prepared by centrifuging 300 µl of 
Ureaplasma growth at 13000 rpm for 20 min at 4º C. The supernatant was carefully 
removed and the cell pellet was resuspended in 50 µl of PCR water and then boiled for 10 
min to lysis the cells and release the DNA. DNA samples were then stored at -20º C until 
needed. 
 
2.6.2 Polymerase chain reaction (PCR) 
PCR reactions were performed in 200 µl PCR tubes (Starlab, Milton Kenes) and run on a 
PCR cycler, the Prime Thermal Cycler (Bibby Scientific Ltd, Staffordshire, UK). PCR 
reagents were purchased from Promega. PCR reactions were prepared as shown in Table 
2.6. All primers used in this study were synthesized by Invitrogen and are shown in Table 
2.7.   
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Table 2.6 PCR ingredients for 20 µl and 50 µl reactions 
Master mix ingredient 20 µl reaction 50 µl reaction 
dH2O 11.15 µl 27.9 µl 
5X Taq buffer 4.0 µl 10 µl 
MgCl2 (25 mM) 1.2 µl 3 µl 
dNTP 0.4 µl 1 µl 
Forward primer 1 µl (5 pmol) 2.5 µl 
Reverse primer 1 µl (5 pmol) 2.5 µl 
Taq DNA polymerase 0.25 µl 0.625 µl 
DNA template 1 µl 2.5 µl 
 
PCR cycling parameters were common in all PCR reactions: denaturation at 95º C for 10 
followed by 35-40 cycles [denaturation at 95º C for 30 seconds; annealing at temperature 
based on the pair primers used (see table 2.7) for 30 seconds; extension at 72º C 
1min/1000bp], followed by a final extension at 72º C for 10 min. The reactions were then 
held at 10º C at the end of the PCR program. After each PCR experiment, PCR amplicons 
were run on agarose gel electrophoresis to confirm the results. 
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               Table 2.7 Primers used in this study 
No Primer Name Sequence (5` to 3`) 
Tm 
(ºC) 
PCR product 
(bp) 
Reference 
 
 
1 
2 
Multiple Banded Antigen 
UM-1  
UMS-125 
UMA-226 
 
 
GTATTTGCAATCTTTATATTTTCG  
CAGCTGATGTAAGTGCAGCATTAAATTC 
 
 
54 
403 (U.p) 
448 (U.u) 
(Teng et al., 1994) 
3 
4 
rev MBA Uu1 
rev MBA Uu2 
AGCCCAATTCATAGGCTATTAAT 
GTTTTGTAGTTTCACCACTTCC 
55.3 
56.5 
 This study 
 
3 
4 
Gentamicin gene 
GentF 
GentR 
 
ACATGAATTACACGAGGGC 
GTTCTTCTTCTGACATAGTAG 
 
54.5 
54 
 
401 
 
This study 
 
5 
6 
7 
8 
9 
10 
11 
12 
13 
pMT85 primers 
pMT85_143R 
pMT85_143R_bio 
pMT85_195F 
pMT85_195R  
pMT85_195R_bio   
pMT85_4780R 
pMT85_346R 
start_uu_mCherry 
pMT85_56R 
 
TTCCACACAATATACGACC 
Biotin-TTTTCCACACAATATACGACC 
GCTATGACCTTGATTACGG 
CCGTAATCAAGGTCATAGC 
Biotin-CCGTAATCAAGGTCATAGC 
GAAAAATAATAAAGGAAGTGAGTC 
GGGACGACGACAGTATCGG 
TAGTTGAAGAAGTAATGGTAGCAC 
CCGTACTAGTGTGTCCAA 
 
52.4 
52.4 
54.5 
54.5 
54.5 
54.2 
61 
57.6 
58 
 
 
 
 
 
 
 
 
 
 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
 
14 
15 
For circularisation: 
pMT85_195R   
pMT85_4294F 
 
CCGTAATCAAGGTCATAGC 
GATGCCAAGTTCACTTCCTAAG 
 
54.5 
58.4 
 
721 
 
This study 
This study 
 
16 
17 
18 
For transposase:  
pMT85_195R  
pMT85_3825F 
pMT85_4244R 
 
CCGTAATCAAGGTCATAGC 
CAACGAAACGAAAAGCCCTCAT 
TTGTGCGCATCAGAAATAACGA 
 
54.5 
58.4 
56.5 
 
1190 (16+17) 
419   (17+18) 
 
This study 
This study 
This study 
Continued  
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         Table 2.7 (Continued)  
No Primer Name Sequence (5` to 3`) 
Tm 
(ºC) 
PCR product 
(bp) 
Reference 
 
19 
20 
21 
22 
For Nested PCR- step1: 
pMT85_195R_bio   
EcoR1-probe-tag 
EcoRV-probe-tag 
SpeI-probe-tag 
 
Biotin-CCGTAATCAAGGTCATAGC 
CAGTTCAAGCTTGTCCAGGAATTCNNNNNNNGAATTC 
CAGTTCAAGCTTGTCCAGGAATTCNNNNNNNGATATC 
CAGTTCAAGCTTGTCCAGGAATTCNNNNNNNATCAGT 
45 Random 
 
This study 
This study 
This study 
This study 
 
23 
24 
For Nested PCR- step2: 
pMT85_143R 
Toleman tag 
 
TTCCACACAATATACGACC 
CAGTTCAAGCTTGTCCAGG 
52 Random 
 
This study 
This study 
 
25 
26 
27 
28 
29 
30 
31 
32 
For Mapping insertion site:  
pMT85_2552F 
pMT85_2949R 
pMT85_2747F  
pMT85_3263R 
pMT85_1975F 
pMT85_2552R  
pMT85_2150F 
pMT85_2657R 
 
CGTAGTTAGGCCACCACTTC 
GCGGTATCAGCTCACTCAAA 
CGTCAGACCCCGTAGAAAAG 
GCTTTCTCATAGCTCACGCT 
AAGACAAATGCACGGTTTAGATT 
CTTTTCTACGGGGTCTGACG 
GAGGGTAAAAAGTGTTTATGCCA 
TAGCTCTTGATCCGGCAAAC 
 
57.99 
57.99 
58.01 
58.07 
57.29 
58.01 
57.28 
57.98 
 
556  (25+26) 
 
516  (27+28) 
 
600  (29+30) 
 
530  (31+32) 
 
 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
33 
34 
35 
36 
pMT85_2995F 
pMT85_3795R 
pMT85_3192F 
pMT85_4137R 
GGACAGGTATCCGGTAAGCG 
GCCATCACGTGTTCTGGGTA 
TTTGCTGGCCTTTTGCTCAC 
GCCGATAATTTCACGGTCGC 
59.97 
60.04 
59.90 
60.04 
800  (33+34) 
 
945  (35+36) 
This study 
This study 
This study 
This study 
 
  Continued  
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 Table 2.7 (Continued)  
No Primer Name Sequence (5` to 3`) 
Tm 
(ºC) 
PCR product (bp) Reference 
For screening  disrupted genes in  Ureaplasma spp. 
37 
38 
pMT85_143R 
pMT85_195R 
TTCCACACAATATACGACC 
CCGTAATCAAGGTCATAGC 
52.4 
54.5 
Random size (combination of 37 or 38 with any 
of UU forward or revers primers,  39-54) 
This study 
 39 
40 
UU390F 
UU390R 
AGTATTCCCATTGCGACAA 
TATTTATTATCTTTTCTGGAGGTT 
52.4 476 This study 
41 
42 
UU187-end_F 
UU188_start_R 
AGGTCACGATGTGTTGTTGCTGA 
CAAATATGGGCAACAGGAGCAG 
58 600 This study 
43 
44 
UU450_219F 
UU450_893R 
TTGAATTGAACCCTCAGAGATCC 
ATTGCTTGATGGAAATGAATCCT 
58 675 This study 
45 
46 
UU520F 
UU520R 
TCGGAGGGAGTTTGTCTCC 
TTTCGCAAAGGTGCAAACCA 
58 730 This study 
47 
48 
UU582_354F 
UU582_1230R 
TTACCACGACCACTACGTCC 
TTATTGGCGTTGCACCAACAG 
58 876 This study 
49 
50 
51 
52 
53 
54 
per UU280F 
pre UU280R 
in UU280F 
inUU280R 
post UU280F 
post UU280R 
GCATATGGTGTTGCTCATCG 
TTCATGACGTGACATACCGT 
ACGTCATGAAGAACGTGTTG 
AATACACCACCATCTGGTCC 
GTAGTGTTAATGCCAGGGGA 
AACGAACCTCTTTAGCTCGT 
57.3 
56.9 
56.7 
56.9 
56.9 
56.9 
858 (49+50) 
 
876 (51+52) 
 
805 (53+54) 
 
 
This study 
 
55 
56 
57 
58 
59 
UU122 Uu 107F 
Up/Uu postUU122 
UU pre UU122 
Up pre UU122 
UU122 Uu560R 
GTGCAGTAATGTTAGGTCTAGG 
CCATAGTAAAAGGCCGAGC 
TATGTTTTAGCTGGTGCTGAAG 
TATGTTTAGCTGGCACTGAAG 
AACAAAAATAAAGTTGGGTGGCT 
56.0 
56.9 
56.7 
56.7 
55.25 
 This study 
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2.6.2.1 PCR for speciation of Ureaplasma spp. and determination of serovars 
PCR for separating the two groups of Ureaplasma spp. into U. parvum and U. 
urealyticum was used as described by (Teng et al., 1994). Primers , UMS-125 and 
UMA226 (PCR UM-1) (Table 2.7), were used to amplify a DNA fragment within the 
MBA gene of U. parvum and U. urealyticum yielding different sizes of PCR product, 403 
bp and 448 bp, respectively.  U. parvum  isolates were further discriminated into the four 
serovars (1, 3, 6, 14) by sequencing with the UM-1 primer set and aligning sequence 
results with the known sequences of MB antigen of the serovars (Kong et al., 2000b). 
Differentiation of the four serovars was based on variations within two regions (between -
54 to -56 and -81 to -83) of the MBA gene (Table 2.8). Diversity within MBA gene was 
also used in this study as an attempt to classify U. urealyticum isolates to known specific 
serovars. Furthermore, in an attempt to identify some unknown U. urealyticum clinical 
isolates, the promoter and MBA coding region were amplified using a set of primers (rev 
MBA Uu1 and rev MBA Uu2) designed based on conserved regions of the known 
genomic sequence of the prototype U. urealyticum serovars (Table 2.7). 
 
                      Table 2.8 Nucleotide variations within MBA gene of U. parvum 
Serovar Location of variation in nucleotides within 
MBA gene 
Region 1 Region 2 
-84 -83 -82 -56 -55 -54 
SV1 G C T A C A 
SV3 A C C A T A 
SV6 A A T T A G 
SV14 A A T A T A 
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2.6.2.2 PCR for unknown Flanking DNA  
This PCR protocol was used to map the insertion site of pMT85Gen plasmid in the 
genome of transformed Ureaplasma strains. This protocol is a modification of a method 
by O'Toole and Kolter (1998), which consisted of two consecutive PCR reactions. In the 
first PCR, a 50 µl PCR reaction for each sample was set up using a known plasmid-
specific biotinylated primer, pMT85_195Rbio and one of three random primers: EcoRI-
probe-tag,  EcoRV-probe-tag or SpeI-probe-tag, (Table 2.7). The first round was run for 
40 cycles under the conditions of 45ºC annealing and an extension time of 2 minute at 72º 
C. The biotinylated PCR products were immobilized on Dynabeads M280-streptavidin 
paramagnetic beads as per manufacturer instructions (Invitrogen, Life Technologies). 
Beads were initially washed three times in 2X wash buffer (2mM EDTA, 4M NaCl, 
20mM Tris-HCl pH7.5), and then, 40 µl of the PCR product was mixed with 40 µl of 
Dynabeads (200 µg of beads) and incubated for a minimum of 15 minutes at room 
temperature. The beads with captured DNA were washed with 1X wash buffer (1mM 
EDTA, 2M NaCl, 10mM Tris-HCl pH7.5). 5 µl of beads with bound DNA fragments 
were then used as DNA template in the second round PCR reaction. This PCR reaction 
utilised a higher annealing temperature (Tm 52º C), an extension time of 2 minutes and 
40 cycles. The primers used (Table 2.7) were a custom designed nested primer for the 
mini-transposon plasmid (pMT85_143R) and a flanking primer designed against the 
common 5` end of the random primers, named in the table as Toleman-tag.  5 µl PCR 
products were run on agarose gel electrophoresis to confirm amplification of plasmid-
specific DNA fragment. Amplicons were then purified using Qiagen PCR clean up kit 
before being submitted to Eurofins for sequencing using the internal primers individually 
from the final nested amplification.  Sequencing results were analysed by homology 
analysis comparing them against the genomic DNA of U. parvum serovar 3 and well as 
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the sequence of pMT85 to confirm and determine the accurate location of pMT85 in the 
genomic DNA. 
 
2.6.3 Agarose gel electrophoresis 
Following a PCR reaction, DNA from a PCR reaction was separated on an agarose gel by 
electrophoresis to determine the presence and size of the amplified DNA fragments. 
Agarose gels were prepared by dissolving a specific amount of molecular grade agarose 
powder (Invitrogen, UK) in a 1X Tris-Borate-EDTA buffer (TBE) (8.9 mM Tris, 8.9 mM 
Borate, 0.2 mM EDTA, pH 8.3) (MP Biomedicals, France). The percentage of agarose 
used was dependent on the expected size of the PCR product (0.7-1.5% w/v), 0.7% for 
DNA bands >2 kb, and 1.5% for DNA bands <500 bp. The agarose mixture was heated in 
a microwave oven until the agarose granules had entirely dissolved, and then it was 
cooled to approximately 60º C, before adding the ethidium bromide (MP Biomedicals, 
France) to a final concentration 1 µg/ml. The melted agarose was then immediately 
poured in a gel casting tray containing a comb and allowed to set at room temperature. 
After the gel was solidified, the casting tray with the gel was placed in the electrophoresis 
chamber, which was filled with the buffer TBE, and the comb was carefully removed. 3-5 
µl of each PCR products (amplified DNA samples), including positive and negative 
controls, were loaded in each well. 5 µl of DNA ladder (Hyperladder IV, Bioline;  or 
Kapa Universal DNA ladder, Kapa Biosystems, USA) was loaded alongside of samples 
and the DNA separated  at 150 V for 30 min. DNA fragments were stained with ethidium 
bromide and visualised with a BioDoc-IT™ UV Tansilluminator (Ultra-Violet products, 
Cambridge) and image was saved as an electronic file on a memory card.  
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2.6.4 Purification of DNA from PCR product for sequencing 
DNA fragments from PCR products were purified using a QIAquick PCR purification kit 
(Qiagen, UK). In which, five volumes of the binding buffer (PB) were added to one 
volume of PCR product (500 µl of buffer PB for every 100 µl of PCR product). Each 
sample mixture was then transferred into a QIAquick spin column that was placed on 2 
ml collection tube and centrifuged at 13000 rpm for 1 min, and the flow-through was 
discarded. The spin column was placed back to the collection tube and 750 µl of Buffer 
PE was added to wash bound DNA. The column was then spun at 13000 rpm for 1 min, 
and the flow through was discarded. The spin column was again centrifuged for 1 min to 
remove any remaining ethanol from Buffer PE. The QIAquick column was transferred to 
a clean 1.5 ml microcentrifuge tube, and the purified DNA eluted with 50 µl of molecular 
grade water by centrifugation at 13000 rpm for 1 min. Assessment of quantity and purity 
of purified DNA was performed by measuring DNA and protein concentrations at 
wavelengths A260/280 nm respectively using a BIO-SPEC-1601 dual beam 
spectrophotometer (Shimadzu, Milton Keynes, UK) comparing absorbance against a 
cuvette containing the eluting buffer as a background control. 
 
2.6.5 Sequencing PCR products 
All DNA samples that were sent for sequencing were prepared by running 2 x 50µl PCR 
reactions for each sample and running 5 µl on an agarose gel to confirm the amplification 
of DNA fragment, followed by purification of the PCR product using a Miniprep kit 
(Qiagen). The DNA samples were then prepared for sequencing according to the 
company recommendations (Eurofins MWG).  Samples were sent in tubes containing 15 
µl of purified PCR DNA with 3 µl primer (10 µM). 
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Returned sequence results were analyzed by BLAST software to search sequence 
similarity and regions of locus similarity (NCBS http://www.ncbi.nlm.nih.gov/).  
 
2.6.6 Purification of plasmid DNA using Miniprep kit  
QIAprep spin miniprep kit (Qiagen, UK) was used to purify plasmid DNA from 5 ml 
growth of transformed E. coli.  Plasmid DNA was screened by restriction digest to 
confirm successful ligation or investigate insert orientation, prior to scale up to obtain a 
higher yield of plasmid DNA that was used for Ureaplasma transformation. Bacterial 
cells (from 3-5 ml overnight growth) were harvested by centrifugation and pellet was 
resuspended in 250 µl Buffer P1 and then transferred to a 1.5 ml microcentrifuge tube. 
250 µl of Buffer P2 was added and mixed by inverting the tube 4-6 times, and then, 350 
µl of Buffer N3 was added and mixed immediately by inverting the tube 4-6 times. The 
tube was centrifuged at 13000 rpm for 10 min at 4º C. The clear supernatant was carefully 
taken and applied to the QIAprep spin column and centrifuged at 13000 rpm for 1 min, 
and the flow-through was discarded. The column was washed by adding 500 µl of Buffer 
PB and centrifuge again for 1 min, and the flow-through was discarded. The QIAprep 
spin column was washed again by adding 750 µl of Buffer PE and centrifuged at 13000 
rpm for 1 min, and the flow-through was decanted. The column was subjected to 
additional centrifugation step for 1 min to remove any traces of the buffer. The QIAprep 
column was placed on a clean 1.5 ml microcentrifuge tube and 50 µl of molecular grade 
water was added to elute the plasmid DNA. Plasmid DNA samples were then stored at -
20º C or directly subjected to restriction digestion by specific restriction enzyme. 
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2.6.7 Restriction digestion 
Restriction enzyme digest was performed in a 0.5 ml microcentrifuge tube in a final 
volume of 20 µl. The enzyme reagents used in this study were obtained for the 
manufacturer, Promega. A list of all enzymes used in this study presented in Table 2.9.  
The reaction was set up by pipette mixing 16.8 µl (0.2-1.5 µg) of plasmid DNA, 2 µl of 
appropriate restriction enzyme buffer,  and 0.2 µl (10 mg/ml) acetylated bovine serum 
albumin (BSA). And then, 1 µl (10 u/ µl) of the restriction enzyme was added and mixed 
gently by pipetting. When a ligation of a vector with compatible overhang ends was 
required, 1 µl shrimp alkaline phosphatase was added to the digest mix to prevent re-
ligation of sticky-ends after digestion.  The tube was then pulse centrifuged for few 
seconds and incubated at the optimum temperature for 1-4 hours. After incubation, 4 µl 
of loading buffer was added and digests were separated by agarose gel electrophoresis. 
Plasmid DNA fragments separated on agarose gel were then visualized and analyzed.  
  
Table 2.9 Restriction endonucleases used in this study  
Enzyme Source 
Recognition 
sequence 
Cut site Temperature 
XbaI Xanthomonas badrii 
5'TCTAGA 
3'AGATCT 
5'---T  CTAGA---3' 
3'---AGATC  T---5' 
37
º
 C 
EcoRV Escherichia coli 
5'GATATC 
3'CTATAG 
5'---GAT  ATC---3' 
3'---CTA  TAG---5' 
37
º
 C 
SpeI Sphaerotilus natans 
5'ACTAGT 
3'TGATCA 
5'---A  CTAGT---3' 
3'---TGATC  A---5' 
37
º
 C 
HindIII Haemophilus influenzae 
5'AAGCTT 
3'TTCGAA 
5'---A  AGCTT---3' 
3'---TTCGA  A---5' 
37
º
 C 
BamHI Bacillus amyloliquefaiens 
5'GGATCC 
3'CCTAGG 
5'---G  GATCC---3' 
3'---CCTAG  G---5' 
37
º
 C 
EcoRI Escherichia coli 
5'GAATTC 
3'CTTAAG 
5'---G  AATTC---3' 
3'---CTTAA  G---5' 
37
º
 C 
BssHII Bacillus stearothermophilus H3 
5' GCGCGC 
3' CGCGCG 
5' ---G   CGCGC--- 3' 
3' ---CGCGC   G--- 5' 
50
º
 C 
(Promega, UK) 
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2.6.8 Ligation  
In preparation, the linearized plasmid DNA (open vector) and the restricted DNA 
fragment (insert)  were separated on 0.7-1% agarose gel stained with crystal violet (10 
µg/ml), and visualised on a standard light box (to avoid formation of thymidine 
dimmers). The bands were then cut out with a clean scalpel and subjected to extraction 
and purification using QIAquick Gel Extraction Kit (Qiagen, UK) as described below. 
Purified linearized plasmid DNA and insert fragment DNA were then ligated using T4 
DNA ligase reagents (Promega, UK). Ligation reactions were performed in 200 µl PCR 
tubes (Starlab, Milton Keynes, UK). The ligation was done by mixing 5 µl of insert 
fragment DNA, 1 µl of vector plasmid DNA, 2 µl of 10X ligase buffer, and 1 µl T4 DNA 
ligase (1U, Weiss units). The ligation mixture was incubated at 16º C overnight 
 
2.6.9 Extracting DNA using QIAquick Gel Extraction Kit 
The DNA band (excised from agarose gel) was weighed and 3 volumes of buffer QG 
were added per 100 mg of gel. The sample was incubated for 10 minutes at 50º C to 
dissolve the gel completely and then 1 ml of isopropanol was added to the DNA-gel 
solution. This solution was then pipetted into a QIAquick column and spun at 13,000 rpm 
for 1 minute. The sample was washed by adding 0.75 ml of buffer PE and spun again for 
1 minute at 13,000 rpm. The DNA was eluted by adding 50 µl of molecular grade water 
to the center of the column and then subjected to centrifugation at 13,000 rpm for 1 
minute.  
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2.6.10 Isolation of plasmid DNA using Midi kit 
To scale up the yield of plasmid DNA, 100 ml growth of transformed E. coli was 
harvested by centrifugation at 6000 x g for 15 min. Plasmid DNA from the cell pellets 
was then isolates and purified using the QIAGEN Plasmid Midi kit (Qiagen, UK). The 
bacterial pellet was first re-suspended in 4 ml of Buffer P1 and mixed to lyse the cells. 
Then, 4 ml of Buffer P2 was added and mixed well by vigorously inverting the tube 4-6 
times and incubated at room temperature for 5 min. 4 ml of chilled Buffer P3 was added 
to the previous mixture and immediately mixed by inverting 4-6 times, and incubated on 
ice for 15 min. The tube was centrifuged at 20000 x g for 30 min at 4º C. The supernatant 
containing plasmid DNA was promptly removed and transferred to another clean 50 ml 
tube and centrifuged again at 20000 x g for 15 min at 4º C. Meanwhile, QIAGEN-tip 100 
was equilibrated by applying 4 ml of Buffer QBT and allowed to empty by gravity flow. 
After centrifugation, the clear supernatant containing plasmid DNA was removed and 
applied to the equilibrated QIAGEN-tip and allowed to enter the resin by gravity flow. 
The QIAGEN-tip was then washed by 2 x 10 ml Buffer QC that was allowed to go 
through the column by gravity flow. The plasmid DNA was eluted from the column by 
applying 5 ml of Buffer QF and collected in a clean 25 ml universal tube. The eluted 
plasmid DNA was then precipitated by adding 3.5 ml of room-temperature isopropanol, 
mixed and then centrifuged immediately at 15000 x g for 30 min at 4º C. The supernatant 
was carefully decanted, and the DNA pellet was washed by adding 2 ml of 70% ethanol 
without disturbing the pellet and centrifuged at 15000 x g for 10 min. The supernatant 
was carefully decanted and the pellet was allowed to air-dry for 5-10 min and then 
redissolved in 100 µl of molecular grade water. The plasmid DNA yield was determined 
using spectrophotometer at 260 nm and stored at -20º C till needed to be used for 
Ureaplasma transformation. 
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2.6.11 Pulsed field electrophoresis (PFGE) 
PFGE in this study was performed according to protocols published by (Moser et al., 
2006; Xiao et al., 2011a).  Ureaplasma growth in 100 ml USM was harvested by 
centrifugation for 30 minutes at 10,000 x g. The supernatant removed and the pellet was 
washed 3 times in 1% PBS. The washed pellet was resuspended in 180 µl of Tris-EDTA 
buffer (10 mM Tris HCl, 1 mM EDTA, pH8). Agarose plugs (0.9%) were made by 
adding an equal volume of 1.8% agarose in TE. The plugs were then incubated overnight 
at 37º C in EC lysis buffer [6 mM Tris, 1 M NaCl, 100 mM EDTA, 0.5% Brij-58 
(Polyoxyethylene 20 Cetyl Ether; Sigma), 0.2% Sodium desoxycholate (Sigma), 0.5% 
sodium lauriylsarcosine (Sigma). The plugs were then overnight treated at 50º C with 
proteinase K in ESP buffer [1 mg/ml 2 mg/ml of lysozyme and 10 mg/ml of proteinase K 
(Sigma), 0.5 M EDTA, pH 9.2, 1% sodium lauroylsarcosine], then washed 4 times in TE 
buffer and stored at 4 ºC in TE buffer until needed for the restriction digestion.  After 
equilibrating in 1X restriction buffer for 30 min, the buffer was removed and 1X buffer 
containing 40U BssHII (Promega, UK) was added and the plugs were incubated at 50 ºC 
for 2 h. Digested agarose plugs were positioned in 1% PFGE grade agarose gel 
(Invitrogen) and PFGE was run on a  CHEF-DR III variable angle system (Bio-Rad, UK) 
using the following parameters: 200 V (6V/cm); temperature 14 ºC; initial switch 1 s; 
final switch 40 s; time 20h. DNA fragments were stained with ethidium bromide and 
visualised with a BioDoc-IT™ UV Tansilluminator (Ultra-Violet products, Cambridge) 
and image was saved as an electronic file on a memory card.  
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2.6.12 In Gel DNA/DNA hybridization 
Ureaplasma genomic DNA was extracted from the Ureaplasma cells using GenElute 
bacterial genomic DNA kit as described above (section 2.6.1).  200 µl genomic DNA was 
subjected to digestion with HindIII; and digests were purified using QIAquick PCR 
purification kit (Qiagen, UK) as described above. The whole volume of purified HindIII 
digested genomic DNA sample (about 30 µl each sample), along with HindIII digested 
pMT85 plasmid as a positive control, were run on 0.7 % agarose gel stained with 
ethidium bromide for 4 h to separate DNA fragments. Separated DNA fragments were 
visualised and images were saved. The gel then was put between two filter papers and 
dried overnight at 50ºC; and then saved till needed.   
To prepare for hybridization, the dried gel was re-hydrated again by soaking in deionised 
water for 5 min at room temperature. The gel then was denatured and neutralized 
subsequently by incubating in neutralising solution (0.5M NaOH and 1.5M NaCl) for 30 
min at room temperature followed by another 30 min incubation at room temperature in 
neutralising solution (0.5M Tris-HCl, pH 7.5, 1.5M NaCl). The gel was transferred to a 
hybridisation tube, and 20 ml of pre-hybridisation solution [6X saline-sodium citrate 
buffer (SSC), 0.1% (w/v) polyvinylpyrrolidone 400, 0.1% (w/v) Ficoll, 0.1% (w/v) Ultra-
high temperature (UHT) whole milk, 0.5 (v/v) SDS and 150 µg/ml denatured herring 
sperm DNA] was added and then incubated overnight at 65ºC in a hybridization oven 
(Techne, Barlow world scientific Ltd, Stone, UK) before being probe with gentamicin 
resistance gene 
32
P dCTP labelled probe. 
Labelling the DNA probe (gentamicin resistance gene) was performed using Prime-It II 
Random Primer Labelling kit and according to manufacturer recommendations 
(Startagen-Agilent Technologies). Gentamicin resistance gene (aac-aphD; 6'-
aminoglycoside N-acetyltransferase) was first amplified by PCR using pMT85 plasmid 
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DNA, which carries the gene, as DNA template and primers set designed against the 
gene; Gent1 (forward) and Gent2 (Reverse) (401 bp amplicon, Tm=54°C, 35 cycles). 
After analysis on agarose gel, PCR amplicon was then purified using the QIAquick PCR 
purification kit before being labelled.  To label the DNA probe, 16 µl of gentamicin 
resistance gene DNA (25ng), 8 µl of DNase-free water, and 10 µl of random 
oligonucleotide primers were add into the bottom of a screw-top eppendorf tube. The 
reaction tube was heated in a boiling water bath for 5 min and then centrifuged briefly at 
room temperature. Then, 10 µl of 5X dCTP primer buffer, 2.5 µl of [α-32P], and 1 µl 
Klenow enzyme (5 U/µl) were added quickly to the tube and mixed thoroughly with the 
pipet tip. The reaction tube was incubated at 37ºC for 15 min. After incubation, the 
reaction was stopped by adding 2 µl stop mix. The labelled DNA probe was then purified 
by removing any unincorporated nucleotides using sephadex G-50 DNA grade column, 
illustra NICK Columns, (GE Healthcare, Amersham, UK). Then, 320 µl of 0.1 M Tris-
HCl buffer, pH7.5, was added into the column and allowed to run through by gravity in a 
collection tube. The column was moved to a new collection tube, and additional 430 µl of 
Tris buffer was added. The run through liquid was collected and boiled for 6 min.  The 
labelled probe, the gentamicin resistance gene 
32
P dCTP labelled probe, was added 
directly to the gel to be probed in hybridisation tube, containing 20 ml pre-hybridization 
solution, and incubated overnight at 65ºC. The next day the gel was washed once with 
100 ml of 2X SSC buffer for 30 min at 65ºC in a hybridisation oven. Then, it was washed 
1-2 times with 0.1X SSC buffer for 30 min at 65ºC. The probed gel membrane was then 
wrapped in clingfilm and transfer to an X-ray cassette.  DNA/DNA hybridisation reaction 
was visualised as an autoradiograph image on an X-ray film (Fujifilm, Tokyo, Japan) 
following an overnight exposure at - 80ºC.  Autoradiograph images were scanned stored 
as TIFF files before being analysed. 
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2.7 Transformation of Ureaplasma  
2.7.1 Bacterial strains  
2.7.1.1 Escherichia coli 
One Shot Top10 chemically competent E. coli cells (Invitrogen; Paisley, Scotland, UK), 
were used as per manufacturer’s instructions.  This bacteria has the genotype F- mcrA 
Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacΧ74 recA1 araD139 Δ(ara-leu) 7697 galU 
galK rpsL (StrR) endA1 nupG λ-. 
 
2.7.1.2 Ureaplasma spp. 
Three U. parvum strains for serovar 1 (DFK-1, O10, and HPA78), serovar 3 (HPA5, U6, 
and HPA56) and serovar 6 (HPA2, HPA61, HPA58) were investigated for the capacity to 
undergo transposon mutagenesis, and these strains were initially isolated from patients, 
but have been purified through sub-cloning and have also been characterised and used in 
previous publications (Beeton et al., 2009b; Beeton et al., 2012). Various ATCC strains 
of U. urealyticum representing serovar 2 (ATCC 27814), 4 (ATCC 27816), 8 (ATCC 
27618), 9 (ATCC 33175), and 10 (ATCC 33699) were generously supplied by Dr. Janet 
Robertson, (University of Alberta, Canada), these strains as well as a clinical isolate, 
W11 (serovar 12) (Beeton et al., 2009b), were investigated in parallel. 
 
2.7.2 Expression constructs and the mini-transposon plasmid 
The Tn4001-based mini-transposon plasmid, pMT85, has been previously described by 
Zimmerman and Herrmann (2005) and was generously provided by Prof. R. Herrmann 
(Heidelberg University, Germany).  The gentamicin resistance gene was not codon-usage 
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optimised for Ureaplasma spp. expression. Expression constructs were generated by 
ligating various DNA fragments into the cloning vector pMT85. These constructs were 
made to try to create florescent Ureaplasma cells and also study the capability of 
Ureaplasma to express foreign genes. DNA insert constructs were synthesised, as 
required, by GenScript (GenScript, NJ, USA) and cloned into the vector pUC57, which 
contains ampicillin resistance gene as a selection marker. Upon arriving, the lyophilized 
plasmid DNA (pUC57) with a custom synthesised DNA insert was centrifuged               
at 6000 xg for 1 minute. DNA was the dissolved in 20 µl of sterilized molecular grade 
water by vortex mixing for 1 min. The plasmid DNA was then stored at -20 until needed.  
DNA inserts were excised from pUC57 (Using the restriction enzyme, XbaI) and ligated 
to the expression vector pMT85 (using T4 ligase).  In this study, the pMT85 plasmid was 
the backbone vector for all DNA fragment inserts used to transform Ureaplasma spp., 
after transformation, validation and amplification in E. coli. All mCherry inserts used in 
this study are listed in Table 2.10. 
 
2.7.3 Generating expression vector with different copy number of mCherry  
Besides carrying a single copy of a variety of modified mCherry inserts, pMT85 was also 
engineered to carry more than one copy of the same DNA fragment under independent 
promoter expression. The aim of this experiment was to investigate the effect of copy 
number on expression of red fluorescent protein (RFP).  A number of different constructs 
with one, two, three, or four copies of mCherry was generated, cloned and tested.  
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Table 2.10 The mCherry inserts used in this study 
 
No Insert name 
Construct  
code 
Description Codon-usage 
Gene 
length 
Reference 
1 Tandem mCherry GRT 
tandem copy of mCherry, with U. parvum 
SV3 EF-Tu promoter 
Most frequent in 
Ureaplasma 
optimised 
UGA 
1804bp This thesis 
2 Zimmerman GRZ 
Fused mRFP1 with M. pneumoniae  EF-Tu 
promoter as described by publisher  
Non optimised 1011bp 
(Zimmerman 
and Herrmann, 
2005) 
3 OPTmCherry3 GR-m 
Optimised mCherry insert with His-tag ,U. 
parvum SV3 EF-Tu promoter and BamHI  
restriction site  
Based on tRNA 
identified by 
Paralanov et al., 
(2012) 
926bp This thesis 
4 uRFP-his uRFP-his 
mCherry with His-tag and U. parvum SV1 
MBA promoter 
Most frequent in 
Ureaplasma 
optimised 
950bp This thesis 
5 Half tandem mCherry GR-½Tn 
½ tandem mCherry of the above construct (1) 
with minmal modification in the codon-usage 
Most frequent in 
Ureaplasma 
optimised 
UGG 
917bp This thesis 
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2.7.3.1 Making expression vector with four-copy insert using tandem mCherry insert 
A construct with 4 copies of mCherry insert was the first to be made by inserting two 
copies of optimised tandem mCherry insert into pMT85. First, pMT85 plasmid was cut 
with SpeI and dephosphorylated with SAP to prevent re-ligation, and then the linearized 
vector was used to receive the first copy of the optimised tandem mCherry insert in the 
SpeI site.  The insert was cut with XbaI (which has a complementary overhang) so that 
following ligation the resultant plasmid could be cut with XbaI without removing the 
insert as the combined XbaI/SpeI ligation site is inactive for both restriction enzymes). 
Both linearised vector and the insert were initially purified using QIAquick Gel 
Extraction kit (see section 2.6.8) before ligation with T4 ligase. The pMT85 vector with 
one copy tandem mCherry was cloned into One Shot TOP10 E. Coli cells, and following 
confirmation of successful ligation by restriction of single colonies, the bacteria 
containing the plasmid was scaled up, extracted and purified using the QIAGEN Plasmid 
Midi kit (Qiagen, UK). Second, the pMT85_1Tn (with one copy tandem mCherry) was 
then cut again with XbaI (with SAP treatment), and another copy of tandem-mCherry was 
ligated into the single remaining XbaI site using T4 ligase. The correct construct with two 
copies tandem mCherry (total of 4 copies mCherry) was scaled up, extracted, and 
purified. After validation, both constructs (with 2 and 4 copies mCherry) were stored at -
20º C until required for Ureaplasma transformation. Glycerol stocks of clonal E. coli 
containing confirmed expression vectors were also made and stored at -80 ºC. 
 
2.7.3.2 Generating expression vector with different copy numbers using other inserts 
In a similar way, other constructs with various numbers of DNA fragments were made. 
Inserts were ligated in the same restriction sites mention above, i.e. XbaI and SpeI sites. 
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Using this method, it was possible to generating expression vectors with one copy and 
two copies using ½ tandem mCherry fragment as well as expression vectors carrying one, 
two, three copies using OPT-mCherry insert. All these constructs were validated using 
restriction digestion analysis and/ or sequencing and then amplified, purified and stored at 
-80 ºC till needed. 
2.7.4 Transformation of bacteria 
Transformation of One Shot Top10 chemically competent E. coli cells was performed as 
per manufacturer’s instructions using heat shock at 42°C and the plasmid containing 
bacteria selected with 15 mg/l gentamicin.  Transformation of Ureaplasma spp. was 
carried out essentially as outlined for M. mycoides in King and Dybvig (1991) with some 
modifications. The key aspect of U. parvum growth is the conversion of urea to 
ammonium ions which increase the pH of the growth medium from pH =6.2 (yellow) to 
pH >9 (dark red).  Three 96-well plates containing 10-fold serial dilutions of Ureaplasma 
(200 ml per well, titrated from Rows A-H) were set out the night before the experiment 
and all of the wells showing pH change consistent with the threshold of detection for 
phenol red indicator (pH =7) were pooled (total volume 10 ml) and utilised for 
transformation as these represent U. parvum in log phase growth.  This 10 ml routinely 
gave titrations of 5x10
8
 CFU and were washed three times (centrifuged at 10000g 
for 20 min) with 1 ml of 1X Dulbecco's phosphate-buffered saline (DPBS) (Invitrogen, 
Paisley, U.K.) at 4°C. The washed pellet was resuspended in a volume of 375 µl of 100 
mM CaCl2 and incubated on ice for 30 min, then a volume of 100 µl of bacterial 
cells containing 10 µg of yeast tRNA, 6 µg of pMT85 and 1 ml of 50% PEG-8000 were 
added at room temperature for 1 min. The transformation mixture was diluted by directly 
adding a volume of 5 ml of USM. Cells were allowed to recover in Ureaplasma selective 
medium (Mycoplasma experience plc, Surrey, UK) at 37°C for 3h and the growing cells 
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were pelleted by centrifugation at 3600g for 15 min at 4 C before being resuspended 
again in 1 ml USM. A volume of 20 µl cell suspension was diluted in USM in a 1/10 
dilution series containing 128 mg/L gentamicin and incubated overnight.  Control 
bacteria treated identically (except for the addition of pMT85) were run in parallel and no 
spontaneous gentamicin resistance was observed.  When the first well of transformed 
bacteria turned the media red, the cells were plated out on Ureaplasma selective agar 
(Mycoplasma Experience ltd) and individual colonies were examined for presence of 
gentamicin resistance gene by PCR, prior to further characterisation.  In some 
experiments a dilution series transformed bacteria were directly plated onto Ureaplasma 
selective agar plates containing 128 mg/L gentamicin to determine transformation 
efficiency relative to Ureaplasma selective plates without gentamicin. Ureaplasma cell 
were also transformed using pMT85 plasmid carrying different DNA fragments to 
investigate the expression of exogenous genes under specific parameters. 
 
2.7.5 Screening of transformed bacteria 
Successful transformation of gentamicin resistant bacterial clones was confirmed using 
PCR and primers (Table 2.7) designed against the gentamicin resistance gene (aac-aphD; 
6'-aminoglycoside N-acetyltransferase); Gent1 (forward) and Gent2 (reverse) (401 bp 
amplicon, Tm=54°C, 35 cycles) using standard PCR methods amplified by Promega 
GoTaq green DNA polymerase. Mapping insertion site of pMT85Gen plasmid in the 
genome of transformed Ureaplasma strains was determined as previously mentioned in 
(section 2.6.2.2). U. parvum genes disrupted by transposon insertion into the genome 
were confirmed using primers against Ureaplasma genes: UU390 (hypothetical 
membrane protein); UU450 (hypothetical membrane protein); UU520 (hypothetical 
membrane protein); UU582 (RNA helicase); intergenic insertion between UU187 and 
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UU188.  Amplifying the ends of the insertion site was performed using one of the above 
primers in combination with pMT85-specific primers (designed close to the 5’ and 3’ 
inverted repeat sequence) 195R (5’- CCGTAATCAAGGTCATAGC-3’, Tm=54.5°C) or 
3192F (5- TTTGCTGGCCTTTTGCTCAC-3’, Tm=57°C) (Tables 2.6 and 2.7) at the 
lowest annealing temperature.  Amplicons were purified using the Qiaquick PCR clean 
up kit (Qiagen, Manchester, U.K.) and submitted to Eurofins MWG Operon (Ebersberg, 
Germany) for sequencing.  Primers specific to pMT85 (Table 2.6) were also used to 
determine if transposon insertion only utilised sequences between the inverted repeats (1-
3437bp) or whether plasmid sequence containing the tnp transposase gene (3438-4820bp) 
were also present in the genome insertion. Figure 2.3 illustrates the way of mapping the 
insertion site of pMT85 plasmid and identifying disrupted genes in U. parvum genome. 
Genomic DNA analysis was performed on a Genomic DNA extracted from gentamicin 
resistant transmutant strains using the GenElute Bacterial genomic DNA Kit (Sigma-
Aldrich) as described above (see section 2.6.1). DNA from each preparation was either 
ethanol precipitated, resuspended in 10 l of molecular grade water and utilised for 
Sanger sequencing of purified genomic DNA to determine the transposon insertion site 
using pMT85 primers 195R or 3192F, or digested with HindIII, separated on a 1% 
agarose gel and utilised for in gel radioactive probe hybridization experiments as 
previously described (section 2.6.12).  
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Figure 2.3 Schematic flow chart illustrates the way of mapping the insertion site of 
pMT85 plasmid and identifying disrupted genes in Ureaplasma genome. Following 
unknown flanking DNA PCR, the transposon insertion site was mapped in one of the 
transmutant strains. The first disrupted gene identified was confirmed using primer set 
designed to amplify open reading frames listed for the U. parvum ATCC serovar 3 strain 
700970. Using standard PCR using both forward and reverse primers designed for the 
disrupted gene combined with plasmid specific primers (pMT85_143R or pMT85_195R), 
all other transmutant strains were screened and new pMT85 plasmid locations mapped 
and other disrupted genes identified. This process was repeated with every successful 
experiment. 
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Immunoblot analysis for strains under investigation was performed as detailed above 
(section 2.4). Blots were probed with either human high titre anti-Ureaplasma sera 
(Beeton et al., 2012) or Virostat plc (Portland, ME) monoclonal anti-multiple banded 
antigen (MBA) antibody (clone 6525 or 6522). Bound human and mouse antibodies were 
detected with appropriate peroxidase-conjugated secondary antibodies from Jackson 
ImmunoResearch Europe Ltd (Newmarket, U.K.) and Pierce ECL detection reagent 
(Fisher Scientific, Loighborough, U.K.). In addition, other antibodies such as polyclonal 
anti-mCherry antibody, anti-His tag antibody, and anti-UU280 antisera (Table 2.3) were 
also used to investigate the expression of specific proteins by Ureaplasma spp. after 
transformation. Serum killing assay was also performed as detailed above (section 2.2.2), 
to screen any changes in serum susceptibility of transmutant strains relative to original 
strains. 
 
2.7.6 Fluorescent microscopy 
Fluorescent microscopy was used to view and analyse the expression of RFP by 
transmutant strains from both E. coli and Ureaplasma spp., under several parameters. 
Plates with growing colonies from transmutant strains were screened and visualized using 
a Leica DM IRE microscope (Leica, Germany) with a Hamamatsu ORCA-ER camera 
(Hamamatsu, Japan) and Imrovision Openlab 3 software (Improvision, UK) under 
objective power lenses 4X and 10X, and an appropriate cut-off filter was used for RFP. 
Images were captured and saved as TIFF files.  
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2.7.7 Qualification of red fluorescence from liquid cultures 
Transmutant strains of E. coli harbouring constructs of mCherry or control strains 
(without mCherry insert) were grown overnight in LB medium supplemented with 15 
mg/L gentamicin at 37 ºC. At an optical density (O.D) at 600 nm (O.D600), the number of 
growing cells was adjusted to 1.0 to equalize the growth in all samples and a 100 µl of 
adjusted growth of each transmutant strain was transferred to a 96-well plate. In contrast, 
Ureaplasma transmutant strains carrying mCherry constructs were grown in USM 
supplemented with 128 mg/L gentamicin by titration in a 96-well plate at 37 ºC for 24 hr. 
Red fluorescence protein was then measured using a fluorometer, FLUOstar OPTIMA 
(BMG LABTECH GmbH, Germany) set at an excitation wavelength of 544 nm and 
emission detection at 590 nm.  
2.8 Statistical analysis 
Statistical analysis of data in this thesis was performed using Graphpad Prism software 
version 5.01 (Graphpad Software Inc). All serum killing assays data were expressed as 
mean and standard error of the mean (SEM). Significance, when needed, was taken as a  
P value < 0.05.  
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3. The complement activity against U. urealyticum  
3.1 Introduction  
The bactericidal activity of normal human serum, which is mediated by complement 
system, plays an important role in the host defence against infection. Complement system 
is composed of more than 30 proteins circulating in serum and bound to cell surfaces. 
This system is activated via three defined pathways, the classical, the alternative, and the 
lectin pathways. Different initiating proteins in these pathways are able to recognise 
specific bacterial ligands and trigger the process of complement activation. The formed 
C3 convertases from these three complement pathways meet at the hydrolysis of the 
central C3 component and activate the common terminal pathway, which leads to the 
formation of membrane attack complex (MAC) (Walport, 2001b). Upon activation, the 
complement system either leads to direct cytolysis (particularly in Gram-negative 
bacteria) or bactericidal activity via opsonisation and phagocytosis, as is the case with 
Gram-positive bacteria (Fierer et al., 1972; Joiner et al., 1984).   
Serum-resistant bacteria are believed to be more pathogenic as they are able to cause 
systemic infection. Many pathogens isolated from blood cultures have been found to be 
serum resistant (Joiner et al., 1984).  While all isolates of a species are not inherently 
serum-sensitive and serum-resistant, serum-resistant isolates for Gram-negative including 
Escherichia, Klebsiella, Enterobacter, Pseudomonas, Salmonella, and Citrobacter have 
been documented (Fierer et al., 1972). The mechanism by which such strains had become 
resistant may vary from one species to another. For instance, one mechanism of serum-
resistance in E. coli clinical isolates was found to be via higher O-antigen-substitution of 
lipopolysaccharide subunits in the outer membrane (Porat et al., 1987). In general, many 
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pathogenic microbes have developed strategies to avoid complement killing and invade 
and cause diseases in humans; many of these evasion mechanisms are now well-defined 
as reviewed in (Celli and Finlay, 2002; Kraiczy and Wurzner, 2006; Lambris et al., 
2008).  
Ureaplasma spp. and other members of the Mollicute class are unique among other types 
of bacteria in that they lack a classical bacterial cell wall that provides a protective coat to 
many bacteria.  There are two human associated species within the genus Ureaplasma: U. 
parvum that consists of four serovars (SVs 1, 3, 6, and 14) and U. urealyticum that 
contains the remaining 10 serovars (SVs 2, 4, 5, 7-13). The first group is more frequently 
isolated from the urogenital tract of healthy men and women, but the second group is 
thought to be more pathogenic in male urethritis (Deguchi et al., 2004; Waites et al., 
2005). The susceptibility of U. parvum to complement-mediated serum killing was 
investigated previously in my host laboratory (Beeton et al., 2012). The results of that 
study showed variations in serum susceptibility among the four representative serovars, 
and complement killing was found to occur via the classical pathway (totally C1q 
dependent). However, complement activity against the other group of human ureaplasma 
is still unknown. Therefore, the aim of this first chapter of my thesis is to investigate the 
complement activity against U. urealyticum. In addition, characterisation and speciation 
of some unknown clinical isolates will be attempted  
  
3.2 Results 
3.2.1 Killing of U. urealyticum by seronegative human serum 
The 10 standard serovars and 11 clinical isolates of U. urealyticum were investigated for 
their susceptibility to complement-mediated serum killing using 3 seronegative sera, two 
Aboklaish A.F.                                                                                                                      Chapter 3: Results 
101 
 
were previously characterised against U. parvum (Beeton et al., 2012) and one identified 
in this study (defined as an inability to detect separated U. urealyticum proteins by 
immunoblot). Complement killing assay was performed as described in section 2.2.2 
using 50% NHuS. The results, summarised in table 3.1, showed that of all the 10 
prototype U. urealyticum serovars, only three serovars, SV4, SV9, and SV13, were very 
sensitive to complement of all seronegative sera utilised (VxF1, VxF9, and VxM18). The 
growth titre reduction (fold-killing) ranged from > 100-fold to > 1000-fold killing 
reduction.  SV5 and SV10 showed intermediate susceptibility to killing with VxF1 and 
VxM18 sera (< 100-fold killing) but were resistant to VxF9 (< 10-fold).  Serum VxM18 
also had intermediate killing activity against SV8 (killing fold reduction is < 100-fold). 
The remaining serovars were resistant to killing by all seronegative sera (>90% survival 
or <10-fold killing) (Figure 3.1). In parallel with known serovars, clinical isolates also 
demonstrated variations in susceptibility to complement killing using seronegative sera. 
HPA17, HPA24, HPA43, and HPA44 were killed by all sera, with a reduction in 
surviving titre of >1000-fold (i.e. fold killing) in most cases. While other clinical isolates 
(HPA3, HPA4, HPA6, HPA12, HPA20, HPA3, and W11) were resistant to complement 
killing (Figure 3.2).  
As all sera used here were previously characterised using immunoblot as seronegative 
(i.e. there were no antibodies against U. parvum), the presence or absence of anti-
Ureaplasma IgG antibodies against U. urealyticum was also investigated in this study 
using immunoblot analysis. Immunoblot analysis of all sera to whole cell lysates from all 
prototype and clinical U. urealyticum isolates confirmed the absence of any detectable 
anti-Ureaplasma antibodies (Figures 3.1 and 3.2). All negative blots were subsequently 
re-probed with seropositive serum to rule out any false negative results. Therefore, this 
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indicates that killing of serovars and clinical isolates by seronegative sera was not 
mediated by the presence of specific anti-Ureaplasma antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Complement killing and immunoblot analysis of U. urealyticum serovars 
using seronegative NHuS. On the left side: graphs show the bactericidal activity of 3 
NHuS: VxF1, VxF9 & VxM18 against all known U. urealyticum serovars (2, 4, 5, 7-13). 
On the right side: immunoblot analysis of whole cell lysate of the serovars probed with 
1:100 dilution of the matched NHuS  on the left side of the image followed by secondary 
antibody (peroxidase-conjugated anti-human IgG).  M: Molecular mass marker (kDa). 
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This immunoblot was serially probed with the three seronegative sera, but showed strong 
bands when subsequently probed with a seropositive serum. 
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Figure 3.2 Complement killing and immunoblot analysis of 11 U. urealyticum clinical 
isolates using seronegative NHuS.  On the left side, graphs show the bactericidal activity 
of 3 NHuS: VxF1, VxF9 & VxM18 against 11 clinical isolates of unknown serovars of U. 
urealyticum (W11 & HPA 3, 4, 6, 12, 17, 20, 24, 31, 43, & 44). On the right side, western 
blot analysis of whole cell lysate of the clinical isolates probed with 1:100 dilution of the 
matched NHuS on the left side of the image followed by secondary antibody (peroxidase-
conjugated anti-human IgG).M; Molecular mass marker (kDa). This immunoblot was 
serially probed with the three seronegative sera, but showed strong bands when 
subsequently probed with a seropositive serum.  
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3.2.2 Killing of U. urealyticum by seropositive human serum 
Serovars and clinical isolates were next challenged with normal human sera that were 
shown to have detectable anti-Ureaplasma antibodies that strongly recognised a large 
number of immunoreactive protein bands from separated U. parvum proteins (Beeton et 
al., 2012). U. urealyticum was incubated with three different seropositive sera (VxF7, 
VxM11, and VxM12) to investigate if the presence of specific anti-Ureaplasma 
antibodies increased the susceptibility to complement attack.  Figures 3.3 and 3.4 show 
that the bactericidal activity of seropositive sera had a greater degree of killing compared 
to seronegative sera. However, wide variations in susceptibility to complement killing 
among serovars and clinical isolates were still observed.  Of the 10 U. urealyticum 
prototype serovars, three were completely resistant to complement-mediated killing from 
all seropositive sera in spite the presence of detectable anti-Ureaplasma antibodies. These 
serovars included SV2, SV11, and SV12. All other serovars (4, 5, 8, 9, 10, and 13) were 
susceptible to serum with killing higher than 1000-fold for the majority of them (Figure 
3.3). One exception was noted, SV7 was sensitive to VxF7 and VxM11 but resistant to 
VxM12.  No increased susceptibility for seronegative-susceptible strains SV4, SV9 and 
SV13 were observed, as they were almost completely killed by seronegative sera (Figure 
3.1). However, complement-mediated killing of serovars 5, 7, 8 and 10 were increased by 
the presence of anti-Ureaplasma antibodies, while they were resistant to killing by 
seronegative sera. 
Similarly, as shown in Figure 3.4, clinical isolates also showed variability to killing by 
seropositive sera. Some clinical isolates were resistant to complement-mediated killing 
even with the presence of anti-Ureaplasma antibodies: clinical isolates HPA3, HPA4, 
HPA6, HPA31, and W11 were resistant to killing by all seropositive sera used (less than 
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10-fold killing) and exhibited a similar susceptibility pattern to that of prototype SV2, 
SV11, and SV12.  Some clinical isolates were more susceptible to a particular serum than 
other sera: HPA12, for example, showed intermediate susceptibility to sera VxF7 and 
VxM11 (> 100-fold killing) but was resistant to serum VxM12. Clinical isolates HPA43 
and HPA44 were highly susceptible to serum killing to both seronegative (Figure 3.2) and 
seropositive (Figure 3.4) sera, while killing was increased for HPA17, HPA20, and 
HPA24 following incubation with seropositive sera relative to seronegative sera.  
Immunoblot analysis using these seropositive sera showed immunoreactivity with a broad 
range of immunoreactive Ureaplasma proteins. This confirmed the presence of specific 
anti-Ureaplasma IgG antibodies (some recognising bands of the same molecular mass 
between isolates, others showing unique bands being recognised), as was previously 
shown for characterisation of U. parvum serum susceptibility (Beeton et al., 2012).  Some 
serovars and isolates had several strong immunogenic bands whereas others have only 
few bands (Figures 3.3 and 3.4). Of all sera, VxF7 recognised a higher number of bands 
with different sizes for each serovar or isolate compared to the other two sera (VxM11 
and VxM12). VxM11 seemed to recognise a common immunogenic protein band at about 
50 kDa in both serovars and clinical isolates and another set of conserved double bands, 
with an apparent molecular mass just higher than 60 kDa, across all serovars.  VxM12 
recognised a few bands with low intensity among both serovars and clinical isolates.  
The presence of immunoreactive protein bands and the intensity of the immunoreactivity 
showed no correlation to the susceptibility to serum killing. In fact, some serovars and 
clinical isolates were totally resistant to complement killing (e.g. SV2 and W11) despite 
the presence of a number of antigenic protein bands, which reacted strongly with 
antibodies (Figures 3.3 and 3.4). In contrast, others had few antigenic bands but showed 
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high susceptibility to the bactericidal activity of serum, (e.g. SV9 and HPA17) (Figures 
3.3 and 3.4).  The antigenic banding pattern detected by antibodies varied among serovars 
and clinical isolates as well as with the different seropositive sera used. However, some 
clinical isolates showed distinctive consistent banding patterns across the three sera 
(HPA20, HPA24, and HPA31); those clinical isolates had interestingly shown similar 
immunoblot banding pattern but had different serum susceptibility. HPA31 was totally 
serum-resistant while HPA20 and HPA24 were serum-sensitive. These observations 
indicate both antigenic diversity and conservation among serovars and clinical isolates. 
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Figure 3.3 Complement killing and immunoblot analysis of U. urealyticum serovars 
using seropositive NHuS. On the left side: graphs show the bactericidal activity of 3 
NHuS: VxF7, VxM11 & VxM12 (seropositive sera) against all known U. urealyticum 
serovars (2, 4, 5, 7-13). On the right side: immunoblot analysis of whole cell lysate of the 
serovars probed with 1:100 dilution of the matched NHuS  on the left side of the image 
followed by secondary antibody (peroxidase-conjugated anti-human IgG).  M: Molecular 
mass marker (kDa). 
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Figure 3.4 Complement killing and immunoblot analysis of U. urealyticum clinical 
isolates using seropositive NHuS.  On the left side, graphs show the bactericidal activity 
of 3 NHuS: VxF7, VxM11 & VxM12 (seropositive sera) against 11 clinical isolates of 
unknown serovars of U. urealyticum (W11 & HPA 3, 4, 6, 12, 17, 20, 24, 31, 43, & 44). 
On the right side, western blot analysis of whole cell lysate of the clinical isolates probed 
with 1:100 dilution of the matched NHuS on the left side of the image followed by 
secondary antibody (peroxidase-conjugated anti-human IgG).M; Molecular mass marker 
(kDa).  
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3.2.3 Segregation of U. urealyticum based on serum susceptibility 
U. urealyticum revealed a wide variation of susceptibility to complement-mediated serum 
killing, ranging from antibody-independent bactericidal activity to complete bactericidal 
resistance despite the presence of anti-Ureaplasma antibodies in the serum as observed 
by immunoblot analysis (Tables 3.1 and 3.2). According to their serum susceptibility, U. 
urealyticum serovars and clinical isolates can be clustered into three groups (Table 3.3): 
Killed by all NHuS (antibody-independent bactericidal activity), killed by seropositive 
sera only (antibody-mediated bactericidal activity) and not killed by any sera (complete 
bactericidal resistance). The first group contained serovars 4, 9, and 13 as well as the 
clinical isolates HPA17, HPA24, HPA43, and HPA44. These were shown to be the most 
serum-sensitive representative of U. urealyticum.  The second group consisted of SV5, 
SV7, SV8 and SV10, with the clinical isolates HPA12 and HPA20. The final group 
composed of SV2, SV11 and SV12 as well as the clinical isolates HPA3, HPA4, HPA6, 
HPA31, and W11, and this group represent the first reported strains of serum-resistant U. 
urealyticum.   Although the unknown clinical isolates were grouped with known serovars 
based on that category, the next step is to try to identify which serovars these isolates 
belong to, to see if serum-susceptibility is correlated to serovar. 
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Table 3.1 Susceptibility of U. urealyticum serovars to killing by normal human serum 
Serovars 
Susceptibility to serum killing 
Presence of immune-reactive bands (kDa) detected  by NHuS 
Seronegative sera Seropositive sera 
VxF1 VxF9 VxM18 VxF7 VxM11 VxM12 VxF1 VxF9 VxM18 VxF7 VxM11 VxM12 
SV2 R R R R R R - - - 
90, 72, 60 
& 56 
220, 120, 80, 
82, 84, 61& 
50 
220, 200, 122, 
90, 72, 61 & 50 
SV4 S S S S S S - - - 90, 72, 61 61& 50 220, 200 
SV5 S R R S S S - - - 
120, 90, 
72, 71, 60 
&56 
61& 50 
220, 200, 90, 
72 & 50 
SV7 R R R S S R - - - 
90, 72, 60 
&56 
61& 50 220 & 72 
SV8 S R S S S S - - - 
90, 72, 60 
&56 
61& 50 220, 200 & 50 
SV9 S S S S S S - - - 
90, 72, 60 
&56 
61& 50 220, 200 
SV10 S R S S S S - - - 
122, 
90,63, & 
60 
61& 50 80 
SV11 R R R R R R - - - 90 & 60 61& 50 220, 200 & 90 
SV12 R R R R R R - - - 
90, 82, 72, 
60 & 56 
61& 50 
220, 200, 90, 
80 & 60 
SV13 S S S S S S - - - 
90, 72, 63 
& 56 
61& 50 
220, 120, 95, 
90 & 50 
R = resistant to complement killing; S = Sensitive to complement killing. 
 - = absence of detestable antibodies against U. urealyticum 
+ = presence of detectable antibodies against U. urealyticum 
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Table 3.2 Susceptibility of U. urealyticum clinical isolates to killing by normal human serum  
Clinical 
isolates 
Susceptibility to serum killing 
Presence of immune-reactive bands (kDa) detected by NHuS 
Seronegative sera Seropositive sera 
VxF1 VxF9 VxM18 VxF7 VxM11 VxM12 VxF1 VxF9 VxM18 VxF7 VxM11 VxM12 
HPA3 R R R R R R - - - 90 & 72 
220, 200, 120, 100, 
72, 58 & 50 
121, 90, 72 & 
50 
HPA4 R R R R R R - - - 90, 72 & 45 
220, 200, 120, 100, 
58 & 50 
220, 200, 90 & 
50 
HPA6 R R R R R R - - - 
90, 72, 62, 63 
& 45 
220, 200, 120, 100, 
55 & 50 
121, 90, 50 & 
43  
HPA12 R R R S S R - - - 
90, 72, 59 & 
45 
220, 200, 120, 100, 
58 & 50 
121, 90, 50 & 
43 
HPA17 S S S S S S - - - 90 
220, 200, 120, 100 
& 50 
220, 200, 90, 
50 & 43  
HPA20 R R S S S S - - - 
100, 90, 72, 
60 & 45   
220, 200, 120, 100, 
72, 60, 58 & 50 
220, 200, 90, 
72, 60, 50 & 43 
HPA24 S S S S S S - - - 72 & 60 
220, 200, 120, 100, 
60, 58 & 50 
121, 90, 60, 50 
& 43 
HPA31 R R R R R R - - - 90, 72 & 60 
220, 200, 120, 100, 
60, 58 & 50 
121, 90, 60, 50 
& 43 
HPA43 S S S S S S - - - 
90, 72, 59 & 
45 
220, 200, 120, 100 
& 50 
220, 200, 90, 
50 & 43 
HPA44 S S S S S S - - - 90, 72 & 60 
220, 200, 120, 100, 
60, 58 & 50 
121, 90, 60, 50 
& 43 
W11 R R R R R R - - - 
90, 85, 72, 60, 
45 & 41 
220, 200, 120, 100, 
72, 60, 58 & 50 
220, 200, 90, 
72, 60, 50 & 43 
R = resistant to complement killing; S = Sensitive to complement killing. 
 - = absence of detestable antibodies against U. urealyticum 
+ = presence of detectable antibodies against U. urealyticum 
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Table 3.3 Segregation of U. urealyticum based on serum susceptibility  
 
 Group I Group II Group III 
Killed by all sera in the absence or presence 
of antibodies 
Antibody-mediated killing
۩
 
Resistant to all sera even in the presence of 
antibodies 
Serovars 
SV4, SV9, and SV13 SV5, SV7, SV8  and SV10 SV2, SV11 and, SV12 
Clinical isolates 
HPA17, HPA24, HPA43, and HPA44 HPA12 and HPA20 HPA3, HPA4, HPA6, HPA31, and W11 
 ۩= some serovars and clinical isolates within this group showed low susceptibility to complement-mediated serum killing by some seronegative 
sera (SV5, SV8, SV10 & HPA20) and others were resistant to killing by one of seropositive sera (SV7 & HPA12).     
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3.2.4 Determination of U. urealyticum serovars and clinical isolates by         
variation in MBA serovar type and apparent molecular mass.  
 Determination of serovars for U. urealyticum is not as easy as it is for U. parvum.  
Historically the serovars were determined by growth inhibition zones around paper 
circles soaked in various rabbit anti-sera (Shepard and Lunceford, 1978). More recently, 
sequence variation within the promoter and coding region for the MBA have validated 
the separation of isolates into SV1, 3, 6 and 14 for U. parvum (Beeton et al., 2009b; Kong 
et al., 1999b; Teng et al., 1994).  However, the sequence variation is not as distinct for U. 
urealyticum.  Only 3 polymorphisms in the promoter region separate SV7/11 from 
SV2/5/8/9 and SV4/10/12/13 (Figure 3.5), while predicted amino acid sequence of the 
entire open reading frame for SV7 and 11 are identical as are SV4, 12 and 13 and SV2, 5 
and 8.  Only SV9 and SV10 have unique MBA amino acid sequence (Figure 3.5).  The 
promoter and MBA coding region were amplified using a set of primers designed based 
on conserved regions of the known genomic sequence of the prototype U. urealyticum 
serovars. The sequences of the amplicons were then compared by nucleotide blast for the 
closest homology in the NCBI database. Based on alignment of sequence results, all 11 
unknown clinical isolates were assigned to known U. urealyticum serovars as presented 
in Table (3.4). Clinical isolates HPA3 and HPA43 were defined as SV9; HPA4, HPA6 
and HPA12 were grouped with SV4/12/13 cluster; and HPA17 and HPA20 were assigned 
to SV2/5/8. HPA24, HPA31 and HPA44 were defined as SV10, of which HPA24 and 
HPA31 were further confirmed with anti-MBA monoclonal antibody generated 
specifically for SV10 (Figures 3.6). The clinical isolate W11 was assigned as SV12 by 
both total genome sequencing and MBA gene homology.   
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Sv11      MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
Sv7       MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
Sv9       MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
Sv4       MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
Sv12      MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
sv13      MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
Sv10      MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
Sv2       MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
Sv5       MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
Sv8       MKLLKNKKFWAITLGVTLVGAGVVAVAASCSSSNVKSKLSSQLVKSKDEKSFYAVYDIEN 
          ************************************************************ 
 
Sv11      FDDLTENDKKALNETEFNVAITSVENKTENATIKGHLLNKKIYVKLPREPKAKEQLTIIN 
Sv7       FDDLTENDKKALNETEFNVAITSVENKTENATIKGHLLNKKIYVKLPREPKAKEQLTIIN 
Sv9       FDDLTENDKKALNEAEFNVAITSAENKTENATTKGHLLNKKIYVKLPREPKAKEQLTIIN 
Sv4       FDDLNENDKKALNEAEFNVAITSAENKTENATTKGHLLNKKIYVKLPREPKAKEQLTIIN 
Sv12      FDDLNENDKKALNEAEFNVAITSAENKTENATTKGHLLNKKIYVKLPREPKAKEQLTIIN 
sv13      FDDLNENDKKALNEAEFNVAITSAENKTENATTKGHLLNKKIYVKLPREPKAKEQLTIIN 
Sv10      FDDLNENDKKALNEAEFNVAITSAENKTENATTKGHLLNKKIYVKLPREPKAKEQLTIIN 
Sv2       FDDLTENDKKALNEAEFNVAITSAENKTENATTKGHLLNKKIYVKLPREPKAKEQLTIIN 
Sv5       FDDLTENDKKALNEAEFNVAITSAENKTENATTKGHLLNKKIYVKLPREPKAKEQLTIIN 
Sv8       FDDLTENDKKALNEAEFNVAITSAENKTENATTKGHLLNKKIYVKLPREPKAKEQLTIIN 
          ****.*********:********.******** *************************** 
 
Figure 3.5 Amino acid polymorphisms within the promoter region of the multiple-
banded antigen (MBA) of U. urealyticum serovars. Multiple sequence alignment results 
indicated that the 10 serovars of U. urealyticum can be separated into three groups: 
SV7/11, SV2/5/8/9 and SV4/10/12/13. 
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Figures 3.6 Immunoblot analysis of total cell lysates of Ureaplasma spp. probed with 
anti-SV10 monoclonal antibody (MAb 8A1.2; Watson et al. 1990). A) The SV10 specific 
antibody detected only SV10 among all 14 known serovars. B) The same antibody 
recognized two unknown clinical isolates of U. urealyticum HPA24 and HPA31 as SV10. 
Molecular mass weight indicated in kilo Daltons. 
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Table 3.4 Summary of sequencing results shows the assigning of the 11 unknown U. 
urealyticum clinical isolates to known serovars based on nucleotide homology in MBA 
gene. 
 
(1): W11 was also defined as SV12 by full genome sequence homology. 
 
 
 
 
 
 
 
 
 
 
Clinical 
isolate 
Defining repeat 
sequence 
Serovar Primer 
HPA3 No repeats- MBA short 
Closest SV9 (92% aa & 96% nt) 
than SV7/SV11 
revMBA Uu2 
HPA4 PEKPGNGTTS SV4/SV12/SV13 revMBA Uu1 
HPA6 PEKPGNGTTS SV4/SV12/SV13 revMBA Uu1 
HPA12 PEKPGNGTTS SV4/SV12/SV13 revMBA Uu1 
HPA17 No repeats 
Closest SV2 (92% aa & 96% nt) 
than SV12 (90% aa) 
revMBA Uu2 
HPA20 PEKPGNGTTS SV4/SV12/SV13 revMBA Uu1 
HPA24 PGSGSTTQ SV10 revMBA Uu2 
HPA31 PGSGSTTQ SV10 revMBA Uu2 
HPA43 KKPETGSTEGGSTEG SV9 revMBA Uu2 
HPA44 No repeats 
Closest SV10 (92% aa), but this is 
the only annotated gene in the 
genebank for U. urealyticum 
revMBA Uu1 
W11 
(1) No repeats Closest SV12 (98% aa) revMBA Uu2 
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3.2.5 Correlation between serum sensitivity and serovar type 
Previously, Beeton et al (2012) had identified that all SV3 types examined were sensitive 
to killing by seronegative sera.  Similarly, using my prototype strains, I found that SV4, 9 
and 13 were sensitive to seronegative sera.  Examination of the typing results for my 
clinical strains (Table 3.4) found that HPA43 was also a SV9, and it was also sensitive to 
killing by seronegative sera, which supports this hypothesis.  However, it is not possible 
to separate serum sensitive SV4 and 13 from serum resistant SV12 by the MBA typing 
method.  It is possible that the resistant clinical isolates W11, HPA4 and 6 were SV12, 
but given the lack of variation in MBA sequence between SV4, 12 and 13, it is not 
possible for the MBA to be the mediator of differential serum susceptibility.  
Furthermore, HPA24 and 31 were found to be SV10, but HPA24 was serum sensitive, 
HPA31 was serum resistant and prototype SV10 was intermediate in its serum sensitivity.  
Therefore, I conclude that serovar type for U. urealyticum does not differentiate the 
serum sensitivity of isolates. 
 
3.2.6 Correlation between serum sensitivity and mass of the MBA 
The purpose of this experiment was to investigate differences in the MBA repeats among 
the 14 standard serovars of Ureaplasma spp., using monoclonal anti-MBA antibodies, 
and correlate such changes with serum susceptibility among serovars.  Immunoblot 
analysis of whole cell lysate of all 14 serovars showed variations in the MBA banding 
pattern among serovars. The MBA band sizes ranged from less than 40 kDa to larger than 
80 kDa (Figure 3.7). The amino acid sequence shows complete conservation of the N-
terminal 63 a.a. residues for U. urealyticum and only 6 polymorphisms in the first 141 
amino acid residues (Figure 3.5).  The repeat units that separate MBA into specific 
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serovars begin at 146 amino acid residues.  The region of short repeat sequences 
determined the varying mass of the MBA by having greater or fewer relative numbers of 
repeats (Chang-tai et al., 2011; Zheng et al., 1995).  Therefore, serovars with a large 
MBA band have greater number of tandem repeat units, while lower MBA bands contain 
fewer tandem repeat units. In addition, some isolates were observed to have more than 
one MBA with different sizes. Correlating these findings with complement killing results, 
which were obtained in this study as well as from the previous Beeton et al (2012) U. 
parvum study, showed no clear relationship between the MBA protein size and 
susceptibility of Ureaplasma to complement-mediated serum killing.  While the 
seronegative-sensitive serovars SV3, SV4, SV9 and SV13 all have the smallest MBA 
isoforms, suggesting that smaller MBA correlate to high serum sensitivity, the totally 
serum resistant strains SV2, SV11, and SV12, did not have the largest MBA with masses 
between sizes 60-72 kDa (Figure 3.7.A and Table 3.3).  Those prototype strains with the 
largest MBA, SV5, 10 and 14, had intermediate susceptibility that was increased by the 
presence of anti-Ureaplasma antibodies in seropositive serum indicating that the MBA 
serves as a target for antibody-mediated complement activation. In a similar way, the 
clinical isolates did show any correlation between the size of MBA and their 
susceptibility to complement killing. This observation was clearly presented in two 
clinical isolates (HPA24 and HPA31) that had a large MBA size but different serum 
susceptibility. HPA24 was very sensitive to complement-mediated serum killing, while 
HPA31 was serum-resistant (Figure 3.7.B and Table 3.3). Failure to correlate MBA size 
to seronegative sensitivity was also shown for HPA17, which was sensitive but had an 
intermediate size of MBA. 
To investigate such a correlation further, several clinical isolates of SV3 of U. parvum 
that have different serum susceptibility were compared with one another based on MBA 
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sizes, which were correlated to their sensitivity to NHuS. Beeton et al (2012) had 
previously published that strains HPA5, 7, 8 and 9 were all sensitive to seronegative sera 
killing, while I have found strains HPA56, HPA57, UHW4 and UHW5 to be sensitive to 
seropositive sera killing, but resistant to seronegative sera killing (detailed in Chapter 4).  
Two conclusions can be drawn from this: 1) SV3 isolates are not all inherently sensitive 
to seronegative sera as previously reported and 2) Comparison of MBA mass in Figure 
3.8 shows no difference in MBA molecular mass between serum sensitive and serum 
resistant isolates. 
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Figure 3.7 Immunoblot analysis of whole-cell lysate from Ureaplasma spp. probed with 
anti-MBA antibody (6522). The blot shows variations in MBA expression among the 14 
serovars (A) and 11 U. Urealyticum clinical isolates. Some serovars and clinical isolates 
expressed only one variant of MBA; while others expressed more than one variant. The 
MBA band size varied from just less than 40 kDa to larger than 100 kDa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Immunoblot analysis of total-cell protein of a number of U. parvum SV3 
strains probed with anti-MBA monoclonal antibody, SV3 specific, (MAb 10C6.6). The 
blot shows variations in MBA expression among SV3 isolates and strains with varying 
sizes. Some of them expressed only one variant of MBA; while others expressed more 
than one variant with different intensity. One strain appeared as MBA-negative clone 
(HPA7), while another one (UHW6) showed weak reactivity. The MBA band size varied 
from 50 kDa to 100 kDa. 
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3.3 Discussion 
Complement-mediated serum killing is one of the effector arms of the innate immunity 
(Walport, 2001a). Many pathogenic bacteria have been shown to be serum-sensitive. 
However, within these bacterial species, serum-resistant strains have also been shown to 
emerge as a way of avoiding clearance by the immune defences. Serum-resistant isolates 
were proven to be more invasive and pathogenic than the serum-sensitive strains (Fierer 
et al., 1972; Joiner et al., 1984). The complement system, as one of the initial innate 
immune barriers that mediate microbial removal, has been targeted by various pathogens 
strategies to prevent or avoid the complement activation, and hence, the subsequent 
innate and acquired immune responses. Gram-negative and Gram positive pathogenic 
bacteria have been known to avoid the complement system activation by several 
mechanisms, many of them shared across species (Zipfel et al., 2007). Although the 
complement system cannot directly lyse Gram-positive bacteria, it is able to opsonize and 
label them to be recognized by the other arsenals of immune system. In turn, Gram-
positive bacteria have evolved several ways to evade such activity. A typical example of 
complement system evasion by Gram-positive bacteria has been reported for S. aureus. 
This pathogen produces and expresses a number of proteins that prevent the recognition 
and inhibit the activation of the classical, lectin, and alternative pathways. Of these 
proteins, two surface-expressed proteins bind to and disrupt IgG function and prevent the 
antibody-dependent activation of the classical pathway:  staphylococcal protein A (SpA) 
and staphylococcal immunoglobulin-binding protein (Sbi). The latter surface protein, Sbi, 
is also believed to impair binding of C1q and hence the activation of the classical 
pathway (Atkins et al., 2008). In addition, Sbi can prevent the activation of alternative 
pathway via binding C3, factor H (FH) and factor H-related proteins (Haupt et al., 2008). 
On the other hand, many Gram-negative bacteria are able to regulate and inhibit 
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complement activation by binding complement regulators; an example of this is P. 
aeruginosa which produces a protein termed pseudomonas CRASP-1 that binds host 
plasminogen and factor H and prevents the activation of the alternative pathway (Zipfel et 
al., 2007). In addition, EF-Tu of this pathogen has also reported to be a binging protein 
for FH and plasminogen (Kunert et al., 2007).  
In this chapter I have presented an extension to the previously published work from our 
laboratory, which investigated the effect of the bactericidal activity of normal human 
sera, from 12 healthy people, upon U. parvum (Beeton et al., 2012). In this study, I 
investigated the complement killing activity against the other important species of human 
Ureaplasma, U. urealyticum, using 5 previously characterised sera and one new 
seronegative serum from a healthy individual. The 10 standard serovars and 11 clinical 
isolates were assessed for their susceptibility to complement killing using 50 % normal 
human serum (with serological status defined by immunoblot absence or presence of 
detectable anti-Ureaplasma antibodies).  
The study by Beeton and colleagues (2012) demonstrated variations in susceptibility to 
complement among the four representative serovars of U. parvum (SV1, SV3, SV6 and 
SV14), which is in agreement with my findings in this study. U. urealyticum serovars and 
clinical isolates also showed wide variations in susceptibility to complement killing. The 
results presented here indicated that a similar pattern of susceptibility between the two 
species could be seen. For example, with U. parvum, it was found that SV3 was very 
susceptible to killing by all sera used even in the absence of anti-Ureaplasma IgG or IgM 
antibodies. Killing of SV3 was found to be C1q-dependent; therefore, mediated by the 
classical complement pathway.  Whether this was mediated through the direct binding to 
C1q or via low affinity anti-bacterial carbohydrate IgM that is not detectable by 
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immunoblot remains to be determined.  Similarly in this study, SV4, SV9 and SV13 were 
found to be highly sensitive to serum killing; and the mechanism of killing by 
complement appeared to be via complement activation, independent of the presence of 
detectable anti-Ureaplasma antibodies.  
Additionally, antibody-mediated killing among U. parvum was also documented. SV1, 
SV6, and SV14 were found to be killed by serum only with the presence of detectable 
anti-Ureaplasma IgG specific antibodies (presumably via the classical pathway of the 
complement).  Although I have not investigated the role of each independent complement 
pathway in the killing of U. urealyticum serum-sensitive strains, the results obtained here 
suggest a similar mechanism of killing. Some U. urealyticum serovars and isolates 
presented a comparable susceptibility pattern; SV5, SV7, SV8, and SV10, for instance, 
were killed by complement in the presence of specific anti-Ureaplasma IgG antibodies, 
which indicates that their complement killing requires activation of the classical pathway 
by binding the C1q to antibody bound to Ureaplasma surface protein(s). Complement-
mediated serum killing in other bacteria has been extensively studied. In Gram-negative 
bacteria, it was found that their killing is mainly derived by the classical pathway, which, 
in most cases, requires binding of C1q to antibody for the activation.  However, antibody-
independent binding of C1q to Gram-negative bacterial cell surface components has also 
been demonstrated (Alberti et al., 1993; Taylor, 1983). Beeton and colleagues have 
studied the role of the three complement activation pathways, the classical, the alternative 
and the lectin (CP, AP, and LP), all together and separately, in complement activation and 
killing of U. parvum. These pathways were investigated by depleting calcium, removing 
C1q or MBL to inactivate AP, CP or LP, respectively (Beeton et al., 2012).  The authors 
concluded that complement killing of U. parvum was mediated by the CP (C1q-
dependent) and that AP and LP had no role in the killing.  
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In contrast to the previous study by Beeton et al., (2012), I found some strains that were 
completely resistant to killing by seropositive sera that was bactericidal to all other strains 
tested. I found serum resistance among prototype U. urealyticum SV2, SV11 and SV12 
strains that were totally resistant to serum bactericidal activity even in the presence of 
specific anti-Ureaplasma IgG antibodies. This observation was also seen among some 
clinical isolates (HPA3, HPA4, HPA6, HPA31, and W11). Evolving resistant strains 
among U. urealyticum can be strong evidence that these tiny bacteria species is also able 
to manipulate the immune defences and develop sophisticated strategies to survive the 
killing mediated by the complement activation. Several potential mechanisms could be 
involved in such resistance. A wide array of evasion mechanisms identified in other 
bacteria to avoid complement killing could also be utilised by Ureaplasma. An excellent 
review on mechanisms used by microbial pathogens to elude the complement lethal 
activity was published by (Lambris et al., 2008).  
In my study I have attempted to test a postulated mechanism of serum resistance that 
could be utilised by Ureaplasma spp. to overcome complement activation. This 
hypothesis was the correlation between serum resistance and MBA size. In the closely 
related species, M. pulmonis, it was found that the variable surface antigens (Vsa), which 
is one of the virulence factors (adhesin molecule), plays a direct role in serum 
susceptibility (Simmons et al., 2004; Simmons and Dybvig, 2003). These antigens have a 
C-terminal variable region that consists of tandem repeats that vary in length from one 
strain to another. Strains that produce a VsaA protein with 40 tandem repeats were found 
to be highly serum-resistant compared to that with short tandem repeats.  However, the 
repeat unit of VsaA was found to contain a glycosylation site that resulted in contributing 
to the glycocalyx of the bacteria as a physical shield against complement attack (Bolland 
et al., 2012).  Similarly, the multiple banded antigens (MBA) is a major surface protein 
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expressed by all Ureaplasma spp. proposed as one of the virulence factors for these 
microorganism. This antigen also has a C-terminal region composed of multiple tandem 
repeat units. It has been found that alterations in the copy number of the tandem repeats 
of that region were responsible for size variations in the MBA (Zheng et al., 1995). 
However, the role of modulations in the C-terminal regions in Ureaplasma pathogenesis 
and susceptibility to complement killing has not been defined yet. I hypothesized that a 
similar role for serum resistance found with VsaA may exist with the MBA (i.e. serovars 
with long tandem repeats would be serum-resistant and those with short repeats would be 
sensitive). Upon testing my hypothesis, I found that such correlation did not exist among 
the species of Ureaplasma, as  some  small-size MBA Ureaplasma strains were serum-
resistant and vice versa. This may be related to the fact that the repeat units for 
Ureaplasma are not predicted to be glycosylated.    
The next chapter of the thesis will focus on investigating some other potential 
mechanisms that lead to serum resistance and avoiding host immune responses among 
Ureaplasma.  
  
  
Chapter 4 
Monitoring and 
determining immunogenic 
proteins and their stability 
under immunological 
pressure
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4. Monitoring and determining immunogenic proteins 
and their stability under immunological pressure  
4.1 Introduction 
The capacity to escape a host immune response is an adaptive strategy employed by 
several microbial pathogens. A variety of bacterial species have developed different 
sophisticated strategies to avoid the bactericidal activity of normal human serum via the 
complement system and survive in their host milieu. For instance, some bacteria use 
molecular mimicry, altering their outer membranes, to resemble host tissues in order to 
avoid complement activation (Janulczyk et al., 2000; Rokita et al., 1998; van den Berg et 
al., 1996; Wurzner, 1999). Other bacterial species express proteins that are able to bind 
host-derived complement regulators such as factor H and factor H-like protein 1 (FHL-1) 
to survive the potentially lethal attack of complement system (China et al., 1993; Kraiczy 
et al., 2001; Neeleman et al., 1999; Pérez‐Caballero et al., 2000).  In a similar way, 
members of the genus Mycoplasma, which is closely related to Ureaplasma, have also 
been shown to alter their surface antigens and manipulate the host immune defences. 
Both antigenic and phase variations are believed to be mechanisms by which 
Mycoplasma overcomes host immune responses and establish chorionic infections 
(Calcutt et al., 1999; Citti et al., 2010; Razin et al., 1998).  
The species of Ureaplasma are opportunistic pathogens that colonise the mucosal 
membranes of the urogenital tract of humans and are associated with several medical 
problems such as non-gonococcal urethritis, infertility, pregnancy complications, 
chorioamnionitis and bronchopulmonary dysplasia in premature babies (Yu et al., 2005). 
Little is known about the pathogenesis of Ureaplasma spp. and their interactions with 
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their human host immune system. Members of the Ureaplasma genus have also been 
shown to use such strategies to manipulate the immune defences by switching their 
surface antigens. A number of studies have demonstrated phase and antigenic variations 
in a major surface antigen of Ureaplasma, the multiple-banded antigen (MBA), both in 
vivo and in vitro (Dando et al., 2012; Monecke et al., 2003; Robinson et al., 2013; Zheng 
et al., 1994; Zimmerman et al., 2011; Zimmerman et al., 2009). Therefore, it was 
suggested as one of the virulence factors that play a pivotal role in the pathogenesis of 
these species. However, the exact role that this antigen plays in the pathogenesis of 
human Ureaplasma, especially serum resistance, is still not fully understood. 
Furthermore, observations of changes in other immunoproteins have not been reported 
yet.  
This chapter is divided into two parts: the first part is an in vitro study, which aims to 
induce serum-resistance of known serum-sensitive strains through repeated sublytic 
challenges by seropositive or seronegative human sera. Changes in Ureaplasma 
antigenicity (size and number of bands detected by Western blotting) as a result of 
immunological pressure will then be determined and a candidate protein(s) will be 
identified and studied. Subsequently, mechanisms of serum resistance and avoidance of 
complement killing among human Ureaplasma will also be identified. The second part of 
the chapter is the examination of serially collected isolates from endotracheal secretions 
obtained from preterm babies, who are intubated for ventilated-assisted breathing, to 
examine phenotypic and antigenic differences that evolve in vivo over a period of time.  
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4.2 Part 1 results: the in vitro investigation 
4.2.1 Generation of serum-resistant strains following serial challenge with 
seropositive serum 
Generation of serum-resistant (SR) strains from serum-sensitive (SS) parental strains was 
accomplished by subjecting serum-sensitive Ureaplasma clinical isolates to repeated 
immunological pressure in vitro, until resistant strains emerged, using a modified 
complement killing assay as described in section 2.2.3. Two serum-resistant strains, SR-
DFK1 (SV1) and SR-HPA2 (SV6) were created from serum-sensitive patients (SS-DFK1 
and SS-HPA2) following serial challenge with a high titre seropositive serum. Induced 
resistance was accomplished with several other strains of the same serovars, SV3 and 
some U. urealyticum strains. However, these two strains were initially chosen for in depth 
investigation of underlying mechanism of serum resistance. The parent strains were 
initially sensitive to seropositive sera but resistant to seronegative sera, and therefore 
repeated serum challenge was performed using seropositive sera. Resistant variants, SR-
DFK1 and SR-HPA2, had emerged after 5 and 4 repeated challenges, respectively, and 
they became completely resistant to seropositive sera compared to their parent strains. 
Altered serum sensitivity was confirmed by the complement killing assay, in triplicate, on 
the induced serum-resistant clones compared with parental strains (Figure 4.1). Matched 
sensitive parental strains and resistant progeny were further investigated using 
immunoblotting and proteomic analyses to identify and study any alterations in 
immunogenic proteins and determine possible mechanisms of serum resistance. 
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Figure 4.1 Serum susceptibility of the induced serum-resistant strains, SR-DFK1 and SR-
HPA2, (red bars) compared with their parent strains (blue bars), DFK1 (SV1) and HPA2 
(SV6). The black dotted arrow indicates the 90% killing threshold.  
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4.2.2 Alterations in immunogenic proteins following challenge with 
seropositive serum  
Immunoblot analysis was performed using the seropositive serum used to generate the 
resistant strains (VxF7) and anti-MBA monoclonal antibodies to identify any changes in 
immunogenic proteins in the induced serum resistant strains compared to the parent 
strains. The results showed significant variations in immunoreactive protein bands 
between the serum-resistant strains and parents, as detected by Western blotting (Figure 
4.2). The high titre seropositive serum detected a loss of a single band at approximately 
90 kDa and gain of two new bands at about 81 and 41 kDa in the SR-DFK1 (SV1) 
compared to the parent strain (Figure 4.2.A). In contrast, the other induced resistant 
strain, SR-HPA2, did not show any loss of immunogenic proteins but expressed an 
immunogenic protein at about 41 kDa (similar to that seen with SR-DFK1) (Figure 
4.2.C). Anti-MBA monoclonal antibody, 2G9 (specific for SV1 and SV6) detected and 
confirmed changes in MBA in only one of the induced resistant strains, SR-DFK1. The 
lost band (90 kDa) and the new emerging band (81 kDa) in DFK1 strains were detected 
with the anti-MBA monoclonal antibody and confirmed as MBA bands with difference in 
size (Figure 4.2.B-1). HPA2 strains did not show any changes in MBA bands and both of 
them (SS-HPA2 and SR-HPA2) expressed MBA bands of the same size (about 80 kDa) 
when detected by anti-MBA monoclonal antibody (Figure 4.2.B-2). The new expressed 
protein band (41 kDa), in both serum-resistant strains (SR-DFK1 and SR-HPA2) was not 
detected by anti-MBA monoclonal antibody (Figure 4.2.B-1 and B-2). This indicated that 
these resistant strains expressed a new immunogenic protein, consistently co-incident 
with induced resistance and was a strong candidate to play a role in direct evasion of 
complement killing.  
Aboklaish A.F.                                                                                                                      Chapter 4: Results 
132 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Immunoblot analysis of total cell lysate from two induced serum-resistant 
strains, SR-DFK1 and SR-HPA2, compared to their serum-sensitive parents,     SS-DFK1 
(SV1) and SS-HPA2 (SV6). Blots A and C were probed with the high titre seropositive 
serum (VxF7). In blot A, blue arrows indicate loss and gaining of immunogenic protein 
bands in the resistant strain, SR-DFK1, whereas red arrows in blots A and C indicate new 
immunogenic protein bands expressed only in the resistant strains, (SR-DFK1 and 
SR,HPA2). Blot B probed with anti-MBA monoclonal antibody (2G9); blue arrows in B-
1 indicate and confirmed changes in MBA bands (change in size) in SV1 resistant strain, 
whereas no change in SV6 strains. M= molecular mass marker.   
Aboklaish A.F.                                                                                                                      Chapter 4: Results 
133 
  
4.2.3 Generation of serum-resistant strains following serial challenge with 
seronegative serum  
To further investigate serum resistance and alterations in immunogenicity of Ureaplasma, 
two representative seronegative-sensitive ureaplasmas (SV9 and HPA5 (SV3)) were also 
challenged with seronegative NHuS. These particular strains were different from the 
above challenged isolates as they were readily killed by both seronegative and 
seropositive sera. SV9 was indicated as one of the serum-sensitive strains identified 
among U. urealyticum, as presented in chapter 3 of this thesis. On the other hand, HPA5 
(SV3) was found to be the most sensitive strain to complement-mediated serum killing 
among U. parvum (Beeton et al., 2012). The results showed that following 9 serial 
challenges with seropositive serum, the serum-sensitive SV9 had become resistant to 
seronegative sera killing. However, this resultant strain, SR-SV9, was also found to 
additionally be resistant to seropositive sera as well (Figure 4.3) as it was totally resistant 
to serum killing. On the other hand, no serum-resistant strains were developed from the 
serum-sensitive HPA5 after 14 consecutive challenges (Figure 4.3). Both SR-SV9 and 
serum-attacked HPA5 (SA-HPA5) were also investigated by western blotting to observe 
any significant differences in immunogenic proteins as compared to their respective 
parental strains. 
 
Aboklaish A.F.                                                                                                                      Chapter 4: Results 
134 
  
 
VxF9 VxF7
1
10
100
1000
10000
100000
1000000 SS-SV9
SR-SV9
SV9
S
e
ru
m
 k
il
li
n
g
  
(k
il
li
n
g
 f
o
ld
 d
e
c
re
a
s
e
)
VxF9
1
10
100
1000
10000
100000
SS-HPA5
SA-HPA5
HPA5 (SV3)
S
e
ru
m
 k
il
li
n
g
  
(k
il
li
n
g
 f
o
ld
 d
e
c
re
a
s
e
)
 
 
Figure 4.3 Serum susceptibility of the induced serum-resistant SV9 strain, SR-SV9 (red 
bars) and serum-attacked sensitive HPA5 (SV3) strain, SA-HPA5 (yellow bar) compared 
to their serum-sensitive parental strains (blue bars). The graphs show clear difference 
between SV9 isolates, whereas the attacked HPA5 remained sensitive to complement 
killing. VxF9 = seronegative serum and VxF7 = seropositive serum.  Black dotted arrows 
indicate the 90% killing threshold. 
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4.2.4 Alterations in immunogenic proteins following challenge with 
seronegative sera  
Immunoblot analysis of total cell proteins of SR-SV9 using monoclonal anti-MBA 
antibody (6522) detected a single band of the multiple banded antigen (MBA) at about 90 
kDa with a significant size variation compared to that of  the parent strain (SS-SV9), with 
an MBA size of approximately 50 kDa (Figure 4.4.B-2). Probing the same blot with 
seropositive serum clearly showed a new immunogenic protein band at about 41 kDa in 
SR-SV9 compared to the parent strain (SS-SV9) (Figure 4.4.C). This protein band was 
exactly the same as the ones seen in both SR-HPA2 and SR-DFK1 above, and was 
coincident with developing serum resistance. In the repeatedly serum attacked HPA5 
strain (SA-HPA5) monoclonal anti-MBA antibody (10C6.6, SV3 specific) detected a 
minor size variation in MBA band (a small decrease of about 1-2 kDa) compared to the 
MBA band (about 50 kDa) of the parent strain, SS-HPA5 (Figure 4.4.B-1). However, no 
alterations in other immunogenic proteins were detected when probed with seropositive 
serum (Figure 4.4. A).   
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Figure 4.4 Immunoblot analysis of total cell lysate from induced serum-resistant strain, 
SR-SV9 and serum-attacked none resistant strain, SA-HPA5, compared to their serum-
sensitive parents, SS-HPA5 (SV3) and SS-SV9. Blots A and C probed with seropositive 
serum; blot (B) probed with monoclonal anti-MBA antibodies, 10C6.6 (B-1) and 6522 
(B-2), respectively. Blue arrows indicate size variations in MBA surface protein. Red 
arrow indicates expression of new immunogenic protein (41 kDa) in SR-SV9 strain. M= 
molecular mass marker.   
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4.2.5 Observation of changes in banding patterns of selected Ureaplasma 
isolates following challenge with seropositive serum 
Selected isolates of Ureaplasma were also serially challenged with seropositive serum. 
The purpose of this work was to generate serum resistant strains but one of the strains 
was already completely resistant to seropositive sera (U. Urealyticum serovar 12 isolate, 
W11) and it was included to see if repeated exposure of the strain to sera induced 
alteration to the MBA size. Two U. parvum serovar 3 isolates, HPA56 and HPA57, were 
included to see if this serovar was capable of induced serum resistance as SV3 HPA5 was 
not, although these strains were different in that they were resistant to seronegative sera.  
Additionally, a clinical isolate (U. urealyticum isolate, Ply128M) was included as serial 
isolates obtained (see section 4.8) did not show any alteration in MBA size in vivo. 
Therefore, it was included to see if alteration in size could be induced in vitro.  
Following repeated challenge with NHuS, the results showed that the MBA changed only 
for one of the tested strains, HPA57, co-incident with induction of serum resistance 
(Figure 4.5-A). Furthermore, this isolate appeared to undergo selection from two isoforms 
of MBA (90 and 80 kDa band) to the single higher MBA isoform. This alteration had 
occurred by or before 3 challenges with seropositive serum and remained persistent after 
7 serum challenges. Expression of MBA in all other strains remained unchanged after 3 
and 7 challenges (Figure 4.5-A). Interestingly, all isolates had expressed a new 41 kDa 
protein band (Figure 4.5-B) similar to that expressed by all induced serum-resistant 
strains (discussed earlier in this chapter) and the endogenously serum-resistant clinical 
isolate, W11 (SV12). Following 7 consecutive challenges, all serum-sensitive isolates 
became resistant to serum killing by seropositive serum. W11 remained serum-resistant 
and did not show any alterations in immunogenic proteins. 
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Figure 4.5 Immunoblot analysis of Ureaplasma total cell lysate from selected 
Ureaplasma isolates serially challenged with seropositive serum. The upper blot (A) 
probed with monoclonal anti-MBA antibody (6522); the lower blot (B) probed with 
seropositive serum. Arrows indicate differentially expressed proteins relative to parent 
strains (loss of immunogenic protein bands (MBA; red arrows) and new immunogenic 
protein bands (41 kDa band; blue arrows). The numbers 3A and 7A indicate 3 and 7 
serial challenges, respectively.  M= molecular-weight size marker.   
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4.2.6 Identification of differentially expressed proteins by proteomic analysis 
Total cell proteins were extracted from both serum-resistant strains (SR-DFK1) and SR-
HPA2) and their serum-sensitive parental strains (SS-DFK1 and SS-HPA2) and separated 
by 2-DE.  Subsequently, the separated protein spots were visualised with Colloidal 
Coomassie blue stain and analysed.  A total of 8 and 20 differentially expressed protein 
spots from DFK1 and HPA2 strains, respectively, were selected and excised from stained 
gels, as shown in Figure 4.6 and then sent for protein identification by mass spectrometry. 
Consequently, 3 of 8 protein spots of DFK1 strains and 9 of 20 protein spots of HPA2 
were identified using MALDI TOF/TOF mass spectrometric analysis (Tables 4.1 and 
4.2). These proteins were identified in the annotated open reading frames (ORFs) of the 
genome of U. parvum serovar 3 (strain ATCC 27815/ 27/ NCTC 11736) as well as in the 
secured genomic database access from the J. Craig Venter Institute (JCVI) for the 
genomes of U. parvum serovar 1 (strain ATCC 27813) and U. parvum serovar 6 (strain 
ATCC 27818).   
The proteomic analysis indicated that all serum-resistant strains (SR-DFK1 and SR-
HPA2) had translation elongation factor Tu protein with altered isoelectric points 
(appeared as chain of protein spots with same molecular mass size but different pI) as 
compared to parental strains (spots A3 & A5 for SV1 strains and spots B6, B7, B15 & 
B16 for SV6) (Figure 4.6.A and 4.6.B). In addition, over-expression of 5`-nucleotidase, 
lipoprotein e (P4) Family in SR-HPA2 (SV6) was observed (spot B10, Figure 4.6.B). 
Alongside with these deferentially expressed proteins, common immunogenic proteins, 
among susceptible and resistant strains, were also identified in both. Conserved 
hypothetical protein-UPA6_A0338 (spot B9), inorganic diphosphatase (spot B3) and 
methylenetetrahydrofolate dehydrogenase (spot B19) for SV6 (Figure 4.6.A) were seen 
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with SV1 strains, while translation elongation factor G (spot A1) was detected among 
SV6 strains (Figure 4.6.B).  
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Figure 4.6 Two-dimensional electrophoretic analysis of total cell protein extract from 
induced serum-resistant Ureaplasma strains compared to serum-sensitive parents. A: SR-
KFK1 and SS-DFK1 (SV1); B: SR-HPA2 and SS-HPA2 (SV6).  Proteins were separated 
on a IPG strip (3-10NL) followed by electrophoresis on a vertical NuPAGE 4-12% Bis-
Tris Zoom gel (1mm) and Colloidal Coomassie blue-stained. A and B indicate selected 
spots sent for identification by tandem mass spectrometry (red circles). Red arrows refer 
to successfully identified spots and Black arrows indicate unidentified spots. 
Representative 2-D gels selected from three repeated experiments. 
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Table 4.1 Proteins putatively identified from U. parvum SV6 (strain HPA2) using tandem mass spectrometry 
 
Spot no. on 
2-D gel ID category٭
 Accession no. 
Protein ID compared to SV6 (strain ATCC-
27818)  
Mascot 
score e value٭٭
 
B3 3 UPA6_A0317 Inorganic diphosphatase (ppa) [3.6.1.1] 35 0.22 
B6 1 UPA6_A0567 Translation elongation factor Tu (tuf) 245 1.9e-022 
B7 1 UPA6_A0571 Translation elongation factor Tu (tuf) 344 2.4e-032 
B9 2 UPA6_A0338 Conserved hypothetical protein  103 3e-008 
B10 3 UPA6_A0571 5`-nucleotidase, lipoprotein e (P4) family 36 0.16 
B15 1 UPA6_A0567 Translation elongation factor Tu (tuf) 303 3e-028 
B16 1 UPA6_A0567 Translation elongation factor Tu (tuf) 296 1.5e-027 
B17 1 UPA6_A0547 Cytosol aminopeptidase family protein 324 2.4e-030 
B19 3 UPA6_A0340 Methylenetetrahydrofolate dehydrogenase 34 0.25 
٭ ID category: Cat 1 (2 or more peptides with e<0.05) and best publication quality data; Cat 2 (one peptide with e<0.0001) which is publication quality with spectra shown; 
Cat 3 is not  publishable but may indicate an ID (one or more peptides with overall E value p <0.05 but p>0.0001 (multiply all the values). ٭٭ expectation value (probability 
that the assignment is a random event). 
 
Table 4.2 Proteins putatively identified from U. parvum SV1 (strainDFK1) using tandem mass spectrometry 
 
Spot no. on 2-D 
gel 
ID category٭ Accession no. Protein ID compared to SV1  (strain ATCC-
27813) 
Mascot 
score 
e value 
A1 1 UPA1_G0171 Translation elongation factor G  180 6.1e-016 
A3 1 UPA1_G0170 Translation elongation factor Tu (tuf) 368 9.6e-035 
A5 1 UPA1_G0170 Translation elongation factor Tu (tuf) 276 1.5e-025 
٭ ID category: Cat 1 (2 or more peptides with e<0.05) and best publication quality data; Cat 2 (one peptide with e<0.0001) which is publication quality with spectra shown; 
Cat 3 is not  publishable but may indicate an ID (one or more peptides with overall E value p <0.05 but p>0.0001 (multiply all the values). ٭٭ expectation value (probability 
that the assignment is a random event). 
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4.2.7 Identification of the novel 41 kDa protein using 1-D gel- based proteomic 
method  
As it was difficult to identify the altered immunogenic proteins via 2-DE-based 
proteomics, an effort to identify these proteins directly from matched 1-DE bands stained 
with Colloidal Coomassie blue was achieved.  Following extraction and separation of 
total cell proteins from DFK1 strains (SR-DFK1 and SS-DFK1) using 1-DE, separated 
proteins on gels were then stained, visualised and analysed. Protein spots from the 90 and 
80 kDa bands, previously identified as MBA protein using monoclonal anti-MBA 
antibody, from both SS-DFK1 and SR-DFK1 respectively and the novel 41 kDa band 
from SR-DFK1 (Figure 4.7) were excised from the gel and sent for MALDI TOF/TOF 
mass spectrometric identification. The aforementioned protein bands were differentially 
expressed bands detected by immunoblot analysis (Figure 4.2). The MBA bands (90 kDa 
and 80 kDa) were indicated as a change in size of MBA protein, but the unidentified 41 
kDa protein was newly expressed in all resistant strains observed in this study.  
Following MS identification, protein spots from 1-DE Colloidal Coomassie blue stained 
gels were identified in the genome of U. parvumserovar 1 strain ATCC-27813 (Table 
4.3).  Both 90 kDa and 80 kDa bands were identified as a multiple banded antigen 
(MBA), and confirmed the previous identification obtained using monoclonal anti-MBA 
antibodies. The candidate potential protein that may mediate serum resistance, the 41 kDa 
band was also identified using this approach as UU280 protein of Ureaplasma, an endo-
1, 4-beta-glucanase.  Further experiments were required to confirm the identity of this 
protein, UU280, and to further investigate the possible role of this protein in serum 
resistance as the 41 kDa was a unique protein expressed in all serum-resistant strains seen 
so far.  
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Figure 4.7 Visualisation of 1D protein profile of serum resistant and serum sensitive 
DFK1 strains. proteins separated by 1-DE. Proteins were extracted from both induced 
serum-resistant DFK1 (SR-DFK1) and their serum- sensitive parent strain DFK1 (SS-
DFK1; SV1) and then separated on 7.5% SDS-PAGE and stained with Colloidal 
Coomassie blue stain. Red arrows indicate bands with variation in protein expression: (A) 
90 kDa band, (B) 80 kDa and (C) 41 kDa, from which protein spots were excised and 
processed for protein identification using mass spectrometry. M= molecular weight 
marker, Mark12. 
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Table 4.3 Proteins putatively identified from U. parvum SV1 (strain DFK1) using tandem mass spectrometry 
 
Band no. 
on 1-DEG
 ID category٭ Accession no. 
Protein ID compared to SV1 strain ATCC-
27813 proteins 
Mascot score e value٭٭ 
A 1 UPA1_B0001 multiple banded antigen 465 3.50e-11 
B 1 UPA1_B0001 multiple banded antigen 496 6.70e-15 
C 1 UPA1_G0515  UU280 (endo-1,4-beta-glucanase) 186 2.40e-13 
٭ ID category: Cat 1 (2 or more peptides with e<0.05) and best publication quality data; Cat 2 (one peptide with e<0.0001) which is publication quality with spectra shown; 
Cat 3 is not  publishable but may indicate an ID (one or more peptides with overall E value p <0.05 but p>0.0001 (multiply all the values). ٭٭ expectation value (probability 
that the assignment is a random event). 
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4.2.8 Immunoblot analysis of proteins separated by 2-DE 
Whole cell protein lysates separated using 2-DE from DFK1 (SV1), HPA2 (SV6), SV9, 
and HPA5 (SV3) were also analyzed using western blotting detected by seropositive 
serum. Immunoblot analysis was done to investigate immunoproteins that showed 
differences in expression by 1-DE western blotting.  2-DE immunoblot analysis revealed 
several immunogenic protein spots in the 20-220 kDa regions with a wide range of 
isoelectric points (Figure 4.8 and 4.9). Although the results revealed some clear 
differences in immunoproteins between the resistant and sensitive strains, it was not 
possible to see such differences in matched gels stained with Colloidal Coomassie blue 
stain in order to identify them, particularly between strains of both SV1 and SV6.  For 
example, there was a significant difference in immunogenic proteins between SR-DFK1 
compared to SS-DFK1; a chain of immunogenic proteins with similar molecular mass 
size and different range of protein charges, seen in SS-DFK1, was completely lost in SR-
DFK1 (Figure 4.8). However, this line of protein spots was not detected by Colloidal 
Coomassie blue stain (Figure 4.6). The only exception (visualized by both immunoblot 
and Colloidal blue stain) was the EF-Tu protein isoforms for DFK1 and HPA2 strains. 
This protein was shown to be immunogenic and the isoforms differentially expressed 
between serum-sensitive and serum-resistant strains (Figures 4.6 and 4.8). SV9 strains 
also revealed a significant difference in EF-Tu isoforms identified by immunoblot 
((Figure 4.9). On the other hand, no differences in EF-Tu isoforms observed by 
immunoblotting between SA-HPA5 and the parent strain (SS-HPA) were observed 
(Figure 4.9).   
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Figure 4.8 Two-dimensional immunoblot analysis of total cell proteins from serum-
sensitive Ureaplasma isolates (DFK1 and HPA2) compared to their serum-challenged 
strains. Separated proteins (65 µg) from serum-resistant strains and their serum-sensitive 
parental strains were detected using a high-titre seropositive serum. White arrows indicate 
loss of immunoproteins with wide range of isoelectric points (pI 5-10) and the same 
molecular mass size (80 kDa) from SR-KFK1 clone. Red circles refer to EF-Tu protein 
isoforms with variations in isoelectric points between serum-sensitive and serum-resistant 
of both SV1 and SV6 strains. On the left side of blots kDa indicates molecular mass 
marker size. Representative immunoblots selected from three repeated experiments. 
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Figure 4.9 Two-dimensional immunoblot analysis of total cell proteins from serum-
sensitive Ureaplasma isolates (SV9 and HPA5) compared to their serum-challenged 
strains. Separated proteins (65 µg) from one serum-resistant strain (SR-SV9) and one 
serum-challenged non- resistant strain (SA-HPA5) and their serum-sensitive parental 
strains were detected using a high-titre seropositive. Red circles refer to EF-Tu protein 
isoforms, with significant variations in isoelectric points between SS-SV9 and SR-SV9 
strains. No differences in EF-Tu or any other immunoproteins were observed with HPA5 
strains. On the left side of blots kDa indicates molecular mass marker size. 
Representative immunoblots selected from three repeated experiments. 
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4.2.9 Alteration in EF-Tu associated with serum resistance in Ureaplasma 
Although differences in EF-Tu isoforms were identified by tandem mass spectrometry 
analysis of Colloidal blue-stained protein spots matching the characteristics of those 
observed by immunoblot with seropositive human serum, these results were also 
confirmed through 2-DE immunoblot analysis using a monoclonal anti-EF-Tu (raised 
against the N-terminus of E.coli EF-Tu). The results showed a consistent change in EF-
Tu charge among all serum-resistant strains, when compared to parental strains.  All 
resistant strains had more acidic pI isoform species of the EF-Tu protein (Figure 4.10).  
This alteration was only seen with serum-resistant strains that emerged from serum-
sensitive strains after being serially put under immunological pressure via serial challenge 
with NHuS in vitro. However, such change was not seen with the HPA5 strain that was 
also subjected to numerous consecutive challenges but remained sensitive (Figure 4.11).  
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Figure 4.10 Altered expression of EF-Tu in Ureaplasma isolates (DFK1 and HPA2) 
following challenges with NHuS. Total cell protein extract separated by 2-DE on an IPG 
strip followed by vertical NuPAGE 4-12% Bis-Tris gel. EF-Tu was detected using anti-
elongation factor Tu antibody. The blots show changes in the EF-Tu protein charge, a 
novel acidic pI isoform (red arrow), in the serum-resistant strains (SR-DFK1 and SR-
HPA) compared to parent strains (SS-DFK1 and SS-HPA2). Representative immunoblots 
selected from three repeated experiments. 
  
 
 
Aboklaish A.F.                                                                                                                      Chapter 4: Results 
151 
  
 
 
Figure 4.11 Altered expression of EF-Tu in Ureaplasma isolates (HPA5 and SV9) 
following challenges with NHuS. Total cell protein extract separated by 2-DE on an IPG 
strip followed by vertical NuPAGE 4-12% Bis-Tris gel. EF-Tu was detected using anti-
elongation factor Tu antibody. The blot on the right-hand side shows a significant shift in 
pI (a novel acidic isoform (red arrow) in the induced serum-resistant strain of SV9 (SR-
SV9) compare to parent strain (SS-SV9). EF-Tu remained similar in HPA5 strains (SA-
HPA5 and SS-HPA5) as seen in the left-hand side blot. Representative immunoblots from 
three repeated experiments.  
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4.2.10 Investigation of glycosylation in total-cell proteins 
Total cell proteins from both serum-resistant and serum-sensitive Ureaplasma strains 
were extracted and separated by SDS-PAGE and then subjected to glycoprotein staining. 
This experiment was performed to investigate any glycosylation in proteins from serum-
sensitive and serum-resistant Ureaplasma strains and to try to link any of these 
glycosylation processes to induced serum resistance in ureaplasmas. In M. pulmonis, the 
repeat unit of VsaA, which was shown to mediate serum resistance, was also found to 
contain a glycosylation site that resulted in contributing to the glycocalyx of the bacteria 
as a physical shield against complement attack (Bolland et al., 2012). Therefore, this 
experiment was conducted to examine the possibility of glycosylation of the repeat unit 
of MBA as well. As it can be seen in Figure 4.12A, the results showed no clear evidence 
of glycosylated proteins within the total cell proteins as no apparent stained proteins were 
visualized with glycoprotein stain compared to positive control bands of glycoproteins, 
which appeared as magenta bands. All proteins were also visualized with Colloidal 
Coomassie blue stain where variations in MBA could be seen among serum-sensitive and 
serum resistant emerged strains (Figure 4.12B). 
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Figure 4.12 Detection of glycoproteins in total cell proteins from Ureaplasma species. 
Serum-resistant or serum-attacked non-resistant clones were compared to their serum-
sensitive parental strains. Proteins were extracted with 1% SDS and separated on 7.5% 
SDS-PAGE gels. Gels were first stained with glycoprotein stain (A) to visualise 
glycosylated proteins and then subsequently stained with Colloidal Coomassie stain, 
RAPIDstain, (B) to visualise other non-glycosylated proteins and enhance staining of 
glycoproteins. Glycoproteins appear as magenta bands as seen in positive control bands 
(blue arrows). Red arrows indicate variations in MBA and green arrows refer to the 
41kDa protein expressed by serum-resistant strains. MW= molecular size marker.    
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4.2.11 Investigation of UU280 protein as the putative 41 kDa induced protein  
Following the successfully identification of the 41 kDa protein as UU280 protein using 
proteomic analysis this protein was further investigated to confirm its role in serum 
resistance among the species of Ureaplasma. In fact, the successfully developed method 
in this thesis for Ureaplasma transformation was also utilised successfully to deliver an 
exogenous copy the UU280 gene to some known serum-sensitive strains and investigate 
its expression and role in avoiding complement killing.  In preparation, the UU280 gene 
insert was first synthesised and cloned to the vector plasmid, pMT85, and which was then 
cloned into E. coli strains, where it was amplified and validated. The pMT85-UU280 
construct was used to transform serum-sensitive Ureaplasma strains under study. In 
parallel with that work, a polyclonal anti-UU280 antibody was also produced against 
UU280 KLH-peptide conjugate (the UU280 hapten consisted of 23 amino acids (322-
343): `N`- CPQRYLHAPIGVATVKAAFD). Anti-UU280 polyclonal antibody was first 
screened and tested by dot blotting with the UU280 peptide to validate it for immunoblot 
analysis. A strong reactivity was observed on the first three 1:10 dilutions of UU280 
protein using both polyclonal anti-UU280 antisera generated, but no reactivity was noted 
using seropositive serum.  
Following a successful delivery of pMT85-UU280 construct, which was carrying UU280 
gene insert tagged with His-tag, expression of UU280 was investigated in both E. coli and 
Ureaplasma by immunoblot analysis using anti-His tag antibody, anti-UU280 antisera 
and seropositive serum. The results showed that UU280 protein was successfully 
expressed by the two E. coli strains (carrying UU280 insert with forward and reverse 
orientations), as it was successfully detected by both anti-his tag antibody (strong 
reactivity) and by anti-UU280 specific antibody (low intensity); however, seropositive 
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serum, which detects the 41 kDa protein, did not detect this exogenous UU280 protein 
expressed in E. coli (Figure 4.13.A, B &C).  
This finding and dot blot analysis indicated that IgG antibodies against ureaplasmal 
UU280 protein were not present in that seropositive normal human serum and what was 
recognised as a 41 kDa protein by NHuS in all induced serum-resistant strains is probably 
not UU280 protein.  Furthermore, the pMT85-UU280 plasmid construct was also 
delivered into Ureaplasma serum-sensitive strains successfully, as was confirmed by the 
presence of gentamicin resistant gene marker using PCR. However, expression of UU280 
protein could not be detected by any of the antibodies used (Figure 4.14.A, B & C). Anti-
his tag antibody did not recognise any His-tag and seropositive serum did not detect any 
41 kDa immunogenic protein in all of transformed strains. Additionally, anti-UU280 
antisera did not react with any band with a similar molecular weight size of that of 41 
kDa band. Instead, anti-UU280 antibody recognised a common immunogenic protein 
band with different size (higher than 41 kDa) expressed by all serum-sensitive and serum-
resistant Ureaplasma strains, which might be endogenous UU280 protein. Besides and 
more importantly, all Ureaplasma  strains cloned with pMT85 carrying UU280 gene did 
not gain resistance to NHuS and remained serum- sensitive similar to the parental strains 
following a successful transformation (see section 5.2.3). 
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Figure 4.13 Expression of UU280 protein by transformed E. coli strains. Two 
transmutant strains carrying UU280 gene (Lanes 2 and 3) with forward and reverse 
orientation, respectively, were compared to another transformed strain carrying an empty 
pMT85 vector (Lane 1) as a negative control. Total cell protein lysate (10 µg) separated 
on 1-DE SDS-PAGE gel and blotted on nitrocellulose membrane. UU280 protein was 
detected by both anti-His tag antibody (A) and anti-UU280 polyclonal antibody (B) but 
not with a high titre seropositive serum (C). Blue arrow indicated UU280 bands. M= 
molecular weight marker 
 
M M M 1 3 2 1 3 2 1 3 2 
50 kDa - 
80 kDa - 
50 kDa - 
40 kDa - 
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Figure 4.14 Investigating expression of UU280 protein by transformed Ureaplasma strains compared to untransformed parental strains (HPA5 
and DFK1). Whole cell proteins extracted and separated on SDS-PAGE gels (7.5%) and then transferred into nitrocellulose membranes. UU280 
protein was not detected with anti-His tag antibody (A), but was detected as 46 kDa band by anti-UU280 antisera (B) in all Ureaplasma strains 
(expressed by all isolates). Re-probing blot (A) with seropositive serum (C) revealed several common immunogenic protein bands with a 
common intense band of about 41 kDa combined with a higher common band with lower reactivity in all Ureaplasma strains.    M= molecular 
weight marker.  
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The development of the transposon mutagenesis method for Ureaplasma spp. has provided 
another alternative and powerful tool to knock out, identify and study gene function(s) for 
Ureaplasma. Subsequent screening of all transformed strains for disrupted genes, after 
transposon mutagenesis as detailed in chapter 5, showed that one of the transmutant strains 
generated from a naturally serum-resistant isolate, W11 (SV12), had lost the 41 kDa 
protein band, which is a similar protein band to that observed in all induced serum-
resistant strains. The loss of that protein was associated with altered susceptibility to 
complement killing as the transmutant strain became sensitive to complement-mediated 
serum killing. In fact this provided another alternative way to accurately identify and 
confirm the involvement of that candidate 41 kDa protein in serum resistance. Based on 
this observation, the role of the “UU280 protein”, as identified by the proteomic approach, 
in serum resistance was re-examined again in the transmutant strain of W11. To achieve 
this, primer sets designed from U. parvum open reading frames to screen the UU280 gene 
region (forward primer pre-UU280 and revers primer post-UU280) were used to check the 
integrity of UU280 gene in the transmutant W11 strain. These primers failed to identify 
the gene disruption for the only transmutant strain of U. urealyticum (W11; SV12) 
indicating the integrity of the UU280 gene and ruling out its involvement in the 
phenotypic alteration seen in this particular strain following transformation. 
Alternatively, sequencing and mapping the integration site of pMT85 mini-transposon in 
the genome of W11 transmutant strain had eventually revealed the identity of the 
disrupted gene responsible for that phenotypic change. The gene was identified as a 
hypothetical protein, UUR10_0137, in the genome of U. urealyticum serovar 10 (ATCC 
strain 33699). Therefore,  an another potential gene that could control the expression of 
the 41 kDa protein is now available for further investigation, in similar way to that 
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applied to UU280 gene, to evaluate its role and function in mechanism of serum 
resistance among Ureaplasma spp. 
 
4.3 Part 2 results:  the in vivo investigation 
4.3.1 Effect of immunological pressure in vivo on the immunogenicity of 
Ureaplasma species 
As the previous part of this chapter focused on investigating the effect of immunological 
pressure on Ureaplasma in vitro, the aim of this part was to investigate the outcome of 
such immunological challenge in vivo.  To achieve this goal endotracheal aspirate 
samples were collected from 57 intubated premature babies from Deriford Hospital in 
Plymouth and 10 of these patients (17.5%) were ureaplasma-positive as detected by 
culture. Following up samples from all ureaplasma-positive preterm babies were then 
serially collected and detected for the presence of Ureaplasma for further investigation. 
Of all collected samples, only the first and last Ureaplasma clinical isolates from the 
previously mentioned patients (20 clinical isolates) were investigated. In addition, other 
clinical isolates were also included in the study: 4 isolates were serially collected for two 
premature babies in the previous study (O1/O10 and W4/W11), two single samples 
collected from two premature babies at the University Hospital of Wales (UHW4; and 
UHW5) and 2 isolates from couples from France who were believed to have passed 
infection to each other (UUf1 and UUg1).  
All these clinical isolates of Ureaplasma spp. were typed by PCR using the UM-1 primer 
set (Teng et al., 1994) to differentiate the two Ureaplasma species and confirm that the 
first and last isolates from a patient were identical. Furthermore, all U. parvum isolates 
were then assigned, to one of the four known serovars (SVs 1, 3, 6, and 14) by 
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sequencing the UM-1 PCR product, while U. urealyticum isolates were grouped into one 
of the three clusters of U. urealyticum serovars based on nucleotide polymorphism in 
MBA gene (SVs 7/11, 2/5/8/9 and 4/10/12/13) as discussed in Chapter 3 of this thesis 
(Table 4.4).  Monitoring changes in immunogenicity in vivo among the first and last or 
other studied clinical isolates was performed using immunoblot analysis. In addition, 
susceptibility to complement was investigated using the complement killing assay. Table 
4.4 shows a summary of all clinical isolates used in this study. 
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Table 4.4 Ureaplasma clinical isolates investigated in this study 
No. 
Clinical 
isolate 
Time 
period  
between 
samples 
Source of isolates Serovar ID Patient source 
1 UUf1 Single 
isolates 
France U. urealyticum 
(SV4,10,12 or 13) 
Adult sexual 
partners 2 UUg1 
3 W4 
3 weeks 
University Hospital 
of Wales 
U. urealyticum 
(SV4,10, 12 or 13) 
Premature baby 
4 W11 
5 01 
3 weeks 
University Hospital 
of Wales 
U. parvum 
SV1 
Premature baby 
6 010 
7 UHW4 
Single 
isolates 
University Hospital 
of Wales 
U. parvum 
SV3 
Neighbouring 
Unrelated 
premature babies 
8 UHW5 
9 Ply101B 
2 weeks 
Deriford 
Hospital Plymouth 
U. parvum 
SV3 
Premature baby 
10 Ply101D 
11 Ply108B 
1 week 
Deriford 
Hospital Plymouth 
U. parvum 
SV1 
Premature baby 
14 Ply108C 
15 Ply128A 
34 days 
Deriford 
Hospital Plymouth 
U. urealyticum 
(SV2, 5, 8 or 9) 
Premature baby 
16 Ply128M 
17 Ply130B 
3 weeks 
Plymouth 
Hospital 
U. parvum 
SV6 
Twin  premature 
baby 18 Ply130G 
19 Ply131B 
17 days 
Plymouth 
Hospital 
U. urealyticum 
(SV2, 5, 8 or 9) 
Premature baby 
20 Ply131F 
21 Ply140A 
1 week 
Plymouth 
Hospital 
U. parvum 
SV3 
Premature baby 
22 Ply140B 
23 Ply141A 
2 weeks 
Plymouth 
Hospital 
U. parvum 
SV3 
Premature baby 
24 Ply141F 
25 Ply144A 
2 days 
Plymouth 
Hospital 
U. parvum 
SV3 
Premature baby 
26 Ply144B 
27 Ply152A 
1 month 
Plymouth 
Hospital 
U. urealyticum 
(SV2, 5, 8 or 9) 
Premature baby 
28 Ply152J 
29 Ply157A 
10 days 
Plymouth 
Hospital 
U. parvum 
SV3 
Premature baby 
30 Ply157C 
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4.3.2 Changes in antigenicity following immunological pressure in vivo    
Monitoring alterations in Ureaplasma immunogenic proteins following immunological 
pressure in vivo were achieved by western blotting using monoclonal anti-MBA 
antibodies and seropositive human serum.  Comparing the immunogenic profile of the 
first and last Ureaplasma clinical isolates showed that 7 Plymouth isolates had variations 
in the MBA which in most cases was a shift in MBA size. These isolates included 
Ply128A/128M, Ply130B/130G, Ply131B/131F, Ply140A/140B, Ply144A/144F, 
Ply152A/152J and Ply157A/157C (Figure 4.15.A). Ply130B/130G and Ply144A/144F 
also showed expression of new variants of MBA bands with low intensity. Besides these 
changes in the MBA some of those isolates (Ply144A/144F, 152A/152J and 157A/157C) 
also showed alterations in other immunogenic proteins (Figure 4.17.B). Ply101B/C and 
Ply108B/108C showed no changes in MBA but there were variations in other 
immunoreactive proteins detected by seropositive serum. In contrast, Ply128A/128M, 
Ply130B/130G, Ply131B/131F and Ply140A/140B had differences in MBA but not in 
other surface immunogenic proteins (Figures 4.15.A&B).  Ply141A/141F showed no 
changes in immunogenicity at all.  
Other clinical isolates also had variations in MBA and/or immunogenic proteins. While 
isolates O1/O10 had only a change in MBA, W4 compared to W11 had a change in other 
immunoreactive proteins. W11expressed new immunogenic protein at about 41 kDa but 
showed identical MBA bands (Figures 4.16.A&B). Single samples collected from 
neighbourhood premature babies, UHW4 and UHW5, showed variations in MBA as well 
as some other immuno-antigens.  In contrast UUf1 and UUg1 which were collected from 
sexual partners were identical and no differences were observed (Figures 4.16.A&B). The 
MBA size in all these clinical isolates ranged from between 40 kDa to 120 kDa.  
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Figure 4.15 Variations in Ureaplasma immunogenicity following immunological 
pressure in vivo (Plymouth isolates). Immunoblot analysis of total cell protein of 
Ureaplasma isolates serially collected from intubated immature babies. First and last 
sample collected from each premature baby were run in parallel. The blots were first 
probed with monoclonal anti-MBA antibody (A) and then subsequently reprobed with 
seropositive NHuS (B). Time periods between isolates is indicted in days or weeks. Red 
arrows indicate changes in MBA recognised by monoclonal antibody (A), and variation 
in other immunodominant antigens identified detected by NHuS (B). M: molecular 
weight marker. 
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Figure 4.16 Variations in Ureaplasma immunogenicity following immunological 
pressure in vivo (UHW and Other isolates). Total cell protein was extracted from 
Ureaplasma and run on 1-DE and analysed by western blotting. The blots were first 
probed with monoclonal anti-MBA antibody (A) and then subsequently reprobed with 
seropositive NHuS (B). Time periods between isolates is indicated in days or weeks. Red 
arrows indicate changes in MBA recognised by monoclonal antibody (A), and variation 
in other immunogenic proteins detected by NHuS (B). Black stars: single samples from 
neighbouring babies; blue stars: single samples from couples. M= molecular weight 
marker. 
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4.3.3 Effect of immunological challenge in vivo on susceptibility of Ureaplasma 
to serum killing 
After monitoring and reporting changes in immunogenicity among Ureaplasma clinical 
isolates collected serially from patients, it was worthwhile to investigate any changes in 
another phenotypic trait which is susceptibility of these clinical isolates to complement-
mediated serum killing. Serum killing was performed by the complement killing assay 
described previously in chapter 2 using both seronegative and seropositive sera. The 
results obtained from screening and comparing first and last Plymouth clinical isolates 
collected from premature babies as well some other clinical isolates showed no 
significant differences in complement susceptibility when compared to each other (Figure 
4.17.A&B). Exceptions were the isolates Ply130B/Ply130G and W4/W11 that showed 
differences in complement susceptibility. The first isolates (Ply130B and W4) were 
sensitive to killing by seropositive serum compared to the last collected isolates (Ply130G 
and W11) which had become serum-resistant (Figure 4.18.B). However, all of them were 
resistant to seronegative serum (Figure 4.18.A). 
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Figure 4.17 Complement susceptibility of Ureaplasma clinical isolates collected serially 
from premature babies at Deriford Hospital Plymouth . First (solid bars) and last (striped 
bars) isolates were compared with each other to monitor changes in serum susceptibility 
after a direct contact over a period of time with the developing immune system of baby 
(in vivo). Graphs A and B show susceptibility to complement from seronegative and 
seropositive sera,  respectively.  
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Figure 4.18 Complement susceptibility of Ureaplasma clinical isolates collected from 
premature babies and adults. First (solid-bars) and last (striped-bars) isolates were 
compared with each other to monitor changes in serum susceptibility. Isolates O1/O10 
and W4/W11 were collected from the same baby after a direct contact over a period of 
time with the developing immune system (in vivo). Isolates UHW4/UHW5 were collected 
from unrelated neonates in adjacent cots whereas isolates UUf1 and UUg1 were isolated 
from sexual partners.  Graphs A and B show susceptibility to complement from 
seronegative and seropositive sera, respectively.  
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4.4 Discussion  
Despite being faced with an extremely powerful complex immune system of their host 
that is ultimately bacteriocidal successful pathogenic microorganisms have in turn 
developed sophisticated and effective approaches that allow them to adapt to the host 
milieu, resist killing and evade immune responses. Many of these strategies have recently 
been characterised and studied intensely, and a number of comprehensive reviews have 
provided some information on ways pathogenic microorganisms overcome the immune 
system of their own host, maintain survival and establish colonisation (Bernet et al., 
2003; Celli and Finlay, 2002; Laarman et al., 2010; Lambris et al., 2008; Sansonetti and 
Di Santo, 2007; Wurzner, 1999; Zipfel et al., 2013; Zipfel et al., 2007). Antigenic 
variation is one of these mechanisms that have been extensively investigated in several 
pathogens as a strategy utilised for avoiding immune defences (Deitsch et al., 2009).  
There are two mechanisms that govern the variation of microbial antigenicity: genetic and 
epigenetic mechanisms. The first mechanisms include mutation and recombination that 
occur in the DNA sequence of a gene (encodes for immunogenic protein) or its 
regulators. The subsequent event of this alteration is a change in the expression level of a 
gene or the amino acid sequence of the gene product. The second mechanisms do not 
alter the basic DNA sequence of a gene, hence the term epigenetic, but leads to 
alterations in a gene expression by other ways such as DNA methylation (Casadesus and 
Low, 2006; Deitsch et al., 2009; van der Woude and Baumler, 2004).  
 
In the closely-related species to Ureaplasma, Mycoplasma, alteration of the expression of 
surface membrane proteins, as a way to manipulate the immune responses is a common 
tactic that have been demonstrated and investigated in a number of their members and the 
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molecular mechanisms by which this antigenic variety occurs have been well-defined 
(Citti et al., 2010). Phase variation in mycoplasma surface lipoproteins is believed to 
occur as a result of spontaneous mutations in sites inclined to DNA slippage by 
nucleotide insertions/deletions in simple sequence repeats or recombination of a DNA 
sequence (Citti et al., 2010). Ureaplasma spp. has also been shown to alter expression of 
one of the surface membrane proteins MBA to adapt to harsh environments both in vitro 
and in vivo and the mechanisms that control such alterations are thought to be similar to 
that utilised by Mycoplasma species (Zimmerman et al., 2009). The main aim of this 
chapter was to monitor the stability of Ureaplasma immunogenic proteins following 
challenges with NHuS (in vitro) and direct interaction with the host immune system (in 
vivo).  The work has also attempted to address and understand the role of Ureaplasma 
antigenic variation as a mechanism of serum resistance and manipulation of the 
complement system. Observations of changes in immunogenic proteins of several 
Ureaplasma strains following serial challenges with NHuS (in vitro) as well as direct 
interaction with the immune system of a number of premature babies (in vivo) have 
indicated the importance of such mechanisms among Ureaplasma in avoiding and 
adapting to harsh environments.  
Several interesting findings were observed in this study that are worth further 
investigations as there was insufficient time to investigate them completely. Serum-
resistant strains emerged following exposure of Ureaplasma to a repeated immunological 
pressure in vitro using NHuS. Those strains were the main focus of investigation in this 
study as they revealed potential ability among these tiny bacteria to overcome the 
complement-mediated serum killing. Significant changes in some immunogenic proteins 
that coincided with the acquisition of serum resistance were seen in all induced serum-
resistant strains when compared with their parental strains. Herein, this chapter seeks to 
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highlight, identify and study the role of some putative proteins that showed alterations in 
expression in avoiding the complement-mediated serum killing. Of these antigenic 
variable proteins, three interesting proteins were identified and investigated. These 
immunogenic proteins included the multiple banded antigen (MBA), the elongation factor 
Tu (EF-Tu) and a putative 41 kDa new expressed antigen that, using a proteomic 
approach, was identified as UU280 protein (endo-1, 4-beta-glucanase), but later and 
following excluding the involvement of UU280 protein and an alternative candidate 
protein was identified in the transmutant strain of W11 as the hypothetical protein 
encoded by the UUR10_0137 gene. 
The MBA is a major surface antigen that is recognised by the immune system during 
Ureaplasma infection and was proposed as one of the virulence factors of Ureaplasma 
spp. that play a role in antigenic variations and pathogenesis of Ureaplasma species 
(Watson et al., 1990; Zheng et al., 1995). Several previous studies have demonstrated 
both phase and size variations in the MBA in vivo as well as in vitro (Monecke et al., 
2003; Zheng et al., 1995; Zimmerman et al., 2011; Zimmerman et al., 2009). It is also 
believed that these events of alteration in expression arise as a result of change in the 
number of the repeat units in the variable regions of the MBA, which might be caused by 
a slipped-strand mispairing mechanism (Teng et al., 1994; Zheng et al., 1994; Zheng et 
al., 1995). In the study by Monecke and colleagues (2003) it was shown that subjecting 
representative serovars (SV3 and SV5) from both species of Ureaplasma to a selection 
pressure using polyclonal anti-MBA antibodies resulted in the emergence of escaping 
MBA-negative clones (Monecke et al., 2003). In another study exposure of Ureaplasma 
to a similar selection pressure with antibodies against the MBA had also created escaping 
MBA-off variants. In these strains the MBA gene (UU375) was found to switch 
expression with an adjacent gene (UU376) through a DNA inversion event at short 
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inversion sequences, as the MBA 5’ region was found to flip and drive expression of the 
adjacent, promoter-less UU376 gene (Zimmerman et al., 2009).  A later report by 
Zimmerman et al has suggested that the ORFs of both genes (UU375 and UU376) are 
part of gene family that comprise the locus of mba gene in Ureaplasma (Zimmerman et 
al., 2011).  
In this study, the MBA variants were identified by both MS identification using a 
proteomic approach and by immunoblot analysis using anti-MBA monoclonal antibodies. 
Antigenic alterations in the MBA expression, following serial challenges with NHuS, 
were observed in a number of representative serovars and clinical isolates, which is in 
agreement with many of the previous studies that indicated size variations in MBA. For 
example, in my study, size variations in MBA size were seen in two of the induced 
serum-resistant strains (SR-DFK-1 and SR-SV9) when compared to their parental serum-
sensitive strains. Nevertheless, no change in MBA size was also observed in another 
equally induced serum-resistant strain (SR-HPA2). This later finding indicated that 
changes in MBA are not necessary for developing serum resistance in Ureaplasma in 
vitro.  
Significantly, all observed changes in MBA size of Ureaplasma induced serum-resistant 
strains in this study were constantly associated with alterations and expression of other 
antigens, which seemed to be involved in developing serum resistance, as will be 
discussed later. Furthermore, similar observations (alterations in MBA size or no changes 
in MBA expression) were also demonstrated in other Ureaplasma strains in this study 
following immunological challenges with NHuS in vitro. Emergence of serum resistance 
among those strains was found to be with or without alterations in MBA expression. 
Further induced serum resistance without MBA alteration include the two different 
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isolates HPA56 and HPA57 which belong to the same serovar (SV3). Although both of 
them became resistant to serum killing following challenge with NHuS only the HPA57 
isolate showed loss of one of the two isoforms of MBA following selection while the 
MBA of HPA56 remained unchanged. Besides, challenging an inherently serum-resistant 
strain with NHuS revealed that alteration in MBA expression cannot be induced when an 
isolate is already serum-resistant suggesting no direct relationship between MBA size 
variation and complement-mediated serum resistance is seen in Ureaplasma.   
MBA size variation was also observed in isolates collected serially from premature 
babies. This experiment represented a real confrontation with the host immune defences 
(in vivo challenge) despite the fact that the immune system of premature babies is still 
underdeveloped.  A number of last collected isolates from these new-born babies showed 
a significant alteration in their MBA size when compared to the first collected isolates 
(parental isolates). This provided additional evidence that Ureaplasma is able to change 
their MBA in vivo when faced with human immune defences. Similar observations were 
also shown in recent studies using animal models where alterations in MBA size in vivo 
were reported (Dando et al., 2012; Knox et al., 2010; Robinson et al., 2013). Despite 
being able to observe these differences in the MBA size in vivo, no significant changes in 
complement susceptibility, which could be linked to such alteration in MBA size, among 
the serum-sensitive isolates over the time (both first and last strains remind the same) 
were observed. One possible explanation for this finding would be the fact that the 
immune system of the premature babies is still not completely mature to raise a 
significant immune response able to eliminate Ureaplasma colonisation.  
Neonates and particularly premature babies have been shown to be deficient in several 
complement components, particularly the complement component C9, which is one of the 
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essential components required for forming the membrane attack complex that lyse 
bacterial pathogens (Lassiter et al., 1992). In fact, such insufficiency could predispose 
these babies to several invasive bacterial infections. In this regard it is presumed that the 
serum-sensitive Ureaplasma isolates have maintained an external, non-invasive type of 
infection whereas if they had survived a strong complement attack that would enforce the 
emergence of serum resistant strains in those premature babies.  However, the remarkable 
variations in MBA expression do suggest exposure to maternal or neonatal specific 
antibody as a driving force for altered MBA expression, which may be an effective 
mechanism (in vivo) for avoiding recognition. On the other hand, isolation of some 
serum-resistant isolates from premature babies may indicate colonisation with strain that 
was already resistant to serum killing, as serum-resistant serovars and clinical isolates 
were reported among Ureaplasma (as discussed in Chapter 3). Moreover, the serum used 
in the killing assay was from immune competent adults, where all arsenals of the immune 
system are fully developed. However, they were infected with other strains as the serum 
and isolate were not matched in these studies. To further validate such findings one 
would use a serum from the same premature babies and/or their mothers to test 
complement killing activity. 
Antigenic variations in the MBA are believed to play an important role in avoiding 
recognition by the host immune system in vivo. In animal models, it has been suggested 
that the ability of Ureaplasma to colonise the amniotic fluid without any detectable 
histological inflammation of the chorioamnion was attributed to variations in this variable 
surface lipoprotein (Knox et al., 2010). The authors of this study have also proposed that 
the severity of chorioamnionitis might depend on the number of MBA size variants in 
some serovars, as it was found that isolates with low number of MBA size variants are 
more virulent.  In many mycoplasmas the high level of antigenic variations in surface 
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exposed lipoproteins is believed to help these microorganisms to evade the immune 
system of their hosts and establish chronic infections. MBA has been demonstrated as one 
of the pathogen-associated molecular patterns (PAMP) recognised by toll-like receptors 
1, 2 and 6, and able of inducing the cytokine NF-κB and antibody production (Shimizu et 
al., 2008; Triantafilou et al., 2013). It has also been speculated that interaction of the 
MBA with TLR2, and not TLR4, might reflect the ability of Ureaplasma to cause chronic 
colonisation and low-level of inflammation in the amniotic epithelial cells that leads to 
premature rupture of membranes (PROM) and premature labour in pregnant women 
(Triantafilou et al., 2013). Initiation of inflammatory responses by TLR2 engenders a 
passive inflammatory response (Hirschfeld et al., 2001) that enables the microorganism 
to establish a chronic colonisation. Therefore, it can be assumed that Ureaplasma would 
be able to overcome such an immune response by changing the MBA via varying the 
number of the tandem repeats of their MBA gene in response to challenge with NHuS 
that contains Ureaplasma-specific antibodies and this probably happens by a slipped 
strand mispairing mechanism (Monecke et al., 2003).  Although, it has been previously 
reported that MBA-OFF variants of Ureaplasma strains could emerge following selection 
pressure in vitro (Monecke et al., 2003; Zimmerman et al., 2009), in this study only 
alterations in size and number of MBA variants were observed. No MBA negative clones 
were seen as MBA expressing species, sometimes with multiple separable isoforms, were 
constantly detected in all investigated Ureaplasma strains. It should be noted that all 
previous studies used rabbit anti-MBA polyclonal antibodies to induce selection pressure 
whereas in this study immunological pressure was achieved by using NHuS from health 
adult volunteers.  
The second immunogenic protein that showed an interesting alteration coincident with 
serum resistance was the elongation factor Tu (EF-Tu). As an abundant protein, EF-Tu 
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was successfully identified using proteomics from several protein spots excised from 
stained 2-D gels. Following further investigation EF-Tu was revealed to be immunogenic 
and had a consistent change in its charge (seen as more acidic pI isoforms species) among 
all induced serum-resistant strains when compared to the parental serum-sensitive strains. 
This observation was not seen in a parallel challenged HPA5 isolate that remained serum-
sensitive following several consecutive challenges with NHuS. EF-Tu is one of the most 
abundant proteins in bacteria and plays a main role in the translation process during 
protein synthesis (Weijland et al., 1992). Besides its main function, EF-Tu has also been 
indicated to have other independent functions in bacterial cells. EF-Tu was suggested to 
be one of the cytoskeletal components of prokaryotic cells. Early studies have suggested 
EF-Tu as a structural protein since it was found to form filamentous structures in vitro 
(Beck, 1979; Beck et al., 1978). Furthermore, in a number of bacterial species including 
M. pneumonia, E. coli, N. gonorrhoeae, Bacillus subtilis, Listeria monocytogenes and 
Mycobacterium leprae , EF-Tu was demonstrated under the cytoplasmic membrane or 
associated to the cell wall. These observations provided more evidence for the role of EF-
Tu in the cytoskeleton of bacteria (Archambaud et al., 2005; Dallo et al., 2002; Defeu 
Soufo et al., 2010; Jacobson and Rosenbusch, 1976; Judd and Porcella, 1993; Marques et 
al., 1998).  
EF-Tu was also suggested to play a role in bacterial virulence as it was found to mediate 
adhesion to host cells and establish colonization (Dallo et al., 2002; Granato et al., 2004). 
For example, Dallo et al., (2002) indicated that EF-Tu in Mycoplasma pneumoniae is able 
to bind fibronectin and may also mediate adhesion to host cells. A similar function for 
EF-Tu as an adhesion protein was also reported in Lactobacillus johnsonii as it was 
shown that EF-Tu mediates adhesion to intestinal cells as well as working as a pro-
inflammatory mediator. In addition, EF-Tu was found to be exposed on the surface of P. 
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aeruginosa mediating binding both FH and plasminogen, resulting in evading the 
activation of the complement system (Kunert et al., 2007). In Ureaplasma, EF-Tu may 
also be associated to the surface membrane and play a role in pathogenesis as it was 
found to be immunogenic and had alternated charge that was coincided with serum 
resistance. Alterations in protein charges are believed to occur via a post-translational 
modification such as phosphorylation and the appearance of a protein as a chain of spots 
with same mass size in 2-D gels is suggestive of phosphorylation. EF-Tu was found to be 
phosphorylated in a number of microbes and proposed to be associated with survival and 
virulence (Archambaud et al., 2005). In M. genitalium and M. pneumoniae, EF-Tu was 
also reported among the phosphorylated proteins (Su et al., 2007). In this study, EF-Tu 
was observed as a series of spots with the same mass size and different pI. Therefore, this 
may indicate phosphorylation of EF-Tu that might play a role in mediating serum 
resistance among Ureaplasma.  Further investigation on EF-Tu and its putative role in 
mechanism of serum-resistance will most likely give new insights into Ureaplasma 
pathogenesis.  
The most interesting finding observed following emergence of serum resistance was an 
expression of a novel immunogenic protein with approximate mass size of 41 kDa. This 
antigen was putatively identified as UU820 protein (endo-1,4-beta-glucanase) using 
proteomic based method (1-DE based proteomics) in the genome of U. parvum serovar 1 
(strain ATCC-27813). Switching on expression of a 41 kDa antigen was seen in all 
induced serum-resistant strains and one an inherently serum-resistant U. urealyticum 
isolate (W11; SV12). Interestingly, this immunogenic 41 kDa protein was only expressed 
in association with the development of serum resistance and challenged strains that had 
not become resistance after the serial selection pressure did not express it. This 
observation indicates that this protein is most likely to be involved in the mechanism of 
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serum resistance and requires more attention and investigation.  Therefore, I put my 
efforts to try to define its role in serum resistance. Unfortunately, upon an extensive 
investigation, I was unable to establish a relationship between UU280 protein using 
specific created reagents and gene expression cassettes and the 41 kDa serum-resistance 
associated protein.  Introducing an exogenous copy of the UU280 gene via transposon 
mutagenesis to known serum-sensitive isolates did not affect their susceptibility to 
complement activity and transmutants failed to express the recombinant UU280 protein 
as detected by immunoblot analysis. In addition, expression of an endogenous UU280 
protein was detected in all serum- sensitive and resistant strains by anti-UU280 antisera. 
Moreover, the recombinant UU280 protein which was successfully expressed by 
recombinant E. coli cells was not recognized by the F7 human hyper-immune serum that 
binds to the 41 kDa protein. These observations suggest misidentification of the 41 kDa 
protein as UU280 using proteomics. Protein bands picked from 1-DE gels may contain 
more than one protein, and hence there is a possibility of contamination that could lead to 
a wrong identification by MS (Huang et al., 2002).  
Fortunately, transposon mutagenesis analysis (detailed in Chapter 5) has revealed an 
interesting phenotypic observation that might lead to resolve the mystery of the 41 kDa 
protein. A transmutant strain from the inherently serum-resistant U. urealyticum isolate 
W11 (SV12) showed an altered susceptibility to complement-mediated serum killing that 
was associated with a loss of the 41 kDa protein. The transmutant strain became 
susceptible to killing by seropositive sera when compared to its parental serum-resistant 
strain. Therefore, it was interesting to identify the disrupted gene in this particular strain 
as this may provide an accurate identification to the candidate 41kDa immunogenic 
protein. In fact, developing and applying of transposon mutagenesis in this study has 
provided another powerful tool to investigate genes involved in Ureaplasma 
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pathogenesis. Mapping the transposon insertion site of pMT85 plasmid in the genome of 
the W11 transmutant strain revealed the identity of the disrupted gene associated with the 
loss of that remarkable protein band. The disrupted gene was identified as a 
UUR10_0137 gene in the fully annotated genome of U. urealyticum serovar 10 (strain 
ATCC 33699) and the gene encodes for a hypothetical protein of unknown function. In 
spite of this significant progress in tracing and studying this 41 kDa protein, I was unable 
to proceed further and investigate the role of this newly identified candidate gene in 
serum resistance due to time constraints. Therefore, further studies in this regard would 
defiantly define the role that this protein and others play in mechanism of serum 
resistance and avoiding complement killing by Ureaplasma.  
It is important to recognise that avoiding complement-mediated serum killing in 
Ureaplasma spp. could be mediated by several mechanisms as it was observed in this 
study. With the exception of the W11 isolate many inherently serum-resistant serovars 
and clinical isolates of U. urealyticum have been reported without seeing the expression 
of the new 41 kDa band protein (UUR10_0137) (as discussed in Chapter 3). Similar 
observation has also been reported among the other group of Ureaplasma, U. parvum 
(Beeton et al., 2012). These findings may indicate that Ureaplasma can utilize multiple 
strategies to manipulate and subvert the complement killing and elude the immune system 
defence in order to survive and establish colonisation. These potential mechanisms would 
be areas very worthy of investigation. Using more than one strategy by a microbe to 
evade the complement system has been reported in several pathogenic microorganisms 
(Zipfel et al., 2007). Of these mechanisms binding complement regulators to mask 
complement, producing proteases to inactivate complement components and expression 
of complement inhibitors are well-defined tactics in a number of pathogens. This project 
has highlighted and addressed some of these possible strategies employed by 
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Ureaplasma. Expression of new antigen (UUR10_0137) and phosphorylation of EF-Tu 
protein could be possible mechanisms used by Ureaplasma to evade host complement 
attack, as these molecules might act as complement regulators or inhibitors. A possible 
protein-protein interaction between the two proteins can be assumed as their altered 
expression following complement attack and the development of serum resistance was 
coincident. These findings need more investigation to reveal the exact roles that both 
proteins have as virulence factors in Ureaplasma.  
Using and developing methodology to study virulence factors of these unusual bacteria 
require a huge amount of time for optimisation and adaptation. I have been able to 
address some of these difficulties and successfully developed and modified a powerful 
method (transformation of Ureaplasma) that would enable further investigation for these 
interesting observations. These tools are now available and doors are open for others in 
this field to benefit from these developments and observations to answer some important 
questions raised in this study.  
Generally, induction of serum resistance among Ureaplasma strains in this study was not 
caused by loss of immune-epitopes (phase variation), since serum resistance was only 
seen when the new 41 kDa immunogenic protein was expressed in association with 
modifications in EF-Tu.  Appearance of a new protein band (switching on gene) might be 
the expression of new protein (potential complement regulator or inhibitor) that could 
play a role in avoiding the bactericidal activity of NHuS. This study also indicates that, 
apart from the MBA, Ureaplasma are able to manipulate a number of other immunogenic 
proteins in order to evade complement activity. Proteomics and genetic based approaches 
such as transposon mutagenesis are currently the most efficient methods in the 
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microbiology field for studying microbial pathogenesis and biology. Therefore, they will 
be useful tools to investigated Ureaplasma.   
  
  
Chapter 5 
Random insertion and gene 
disruption via transposon 
mutagenesis of Ureaplasma 
parvum using a mini-
transposon plasmid
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5. Random insertion and gene disruption via transposon 
mutagenesis of Ureaplasma parvum using a mini-
transposon plasmid 
5.1 Introduction 
While transposon mutagenesis has been widely and successfully used for many 
microorganisms including the closely related species, Mycoplasma spp., to disrupt and 
determine non-essential genes (Choi, 2009; Hutchison et al., 1999), previous attempts 
with Ureaplasma spp. have been unsuccessful. There is evidence of transposon gene 
delivery into the Ureaplasma spp. genome that has occurred in nature.  The fully 
sequenced genome for U. urealyticum serovar 9 (strain ATCC 33175), which exists as a 
whole genome shotgun sequence (NZ_AAYQ02000002.1) in the NCBI database, shows 
the presence of the tetracycline resistance tetM gene (UUR9_0151) adjacent to a 
conjugal transfer protein (UUR9_0147), transposase (UUR9_0146), and integrase 
(UUR9_0149).  The tetM gene for this genome is accepted to be part of a Tn916 a 
conjugative transposon also called integrative conjugative element (ICE). Tetracycline 
resistance for many U. parvum and U. urealyticum genomes have been reported to be 
due to transposon-associated tetM gene presence in the bacterial genome from isolates 
from distant countries, including: UK, France, South Africa, Russia, Tunisia, USA 
(Beeton et al., 2009b; de Barbeyrac et al., 1996; Govender et al., 2012; Mardassi et al., 
2012; Roberts, 1990; Taraskina et al., 2002) and donation from transposon-carrying 
Enterococcus faecalis to a close relative to Ureaplasma (Mycoplasma hominis) during 
co-culture was demonstrated through mating at a frequency of 10
-6
 to 10
-7
 (Roberts and 
Kenny, 1987). 
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Transposon-carrying plasmids were first successfully used to insert selectable markers in 
the genomes of M. pulmonis, Mycoplasma hyorhinis and Acholeplasma laidlawii in the 
late 1980’s (Dybvig and Alderete, 1988; Dybvig and Cassell, 1987; Mahairas and 
Minion, 1989a, b), which showed random genome insertion allowing both investigation 
of disrupted genes as well as the delivery of exogenous genes.  The methods and reagents 
used to study essential genes and the physiological effects of delivering exogenous genes 
has continued to expand and be refined (Lartigue et al., 2009; Paralanov et al., 2012). 
Experimental infection in primates have definitively proven that intrauterine infection of 
Ureaplasma, as a sole pathogen, induces preterm birth and associated neonatal 
respiratory disease (Novy et al., 2009); however, the ability to study the role of individual 
bacterial genes in pathogenesis experimentally has been hampered by a lack of tools to 
deliver or knock-out genes. To date, no report has been made to show successful 
experimental delivery of transposons or plasmids into Ureaplasma spp.  Therefore, the 
aim of this chapter is to develop a genetic tool (transposon mutagenesis) that allows 
genetic manipulation of Ureaplasma spp. 
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5.2 Results 
5.2.1 Transposon mutagenesis of Ureaplasma 
Transformation with pMT85 was performed in parallel for nine representative strains of U. 
parvum and U. urealyticum.  Between 1-5 successful transformants survived per 10
8
 cells 
used in the transformation reaction for each experiment; however, all parallel 
transformations of ATCC strains of U. urealyticum failed with the exception of one 
clinical isolate of U. urealyticum (strain W11; SV12), which was successfully 
transformed.  Using the broth culture method previously utilised to determine MIC for 
other antibiotics (Beeton et al., 2009b), the gentamicin MIC90 for U. parvum was 
determined to be 44 mg/L and for U. urealyticum was 66 mg/L.  Therefore, the gentamicin 
selection was performed at 128 mg/L (Figures 5.1).  Following transformation, all 
transformed resistant clones were found to contain the aac-aphD resistance gene from 
pMT85, which was not found in untransformed controls (Figure 5.2).  Classical insertion 
into the genome should only insert the genes bordered by the inverted repeats at position 
1bp and 3437 bp in pMT85; therefore, PCR was used to investigate the presence of 
plasmid sequence beyond the second inverted repeat, including the transposase gene 
(Figure 5.2).  Prototype serovar 3, strain HPA5, was successfully transformed in 16 
separate experiments with pMT85 and only transfer of plasmid DNA bordered by the 
inverted repeats (i.e. no transposase gene sequence) was observed.  Furthermore, 2 other 
different strains of serovar 3 (U6 and HPA56), 3 different strains from serovars 1 (O10, 
DFK1 and HPA78) and 2 strains of serovar 6 (HPA58 and SR-HPA2) of U. parvum were 
transformed, but not all of them behaved as the strain HPA5.  Probing undigested genomic 
DNA from these isolates found that aac-aphD gene was located on the chromosome, and 
probing of HindIII-digested genomic DNA revealed that, with the exception of 3 strains, a 
single copy was inserted into the genome (Figure 5.3). Portions of the transposase (trp) 
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gene from pMT85 integrated into the genomes of two strains from serovar 1 (O10 and 
HPA78), one strain from serovar 3 (HPA56) and one strain from serovar 6 (HPA58) 
(Figure 5.2.B&C).  Moreover, in 3 separate experiments with prototype serovar 1 strain 
(DFK-1), only two out of three transmutant strains followed classical integration (Figure 
5.2.C).  Sanger sequencing of purified genomic DNA from strains HPA56 and HPA58 
confirmed that genomic integration included transposase sequence.  Sequencing with 
primer 195R (designed to sequence across the IR at pMT85 position 1) confirmed 
genomic integration with interruption of the gene UU047 (predicted ATP/GTP binding 
protein) at position 390 bp in the coding region for HPA56 and interruption of the gene 
UU526 (hypothetical open reading frame) at position 543 bp in the predicted reading 
frame for HPA58, respectively.  However, Sanger sequencing of genomic DNA with 
primer 3192F (designed to sequence across the IR at position 3437) showed no integration 
and the intact presence of the pMT85 transposase gene sequence.  On the other hand, the 
genomic DNA sequencing of the transmutant strain HPA78 (Figure 5.2.C) with the same 
primers, did not confirm the presence of transposase gene as both IR were found to 
interrupt the gene UU440 for this strain. 
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Figure 5.1 Schematic diagram illustrates Ureaplasma growth in USM and USM with 
gentamicin after transformation with pMT85 plasmid. Image (A) shows unsuccessful 
transformation, strain I (U. urealyticum SV2) grows only in USM without gentamicin; 
image (B) shows successful transformation, strain II (HPA5; U. parvum SV3) grows in 
both USM and USM with gentamicin.  
 
 
 
 
 
 
 
 
 
 
Aboklaish A.F.                                                                                                                      Chapter 5: Results 
186 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 PCR mapping of regions of mini-transposon plasmid pMT85 (A) present in the genomes of gentamicin resistant clonal strains 
(B&C).  Presence of the gentamicin resistance gene (primers 1518F to 1898R) was only found in transposon mutated strains. PCR probing for 
different regions of the plasmid identified that strains such as HPA5, U6, SR-HPA2 and W11 only contain plasmid DNA from between the 
inverted repeat (IR) regions. Whereas, other transposon mutated strains contain mini-transposon plasmid DNA that include some of the 
transposase (Tnase) gene. Expected amplicon size is indicated to the right of the figure. 
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Figure 5.2 (continued) PCR mapping of regions of mini-transposon plasmid, pMT85, in the genomes of Ureaplasma transmutant strains. 
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Figure 5.3 In gel DNA/DNA hybridization detection of gentamicin selection gene. DNA 
was extracted from a 100 ml culture of transposon mutated Ureaplasma and run on a 1% 
agarose gel comparing HindIII digested (2) and undigested (1) genomic DNA.  Panels on 
the left show ethidium bromide visualisation of the DNA prior to probing with the 
gentamicin resistance probe (labelled with [
32
P]) (visualised by autoradiography in the 
panels on the right).  Strains in the upper panels: HPA5+Tn8 (UU390::mTn), HPA5+Tn5 
(UU178/188), HPA5+Tn13 (UU520::mTn), HPA5+Tn16 (UU582::mTn) and U6+Tn1 
(UU450::mTn); in the lower panels: W11+Tn1 (UUR10_137::mTn), O10+Tn1 
(unknown), HPA56+Tn1 (UU047::mTn), HPA58+Tn1 (UU526::mTn), DFK1+Tn2 
(unknown) and HPA78+Tn1 (UU440::mTn). Three strains (HPA5+Tn13, O10+Tn1and 
DFK1+Tn2) show 2 bands (red arrows) suggesting a mixed colony or 2 insertion sites.  
No undigested samples show any extra-chromosomal plasmid DNA. All the remaining 
examined isolates show a single insertion site into the genome.  HindIII-digested and 
undigested pMT85 vector is shown along with the KAPA Universal DNA ladder for size 
comparison. 
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5.2.2 Interruption of U. parvum genes by random genomic insertion 
Identification of plasmid insertion site and interrupted genes of U. parvum were performed 
by an unknown flanking DNA PCR followed by a basic PCR protocol to confirm results 
and screen other transformants (as described in chapter 2, Figure 2.3). Verification of gene 
interruption in transmutant strains was performed using primer pairs that were designed 
based on the genomic sequence for U. parvum serovar 3 (ATCC strain 700970) for genes 
UU390, UU450, UU520, UU582, and intergenic region between UU187 and UU188. 
These primers successfully amplified these genes by PCR in all parent strains of 
Ureaplasma, while single failure for each primer set to amplify these genes in mutated 
strains (Figure 5.4) was due to transposon integration and disruption of these genes. These 
disruptions were then confirmed by sequencing the integration interface (Figure 5.5)  
Sequencing of the junctions between transposon insertion site for these genes found 8 bp 
direct repeats that were unique for each clone, adjacent to the inverted repeat from pMT85 
(Figure 5.5). The 8 bp direct repeat for the intergenic insert between UU187 and UU188 
replicated the last two bases of the TAA stop codon from UU187 ensuring that UU187 
was not disrupted. All disrupted genes identified in this study are listed in Table 5.1.  
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Figure 5.4 PCR amplification of U. parvum genes (as designated by ATCC strain 700970 
nomenclature) UU390, UU450, UU520, and UU582 using primers designed within the 
coding region of these genes.  An additional primer set amplifying the end of gene 
UU187 and the beginning of UU188 (including the 32 bp intergenic region) was also 
included.  Non-mutagenised HPA5 and U6 serovar 3 U. parvum are included as controls. 
Single clones with disrupted genes are shown for each primer set as well as 7 additional 
clones successfully transformed with the mini-transposon to show specificity. 
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   End of UU187   8bp DR   pMT85 IR (position 1)                    pMT85 IR (position 3439)  8bp DR   start UU188 
TGATGAAGAGAACTTCTAAATAATAGATAAAGTCCGTATAATTGTGTAAAAACCC.........CCCTTTTACACAATTATACGGACTTTATCAAATAATA...ATGAGTCAAA 
 
     Mid UU390    8bp DR   pMT85 IR (position 1)                    pMT85 IR (position 3439)  8bp DR  mid UU390 
TTAAACTAGATGCATCTGAAAAATAGATCAAGTCCGTATAATTGTGTAAAAACCC.........CCCTTTTACACAATTATACGGACTTTATCGAAAAATAAAATAAATATT 
 
     Mid UU450    8bp DR   pMT85 IR (position 1)                    pMT85 IR (position 3439)  8bp DR  mid UU450 
AAACTTATATTTTGATTATTTTTTTGATAAAGTCCGTATAATTGTGTAAAAACCC.........CCCTTTTACACAATTATACGGACTTTATCATTTTTTTGAATTAATTCA 
 
     Mid UU520    8bp DR   pMT85 IR (position 1)                    pMT85 IR (position 3439)  8bp DR  mid UU520 
ATTAATTTTAATTGTTGTAATTGTTGATAAAGTCCGTATAATTGTGTAAAAACCC.........CCCTTTTACACAATTATACGGACTTTATCTAATTGTTGCTCATCATAAA 
 
     Mid UU582    8bp DR   pMT85 IR (position 3439)                 pMT85 IR (position 1)     8bp DR  mid UU582 
TGCAATAAGCAGTTGGCTTTTATTTGATAAAGTCCGTATAATTGTGTAAAAGGG.........GGGTTTTTACACAATTATACGGACTTTATCTTTTATTTAGAAGTTCTCT 
 
 
 
 
Figure 5.5 Sequence alignments of transposon insertion boundaries for HPA5 187/188 intergenic insertion, HPA5 UU390::mTn, U6 
UU450::mTn, HPA5 UU520::mTn, and HPA5 UU582::mTn.  Inverted repeats are highlighted in green, coding regions of genes are highlighted 
in grey.  The Tn insertion sites are bordered by 8-basepair direct repeats, with 100% identity intrastrain, but unique when compared intrastrain 
(except being very AT-rich). The direct repeat for the 187/188 insertion shows that the direct repeat contains the stop codon for UU187 (TAA), 
therefore no disruption to either UU187 or the promoter for UU188 occurs. 
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         Table 5.1 Genes disrupted in the genome of Ureaplasma transmutant strains 
Gene name Product 
Gene length 
(bp) 
Transmutant strain name 
UU187 /UU188  
DNA-directed RNA polymerase subunit beta/ DNA-
directed RNA polymerase subunit beta 
1434/1305 HPA5(SV3) + Tn5 
UU390 Hypothetical membrane protein 816 HPA5(SV3) + Tn8 
UU520 Hypothetical membrane protein 1863 HPA5(SV3) + Tn13 
UU582 ATP-dependent RNA helicase 1332 HPA5(SV3) + Tn16 
UU450 Conserved hypothetical membrane protein 1164 U6(SV3) +Tn1 
UU047 ATP/GTP binding protein 2604 HPA56(SV3) +Tn1 
UU526 Hypothetical protein 1512 HPA58(SV6) +Tn1 
UU440 Membrane lipoprotein 1500 HPA78(SV1) +Tn1 
UUR10_0137 Hypothetical protein 696 W11(SV12) +Tn1 
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5.2.3 Susceptibility of Ureaplasma transmutants to complement killing 
Complement killing assay was performed to test the susceptibility of Ureaplasma 
transmutant strains to killing by human complement compared to their parents. All strains 
were exposed in parallel to their parents to seronegative serum or seropositive serum for 1 
hr and then titrated out to determine the fold killing reduction of survival relative to the 
original parent strains after the challenge. The aim of this experiment was to screen any 
changes in complement killing that might have occurred as a result of gene disruption 
following transposon mutagenesis. In fact, this would be very helpful to understand the 
interaction between Ureaplasma and host immune system. My findings showed no 
variation in complement killing in all U. parvum transmutants, but the only transformed 
strain of U. urealyticum (W11 + Tn1) that did show a loss of resistance to serum killing. 
This particular transmutant strain became sensitive to seropositive serum (but remained 
resistant to seronegative serum) compared to the untransformed parent strain following 
transposon mutagenesis (Figure 5.6 and 5.7). The other 25 strains remained unchanged 
relative to their parent strains (i.e. the sensitive strains remained sensitive and the 
resistant strains remained resistant) (Figures 5.6 & 5.7). 
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Figure 5.6 Complement activity against Ureaplasma transposon-mutated strains compared to their parents. Strains were challenged with 
seronegative serum (shows no reactivity by western blot); Red bars indicate parent strains and blue bars indicate transposon-mutated strains. The 
black dotted line indicates the 90% killing threshold. No changes observed between untransformed and transformed strains. 
 
Aboklaish A.F.                                                                                                                      Chapter 5: Results 
195 
  
anti-Ureaplasma seropositive serum
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Figure 5.7 Complement activity against Ureaplasma transposon-mutated strains compared to their parents. Strains were challenged with 
seropositive serum; Red bars indicate parent strains and blue bars indicate transposon-mutated strains. The black dotted line indicates the 90% 
killing threshold. No changes observed between untransformed and transformed strains.  
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5.2.4 Screening Ureaplasma transmutants for altered expression of the major 
surface antigen 
 Immunoblot analysis using monoclonal anti-multiple banded antigen (MBA; UU375) 
antibody was carried out to examine if any of the transformed strains had altered size or 
expression of the major surface antigen, MBA, relative to the untransformed parent strains.  
In 26 transformed clones from four different Ureaplasma serovars, MBA-negative clones 
(phase variation) were never observed, and only three clones showed a small alteration to 
the MBA mass (Figure 5.8).  The site of genomic integration for one strain (U6) is known 
to be at the gene UU450, which is not close to the gene encoding the MBA, therefore the 
observed MBA mass alteration for this strain is not due to direct interference with the 
coding gene. Of the three transposon-mutated DFK1, one altered MBA size to a lower size 
and the other expressed two MBA size variants while the third remained unchanged 
compared to the original strain. HPA78 transposon-mutated strain had 2 MBA bands and 
following transmutation was reduced to a single MBA band; this likely represents 
selection of a single strain from a mixed parent population, as clonal strains, based on my 
experience, only exhibit a single MBA species (Figure 5.8). 
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Figure 5.8 Immunoblot analysis of SDS solubilised total cell bacterial protein probed with monoclonal anti-multiple banded antigen antibody. 
Of 26 individual transformation experiments only three strains (U6, DFK1 and HPA78) showed altered mobility of the MBA following 
transposon mutagenesis (+ Tn). Red arrows indicate changes in MBA. 
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5.2.5 Screening Ureaplasma transmutants for altered expression in 
immunogenic proteins recognised by seropositive serum 
To investigate any changes in expression of immunogenic proteins, other than the MBA, 
following the transposon mutagenesis, all Ureaplasma transmutants and original strains 
were screened with immunoblot analysis using the high titer seropositive serum. As 
presented in chapter 3 of my thesis, Ureaplasma spp. were capable of altering their 
immunogenic proteins after immunological challenge with human serum in vitro. These 
changes in immunogenicity were observed in the multiple banded antigens, MBA, as well 
as other immunogenic proteins. The results of this experiment showed that of 26 
transmutant strains, only one had a change in immunogenic proteins. The U. urealyticum 
strain W11+Tn1 lost a 41 kDa band compared to the parent strain (Figure 5.9 and 5.10).  
Apart from the alterations seen in MBA mobility that were presented previously , all U. 
parvum transmutant strains did not show any other variation in immunoproteins detected 
by human serum. 
The immunogenic change (loss of 41 kDa protein) in W11 transmutant strain relative to 
the serum-resistant parent strain was an interesting finding in this study, as it was 
associated with alteration in complement susceptibility. Following transposon 
mutagenesis, the transmutant strain of W11 became significantly more susceptible to 
complement-mediated killing (Figure 5.10). While remained resistant to seronegative 
serum, the transmutant strain was readily killed by sera containing anti-Ureaplasma 
antibodies (seropositive sera). Genomic DNA analysis identified a single genomic 
insertion site by in gel hybridization for the aac-aphD gene (Figure 5.4). Sanger 
sequencing of purified genomic DNA sequencing from the transmutant strain of 
W11found that the gene UUR10_0137 (ATTCC strain 33699 serovar 10 gene annotation 
numbering) was disrupted at amino acid 126 of 231.  
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Figure 5.9 Immunoblot analysis of SDS solubilised total cell bacterial protein probed with seropositive serum. The transposon-mutated strain of 
U. urealyticum W11 lost a 41 kDa band (red arrow) compared to the parent strain following transposon mutagenesis (+ Tn) when detected by 
human high seropositive. And apart from the changes in MBA (blue arrows), none of 25 U. parvum transposon-mutated clones (+Tn) showed 
alterations in expression of other immunoproteins detected by humane serum. M= molecular marker. 
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Figure 5.10 Serum killing (A) and immunoblot analysis using human high titre 
seropositive serum (B) for parental U. urealyticum strain W11 (SV12) and following 
successful transposon mutagenesis (+Tn). Serum killing was increased significantly 
following 1 hr challenge with human serum containing antibodies; and analysis of this 
serum shows the serum-sensitive transposon mutated strain has lost a 41 kDa band that 
was immunoreactive with the challenging serum. Bar graph shows mean +/- SEM of 
experiments performed in triplicate. Representative immunoblot from three repeat 
experiments shown.   
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5.2.6 Disruption of RNA helicase (UU582) gene altered Ureaplasma growth 
kinetics 
Random transposon insertion was found to disrupt the gene UU582 as shown in Figures 
5.4 and 5.5.  UU582 encodes the only copy of an ATP-dependent DeaD-box bacterial 
RNA-helicase in the U. parvum genome and disruption of this gene was found to alter 
final titre and growth kinetics for the bacteria at a range of incubation temperatures.  Of all 
the transposon mutated Ureaplasma strains, only the disruption of gene 582 (UU582:: 
mTn) had this effect.  Maximum bacterial titre was obtained for parent and all other 
transposon mutated strains by 36 hr at 37°C (Figure 5.11), while UU582::mTn did not 
reach maximum titre until 60 hr and had a 3 to 4 log reduction in final bacterial titre.  As 
DEADbox RNA-helicase mutants are reported to be unable to replicate at lower 
temperatures (Owttrim, 2013), I also investigated growth kinetics at 33°C and 25°C (an 
example of growth for the parent strain at these temperatures is shown in figure 5.12).  
Under these conditions the maximum titre for other Ureaplasma strains took longer to 
attain and UU582::mTn titres were 10
8
-fold lower at 25°C.  
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Figure 5.11 Growth kinetics for U. parvum parent strain (HPA5) compared to membrane 
protein disruption (UU390::mTn) or DEAD-box RNA-helicase gene disruption 
(UU582::mTn) strains when incubated at 37 
º
C (A), 33 
º
C (B) or 25 
º
C (C). Strains were 
titrated out in a 10-fold dilution series and growth measure at time points indicated by 
urease conversion of urea to ammonium ions. Ureaplasma growth is shown as colour (pH 
indicator) changing units per ml. Mean and standard deviation of dilutions performed in 
triplicate. Results were consistent through three repeated experiments.  
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Figure 5.12 Growth of U. parvum HPA5 in triplicate at 25, 33, and 37 ºC as measured by 
colour change of USM. 180 µl were placed in each well and 20 µl of prototype laboratory 
U. parvum strain HPA5 was inoculated into the first well (in triplicate). Filter tips were 
changed between each dilution (transfer of 20 µl) across the plate. The plates were then 
incubated in separate incubators at the listed temperatures and the growth documented at 
various time points. These images were taken at the 48 hr time point for one of the 
repeats of the experiment. 
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5.3 Discussion 
 Large scale analysis of random genome integration has been used for Mycoplasma spp. to 
determine the essential genes of a minimum genome, the underlying presumption being 
that essential genes cannot be disrupted.  M. genitalium has the smallest genome and 
saturating Tn mutagenesis on this organism led to the proposal of a between 265-350 
genes as being the minimum required to sustain self-replicating independent life 
(Hutchison et al., 1999). Further refinement of this method identified all 43 RNA-coding 
genes to be essential and 382 of 482 M. genitalium protein-coding genes to be essential for 
culture growth of M. genitalium (Glass et al., 2006). These studies were hugely influential 
in the construction of the minimum synthetically assembled genome based on M. 
genitalium in 2008 (Gibson et al., 2008).  However, comparison of the smallest 
Mycoplasma and Ureaplasma spp., which vary in their use of glycolysis, arginine-
metabolism and urea-metabolism for survival, showed U. parvum, M. hominis and M. 
genitalium only have an overlap of 247 coding sequences (Pereyre et al., 2009) suggesting 
much is yet to be learned from minimum genome analysis of the other mollicutes. 
Comparison of 19 sequenced genomes for human Ureaplasma spp. has identified an 
average of 608 predicted genes for each U. parvum genome and 664 for U. urealyticum 
(Paralanov et al., 2012). A total of 1020 possible predicted protein coding genes, including 
singletons, were identified with a core conserved genome of 515 genes.  Now that 
transposon mutagenesis is routinely successful with U. parvum, determination of non-
essential genes in a microbe that does not use the glycolysis pathway will add empirical 
verification to the composition of a hypothetical minimum gene set. However, I 
acknowledge that my studies have not examined whether transposon insertion into the 
genome had altered gene expression.  Two of the transposon-mutated strains showed 
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phenotypic alteration, and I would predict that all of the other identified open-reading 
frame disruptions that I identified should result in a failure to express fully functional 
proteins, as the predicted open reading frames were disrupted between 150-704 bp into the 
expected coding region.  However, as they are hypothetical open reading frames of 
unknown function, they may not be expressed in parent strains. The one exception may be 
the integration between UU187(rpoB)) and UU188 (rpoC), both of which are predicted to 
be homologues of DNA-directed RNA polymerase subunit beta; as the stop codon of 
UU187 and the intergenic region between the genes was conserved, expression of both of 
these genes may be conserved and no phenotypic alteration was observed for this strain.  
Most of the disrupted genes were of unknown function and only listed as predicted open-
reading frames (Table 5.1).  Genes UU390, UU450, and UU520 may encode membrane 
proteins, UU047 is predicted to encode a conserved hypothetical ATP/GTP-binding 
protein, UU526 is predicted to encode an MBA paralogue that should be expressed as a 
surface-associated membrane lipoprotein, as is UU440 which is also predicted to be a 
hypothetical membrane lipoprotein, while UUR10_137 is a predicted protein of unknown 
function.  
I have also identified an intermediate level of gene class here, where disruption of the only 
annotated RNA helicase in the U. parvum genome (UU582) resulted in a significant 
physiological growth alteration that would likely affect the ability of the resultant strain to 
survive in vivo.  RNA helicases largely belong to superfamily two of the six families of 
nucleic acid helicases, and the U. parvum RNA helicase in particular belongs to the 
DEAD-box family based on the signature sequence, Asp-Glu-Ala-Asp (Fairman-Williams 
et al., 2010). While many bacteria encode a few RNA helicases, a substantial number of 
sequenced bacterial genomes only contain a single DEAD-box helicase (Zolldann et al., 
2005). Although E. coli encodes 5 RNA helicases, assessment following individual 
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disruption of each found that the ΔdeaD mutation was primarily responsible for observed 
growth defects at 37°C including increased doubling time and ΔdeaD (as well as the 
ΔsrmB) mutation exhibited a cold sensitive phenotype (Jagessar and Jain, 2010), very 
similar to my observations for U. parvum. 
I was unable to successfully deliver the mini-transposon to a range of U. urealyticum 
strains despite being performed in parallel with the same conditions and reagents used to 
successfully mutagenise U. parvum.  The only exception was a single experiment where a 
clinical strain (W11) was successfully transformed resulting in delivery of the gentamicin 
resistance gene.  This strain exhibited my second observed phenotypic change: altered 
survival following serum challenge.  Previously Beeton et al. (2012) had characterised the 
complement sensitivity of U. parvum strains and found that some strains (such as HPA5) 
were very sensitive and killed by seronegative serum, some strains were readily killed only 
by serum containing anti-Ureaplasma antibodies (such as HPA2 and DFK-1), and others 
were inherently resistant.  However, I did not observe any alteration of serum sensitivity or 
resistance of the mutagenised U. parvum strains compared to the parent strains in this 
study (Figures 5.8 and 5.9).  As presented in chapter 3 of my thesis, characterisation of the 
W11 strain found it to be completely resistant to all previously characterised seropositive 
sera containing anti-Ureaplasma antibodies.  However, following transposon integration 
into the W11 genome, the resultant strain was sensitive to killing by seropositive sera.  
The altered phenotype was co-incident with loss of a 41 kDa protein detected by the 
human high titre seropositive serum used to challenge the Ureaplasma strains and the 
single transposon insertion site was found to disrupt the hypothetical gene UUR10_137 
(ATCC 33699 serovar 10 gene annotation numbering). The predicted mass of this open 
reading frame is 27 kDa, but the size may be increased by post-translational modification. 
It is also possible that the disruption of this gene may not have any direct bearing on the 
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loss of the expression of the 41 kDa protein or alteration of serum resistance. Further 
experiments are required to determine if isolated expression of this gene is capable of 
solely mediating serum resistance.  
The major surface antigen MBA (gene UU375 in U. parvum serovar 3 ATCC strain 
700970) has also previously been shown to be susceptible to phase variation following 
bacterial stress (Zimmerman et al., 2011; Zimmerman et al., 2009) or alteration of size 
(Robinson et al., 2013). I only observed three strains with alteration in MBA size and no 
strains with loss of MBA expression. Therefore, the temperature-shock and selection in 
gentamicin associated with transformation do not appear to trigger phase variation and I 
would expect that loss of MBA expression would require gene disruption. 
In general, I have succeeded in developing a methodology that is capable of delivering a 
mini-transposon to the U. parvum genome, which results in random gene disruption.  This 
methodology can now be utilised to determine the minimal genome contingent for a 
bacterial class that do not utilise glycolysis to survive and shed further light on core 
essential genes.  Characterisation of disrupted gene strains with pathogenesis studies in 
experimental in utero model infections will also be a key to identifying pathogenic 
markers within the U. parvum genome, as it has been shown to initiate preterm labour and 
chronic lung disease in preterm neonates experimentally as a sole pathogen (Novy et al., 
2009). Transposon mutagenesis will also be valuable in enabling delivery and expression 
of exogenous genes to U. parvum for in vivo tracking and possibly as a mucosal vaccine 
delivery tool of the future. 
  
 
Chapter 6 
Expression of foreign genes 
in Ureaplasma
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6. Expression of foreign genes in Ureaplasma 
 
6.1 Introduction 
Expression of foreign genes, in most Mollicutes, has been challenging due to the unusual 
codon usage that this group of bacteria have. During their evolution, Mollicutes have 
gone under a remarkable genome reduction co-incident with a shift to very low G + C 
content.  As a result of this, an alteration in usage of the UGA (opal) stop codon to 
tryptophan codon has occurred, with the only exception of the species A. laidlawii, which 
have maintained a normal tryptophan codon usage (the UGG codon) (Razin et al., 1998). 
In fact, the unusual codon usage makes it difficult to express Ureaplasma genes in other 
bacteria and vice versa as this would lead to truncated immature gene products. Previous 
attempts to solve this issue have not been fully successful (Jarhede et al., 1995).  
  
As it has become possible to deliver and disrupt genes in Ureaplasma spp. by means of 
transposon mutagenesis (as discussed in Chapter 5), the aim of this final results chapter 
was therefore to investigate the ability of these microbes to express exogenous genes 
subsequent to successful delivery. The mCherry that encodes for a monomeric red 
fluorescent protein (RFP) mCherry was delivered to and investigated for expression in 
Ureaplasma. Furthermore, expression of this foreign gene was examined under several 
parameters that influence gene expression efficiency, such as the strength of the 
transcriptional promoter, the codon-usage, and the number of copies of the gene to 
evaluate the effect of these factors on expression of exogenous genes in Ureaplasma. In 
other prokaryotes such as E. coli (“the work-horse for gene expression”), it has been 
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found that many factors including the above mentioned parameters influence expression 
of foreign genes (Glick and Whitney, 1987). Fluorescent proteins have been widely used 
in many different applications, for instance as probes that enable tracing and localizing 
microbes in vivo.  Optimisation of RFP gene expression as a probe for Ureaplasma 
would be a useful technique that opens doors for studying the biology and pathogenesis 
of these tiny pathogens. Generation of fluorescent Ureaplasma would also be a useful 
method that allows for tracing and studying Ureaplasma infection in animal models.  
 
6.2 Results 
6.2.1 Generation of pMT85 expression vector with modified mCherry inserts 
In this study, all mCherry inserts under investigation were constructed and cloned into 
pMT85 Tn4001 mini-transposon plasmid as an expression vector (Figure 6.1).  As 
previously described in chapter 5, this plasmid was successfully delivered to several 
Ureaplasma isolates through PEG-mediated transposon mutagenesis. Construction of the 
plasmid with inserts of interest was as described in chapter 2. The mCherry inserts were 
modified and synthesized in different ways to investigate some fundamental factors that 
control and affect gene expression (see Table 2.10).  Vector pMT85 plasmids carrying 
various inserts with different copy numbers, selected transcriptional promoters and/or 
optimized codon-usage were generated and cloned into E. coli where plasmid vector 
constructs were amplified and validated before being introduced into Ureaplasma strains, 
where efficacy of expression was evaluated. Nucleotide sequence and detail of the 
pMT85 vector are shown in Appendix I. 
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Figure 6.1 A map of pMT85 showing the cloning site of mCherry inserts (A) and restriction digestion profile of pMT85 vector with an insert 
(B). Lane 1: Undigested pMT85 plasmid; lane 2: pMT85 plasmid digested by XbaI; lane M: KAPA universal ladder; lane 3: Undigested pMT85 
plasmid with mCherry insert; lane 4: pMT85 plasmid with single RFP (mCherry) insert digested and released by XbaI.   
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The first construct insert generated and used in this study consisted of a tandem mCherry 
insert (GRT), i.e. two separate copies of mCherry, under the control of the expression 
promoter of elongation factor Tu (EF-Tu) gene of U. parvum serovar 14 (ATCC strain 
33697 as provided by GeneBank id: emb|Z34275.1); each independent copy of the 
mCherry had its own promoter, and the codon- usage of the gene was optimized for 
Ureaplasma spp. expression by converting the amino acid sequence of synthetic 
monomeric red fluorescent protein (GeneBank id: gb AAV52164.1) into a synthetic gene 
by using the most common U. parvum codons utilised (Figure 6.3), as provided by the 
website:  
http://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=134821&aa=14&style=N  
The tandem mCherry insert (GRT) and all other inserts in this study (see Table 2.10) 
were cloned into the XbaI site of the pMT85 vector (Figure 6.1). Constructed pMT85 
vector with forward (GRT
1
-F) and reverse (GRT
2
-R) orientations of tandem mCherry 
insert were obtained and confirmed by sequencing before being delivered into 
Ureaplasma cells. The placement of the tandem mCherry insert altered by cloning the 
tandem expression construct  into the SpeI site of the pMT85 vector (Figure 6.1) to make 
another different construct (GR-1Tn) (Figure 6.2) that was equivalent to GRT inserts. 
However, the GR-1Tn plasmid could then receive a second tandem expression construct 
into the XbaI site resulting in a total of 4 copies of mCherry (GR-2Tn) (Figure 6.2). 
Furthermore, plasmid constructs with one copy and two copies of single mCherry (GR-
½Tn and GR-½Tn(2)) were separately constructed using a ½ of the tandem mCherry 
insert described above under the control of the same promoter (EF-Tu) used with tandem 
mCherry (Figure 6.2). The codon usage of the ½ tandem mCherry insert was identical to 
that of tandem mCherry insert; the only difference was that the three tryptophan UGA 
codons (Ureaplasma tryptophan codon) in the coding region of the synthetic gene were 
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replaced by the standard UGG tryptophan codon (Figure 6.3). These constructs with 
different copy number of mCherry were mainly optimized to be expressed exclusively in 
Ureaplasma and generated to investigate the effect of copy number on expression of 
exogenous genes; however, the constructs differing only by the use of tryptophan codon 
were designed to determine the influence of that single codon. I also examined the 
expression of a previously reported mCherry construct that was expressed in M. 
pneumoniae by Zimmerman and Herrmann (2005), an insert I have designated GRZ, 
which was a recombinant fusion protein of the M. pneumoniae high expression protein 
Pmp200 and mCherry. This construct was originally designed to assess expression of a 
small, cysteine-rich, peptide that is only 29 amino acid long (PmP200) using the 
monomeric red fluorescent protein (mRFP1) in M. pneumoniae as a reporter (Zimmerman 
and Herrmann, 2005). Expression of the GRZ construct was driven by EF-Tu promoter 
from M. pneumoniae and modified by adding a 7x His-tag to the C-terminus. The codon-
usage of this particular insert was not modified and only one copy was present in the 
pMT85 vector.  
OPT-mCherry insert (GR-m) was an additional construct generated that was codon-
optimized based on the reported tRNA genes identified by genomic analysis of 19 
serovars by (Paralanov et al., 2012); however, the UGG codon was used for this construct 
so that it was also expressed in E. coli (Figures 2 and 3). The promoter used in this insert 
was EF-Tu promoter of U. parvum SV14, and the insert was also modified by adding 
BamHI site downstream the promoter to allow flexibility to change prompters 
(XbaI/SpeI/promoter/BamHI/RFPgeneSacI/XbaI). Following cloning into pMT85,, three 
different pMT85 constructs with one (GR-1m), two (GR-2m) and three copies of RFP 
insert (GR-3m) were generated by chance and identified by characterization of several 
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colonies (Figure 6.4) and were introduced into both E. coli and Ureaplasma to investigate 
expression level mediated by copy number.  
The last insert constructed and used in this study was an Ureaplasma-optimized mCherry 
insert (uRFP-his) that was synthesized as an identical codon usage to the original tandem 
mCherry construct, utilizing the UGA codon for tryptophan (Figure 6.3). However, this 
insert, has an additional 6-histidine tag added in frame at the end of the gene, and the 
promoter controlling its expression was the multiple banded antigen (MBA) promoter of 
U. parvum serovar 1. For direct comparison to the tandem mCherry construct, two copies 
of uRFP were cloned into pMT85 (one into the SpeI site, one into the XbaI site) prior to 
delivery into Ureaplasma to examine expression (Figure 6.2.) 
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Figure 6.2 Diagrammatic representation of mCherry expression constructs delivered into 
the Ureaplasma strains by mini-transposon plasmid, pMT85.  Two separate mCherry 
constructs (identified by blue and violet rectangles) were created that differed by the 
codons utilised to encode the synthetic gene.  Of critical importance were those constructs 
where tryptophan was determined by the UGA codon (Ureaplasma expression only) 
relative to the UGG codon (all prokaryotes).  A grey box identifies constructs where 7 
consecutive histidine residues (His-tag) have been added in frame prior to the stop codon.  
The relationship of the different constructs utilising the EF-Tu promoter and mCherry are 
shown by the insertion of single promoter-gene or double tandem promoter-gene 
expression constructs into the available XbaI and SpeI restriction sites (RE) to determine 
copy number on each plasmid. Green arrows indicate EF-promoter and orange ones 
indicate MBA-promoter. 
 
Continued  
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Figure 6.2 (continued) Diagrammatic representation of mCherry expression constructs 
delivered into the Ureaplasma strains by the mini-transposon plasmid, pMT85.  Two 
separate mCherry constructs (identified by blue and violet rectangles) were created that 
differed by the codons utilised to encode the synthetic gene.  Of critical importance were 
those constructs where tryptophan was determined by the UGA codon (Ureaplasma 
expression only) relative to the UGG codon (all prokaryotes).  A grey box identifies 
constructs where 7 consecutive histidine residues (His-tag) have been added in frame 
prior to the stop codon.  The relationship of the different constructs utilising the EF-Tu 
promoter and mCherry are shown by the insertion of single promoter-gene or double 
tandem promoter-gene expression constructs into the available XbaI and SpeI restriction 
sites (RE) to determine copy number on each plasmid. Green arrows indicate EF-
promoter and orange ones indicate MBA-promoter. 
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Opt mCherry UGG 
GUA V 0.36 AGC S 0.08  AAG K 0.10 GGC G 0.15  GAC D 0.11  AAC N 0.19 GCA A 0.37 AUC I 0.15 UUC F 0.11  
CAC H 0.25  UAC Y 0.24 UGG W 0.25  UUG L 0.05  
atggtaagcaagggcgaagaagacaacatggcaatcatcaaggaattcatgcgtttcaag 
 M  V  S  K  G  E  E  D  N  M  A  I  I  K  E  F  M  R  F  K  
gtacacatggaaggcagcgtaaacggccacgaattcgaaatcgaaggcgaaggcgaaggc 
 V  H  M  E  G  S  V  N  G  H  E  F  E  I  E  G  E  G  E  G  
cgaccatacgaaggcacacaaacagcaaagttgaaggtaacaaagggcggcccactacca 
 R  P  Y  E  G  T  Q  T  A  K  L  K  V  T  K  G  G  P  L  P  
ttcgcatgggacatcttgagcccacaattcatgtacggcagcaaggcatacgtaaagcac 
 F  A  W  D  I  L  S  P  Q  F  M  Y  G  S  K  A  Y  V  K  H  
ccagcagacatcccagactacctaaagttgagcttcccagaaggcttcaagtgggaacgt 
 P  A  D  I  P  D  Y  L  K  L  S  F  P  E  G  F  K  W  E  R  
gtaatgaacttcgaagacggcggcgtagtaacagtaacacaagacagcagcctacaagac 
 V  M  N  F  E  D  G  G  V  V  T  V  T  Q  D  S  S  L  Q  D  
ggcgaattcatctacaaggtaaagttgcgaggcacaaacttcccaagcgacggcccagta 
 G  E  F  I  Y  K  V  K  L  R  G  T  N  F  P  S  D  G  P  V  
atgcaaaagaagacaatgggctgggaagcaagcagcgaacgtatgtacccagaagacggc 
 M  Q  K  K  T  M  G  W  E  A  S  S  E  R  M  Y  P  E  D  G  
gcactaaagggcgaaatcaagcaacgattgaagctaaaggacggcggccactacgacgca 
 A  L  K  G  E  I  K  Q  R  L  K  L  K  D  G  G  H  Y  D  A  
gaagtaaagacaacatacaaggcaaagaagccagtacaattgccaggcgcatacaacgta 
 E  V  K  T  T  Y  K  A  K  K  P  V  Q  L  P  G  A  Y  N  V  
aacatcaagctagacatcacaagccacaacgaagactacacaatcgtagaacaatacgaa 
 N  I  K  L  D  I  T  S  H  N  E  D  Y  T  I  V  E  Q  Y  E  
cgtgcagaaggccgacacagcacaggcggcatggacgaattgtacaagcaccaccaccac 
 R  A  E  G  R  H  S  T  G  G  M  D  E  L  Y  K  H  H  H  H  
caccaccactaa 
 H  H  H  -   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Codon usage for key constructs (OPT-mCherry UGG, Half-tandem UGA and 
uRFP).  Where best U. parvum codon is used in sequence, the codon is highlighted at first 
use. 
Continued 
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uRFP 
AGU S 0.38 actually higher than tandem S UCA S 0.24 
atggttagtaaaggtgaagaagataatatggctattattaaagaatttatgcgttttaaa 
 M  V  S  K  G  E  E  D  N  M  A  I  I  K  E  F  M  R  F  K  
gttcatatggaaggtagtgttaatggtcatgaatttgaaattgaaggtgaaggtgaaggt 
 V  H  M  E  G  S  V  N  G  H  E  F  E  I  E  G  E  G  E  G  
cgtccatatgaaggtacacaaacagctaaattaaaagttacaaaaggtggtccattacca 
 R  P  Y  E  G  T  Q  T  A  K  L  K  V  T  K  G  G  P  L  P  
tttgcttgagatattttaagtccacaatttatgtatggtagtaaagcttatgttaaacat 
 F  A  W  D  I  L  S  P  Q  F  M  Y  G  S  K  A  Y  V  K  H  
ccagctgatattccagattatttaaaattaagttttccagaaggttttaaatgagaacgt 
 P  A  D  I  P  D  Y  L  K  L  S  F  P  E  G  F  K  W  E  R  
gttatgaattttgaagatggtggtgttgttacagttacacaagatagtagtttacaagat 
 V  M  N  F  E  D  G  G  V  V  T  V  T  Q  D  S  S  L  Q  D  
ggtgaatttatttataaagttaaattacgtggtacaaattttccaagtgatggtccagtt 
 G  E  F  I  Y  K  V  K  L  R  G  T  N  F  P  S  D  G  P  V  
atgcaaaaaaaaacaatgggttgagaagctagtagtgaacgtatgtatccagaagatggt 
 M  Q  K  K  T  M  G  W  E  A  S  S  E  R  M  Y  P  E  D  G  
gctttaaaaggtgaaattaaacaacgtttaaaattaaaagatggtggtcattatgatgct 
 A  L  K  G  E  I  K  Q  R  L  K  L  K  D  G  G  H  Y  D  A  
gaagttaaaacaacatataaagctaaaaaaccagttcaattaccaggtgcttataatgtt 
 E  V  K  T  T  Y  K  A  K  K  P  V  Q  L  P  G  A  Y  N  V  
aatattaaattagatattacaagtcataatgaagattatacaattgttgaacaatatgaa 
 N  I  K  L  D  I  T  S  H  N  E  D  Y  T  I  V  E  Q  Y  E  
cgtgctgaaggtcgtcatagtacaggtggtatggatgaattatataaacatcatcatcat 
 R  A  E  G  R  H  S  T  G  G  M  D  E  L  Y  K  H  H  H  H  
catcatcattaa 
 H  H  H  -   
 
  
 
 
Figure 6.3 (continued) Codon usage for key constructs (OPT-mCherry UGG, half-
tandem mCherry UGA and uRFP). Where best up codon is used in sequence the codon is 
highlighted at first use. 
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Figure 6.4 Mini-transposon plasmids (pMT85) carrying different copy-number of OPT 
mCherry insert. Purified plasmids with one (GR-1m) (A), two (GR-2m) (B) and three 
(GR-3m) (C) copies of mCherry insert were digested with three different restriction 
enzymes XbaI, SpeI (3) and BamHI (4) to verify the copy number of the mCherry insert. 
Lanes: (1) undigested pMT85 plasmid and M; molecular weight marker (the KAPA 
universal ladder). The copy number was determined based on the differential bands 
produced by BamHI digest, which is not encoded within the insert (4).  
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6.2.2 Expression of tandem mCherry insert in Ureaplasma  
The tandem mCherry insert was the first RFP insert to be delivered to and observed for 
expression in Ureaplasma. The pMT85 plasmid vector carrying a tandem mCherry insert 
was successfully delivered to several Ureaplasma strains as confirmed by the presence of 
the gentamicin resistance gene by PCR using gentamicin primers as previously detailed in 
chapter 5 of this thesis. Using immunoblot analysis, the findings showed that all 
Ureaplasma strains transformed with this RFP insert were able to express the fluorescent 
protein mCherry compared with untransformed parental negative controls and clones with 
empty pMT85 vector (Figure 6.5). The RFP was positively detected by anti-mCherry 
antibody and appeared as a single band with approximately 23 kDa combined with a 
double band with higher molecular mass size (about 30 kDa), which is  probably a 
glycosylated isoform of RFP. The mCherry protein was completely absent in parental 
strains and strains cloned with an empty pMT58 vector. Expression of emitted red 
fluorescence (mCherry) was also observed in Ureaplasma colonies growing on USM 
agar medium using a fluorescent microscopy. Although RFP was clearly detected by 
Western blotting, the emission of red fluorescence from colonies viewed under a 
fluorescent microscope was of a low degree (Figures 6.6). An attempt to measure the red 
fluorescent protein from bacterial cells growing in broth media (USM) using a 
fluorometer failed. In contrast, no mCherry expression in E. coli cells transformed with 
pMT85- tandem mCherry (GRT) was seen (Figure 6.8), which is expected as the UGA-
tryptophan tRNA is only present in Ureaplasma and other mollicutes and this protein 
would be truncated at 62 amino acids (first occurrence of tryptophan in the coding region 
out of 256 amino acids for the full-length protein).  
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Figure 6.5 Expression of RFP in a number of representative transformed strains of 
Ureaplasma. Total protein extract was separated by SDS-PAGE (12.5%) and blotted onto 
nitrocellulose membrane. anti-mCherry polyclonal antibody was used to detect the RFP 
expression in transmutants with tandem mCherry insert (GRT) compared to 
untransformed parents and one HPA5 transmutant strain with empty vector. Another 
HPA5 transmutant clone carrying different RFP insert, Zimmerman mRFP1 construct 
(GRZ) was also run alongside.   With exception of HPA5_GRZ clone, all transformed 
clones were found to express the delivered exogenous RFP gene (tandem mCherry insert) 
with molecular mass of about 23 kDa associated with a larger double band of about 30 
kDa size (probably glycosylated RFP as it was seen in all clones expressed RFP). Lane 
M= molecular mass marker. 
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Figure 6.6 Detection of RFP expression by Ureaplasma colonies. Colonies from 
representative transformed strains carrying different constructs of mCherry were screened 
and observed using a fluorescence microscope. Colonies from the same microscopic filed 
are shown in both visible light (A) and fluorescence (B). Strains from up to down: 
Parental strain HPA5 (SV3) (I), transformed HPA5 strains: with forward tandem 
mCherry (HPA5_GRT-F) , with reveres tandem mCherry (HPA5_GRT-R) (III), with 
tandem mCherry in SpeI cloning site (HPA5_GR-1Tn) (IV), and two copies tandem 
mCherry (HPA5_GR-2Tn) (V). All transmutants expressed a low degree of RFP and no 
fluorescence was observed in the parental HPA5 strain.  
 222 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 223 
 
 
6.2.3 Optimization of RFP gene expression in Ureaplasma  
To investigate some of the factors that affect the expression level of foreign genes in 
Ureaplasma, a number of constructed mCherry inserts were created to examine codon-
usage, copy number of mCherry and/or use of different promoters as stated above. The 
pMT85 vectors with all these different inserts with varying parameters were transferred 
into the U. parvum serovar 3, HPA5 isolate. Following successful transformation, 
expression levels of RFP were investigated by immunoblot analysis. Whole cell lysates 
were extracted, and 10 µg protein loads from all transmutant strains under investigation 
were run alongside each other and separated using 1-DE (12.5 % SDS-PAGE). 
Expression level of RFP was investigated by comparing intensity of mCherry protein 
bands obtained from all transmutant clones. As it can be seen in figure 6.7, RFP was 
found to be successfully expressed, albeit with different levels of expression by most of 
the transmutant strains (HPA5_GRT
1
-F, HPA5_GRT
1
-R, HPA5_GR-1Tn, HPA5_GR-
2Tn, HPA5_GR-½Tn and HPA5_GR-½Tn-2, HPA5_uRFP-his, HPA5_GR-1m, 
HPA5_GR-2m, and HPA5_GR-3m). The only exception was the transmutant strain 
HPA5_GRZ that showed no detectable RFP by western blot analysis. This transmutant 
strain contained the RFP insert that was constructed as fused protein with EF-Tu 
promoter from M. pneumoniae, and was not codon-usage optimized for Ureaplasma. 
Variations in expression level observed among the transmutants were basically attributed 
to different modified parameters tested. By analyzing the results, it was found that all 
mCherry inserts derived by EF-Tu promoter of U. parvum SV14 were expressed at a 
higher level compared with the insert under the control of the MBA promoter of SV1. 
This observation was especially obvious in comparison to the transmutant strain 
HPA5_GR1½Tn, which only contained one copy of ureaplasma-optimized mCherry 
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insert with EF-Tu promoter.  By comparison HPA5_uRFP-his had two copies of the same 
Ureaplasma-optimized mCherry insert, but controlled by the MBA promoter of SV1. 
Despite being having different copy numbers of mCherry, the two transmutants showed 
similar levels of RFP expression seen as immunoreactive bands with comparable 
intensity. By comparison, Ureaplasma containing two copies of mCherry (as for uRFP-
his) but under the EF-Tu promoter (GRT-F/GRT-R) showed enhanced levels of 
expression compared to the transmutant strain HPA5_uRFP-his (Figure 6.7).  
 
The majority of transmutant strains carried mCherry inserts were codon-usage-optimized 
for Ureaplasma, however, there were three transmutants (HPA5_GR-1m, HPA5_GR-2m 
and HPA5_GR-3m) which carried increasing copy numbers of mCherry that were codon-
usage optimized based on identified tRNA species in the analysed 19 Ureaplasma 
genomes and using the UGG tryptophan codon so that it could be expressed in E. coli as 
well (Figure 6.3). The expression of this construct was under the control of EF-Tu 
promoter from SV14. Plasmid vectors carrying 1, 2 and 3 identical copies of this 
construct were created and characterized (Figure 6.2). Following, delivery into HPA5, the 
immunoblot results revealed that expression of these constructs was almost negligible 
relative to the other successfully delivered constructs (Figure 6.7). However, due to the 
use of the UGG codon for tryptophan, these constructs were expressed in E. coli and at 
much higher levels compared with expression in Ureaplasma (Figure 6.8). The effect of 
the copy number of mCherry on RFP expression in E.coli could be measured using a 
fluorometer for HPA5_GR-1m, HPA5_GR-2m and HPA5_GR-3m; transmutants with 
more than one copy numbers of the gene showed an enhanced expression compared with 
that of one copy insert (Figures 6.9). 
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The effect of gene copy number on level of expression was also investigated in constructs 
that were codon-usage optimized for Ureaplasma. As previously mentioned in section 
6.2.1 of this chapter, constructs with different copy number of tandem mCherry and ½ 
tandem mCherry inserts were generated and transmutants with one copy 
(HPA5_GR½Tn), two copies (HPA5_GRT
1
-F, HPA5_GRT
1
-R, HPA5_GR-1Tn and 
HPA5_GR½Tn(2)), and four copies (HPA5_GR-2Tn) were created and investigated. 
While the right promoter and codon-optimization were crucial factors for expression of 
foreign genes in Ureaplasma, the results also showed that increasing gene copy number 
for mCherry had an increasing effect on expression of RFP in Ureaplasma as well. Of all 
transmutants studied, those with 2 and 4 copies of mCherry showed the highest 
expression, with 4 copies being the best detected by immunoblot analysis (Figure 6.7). 
Attempts to measure fluorescence of mCherry produced by Ureaplasma cells growing in 
USM using a fluorometer were unsuccessful as both untransformed and transformed 
Ureaplasma cells gave similar reading. In addition, the negative control USM broth 
(uninoculated) also gave a comparable fluorescence reading to that of USM with growing 
bacteria. It is believed that there are several factors might cause such problems, which 
mainly relate the ingredient of media.  The presence of phenol red and 10% porcine 
serum in the growth medium are thought to confound the ability to detect additional 
fluorescence over the autofluorescence and/or quenching (Straight, 2007).  
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Figure 6.7   Comparison of RFP expression under different parameters by U. parvum 
SV3 (isolate HPA5). Total cellular protein was extracted and 10 µg protein of each 
sample was loaded and separated by SDS-PAGE (12.5%). Separated proteins were then 
blotted to a nitrocellulose membrane. RFP was detected with anti-mCherry polyclonal 
antibody as a band of approximately 23 kDa combined with detectable higher molecular 
mass double band. Lanes: parental strain (HPA5; SV3); HPA5 transmutant clone with 
empty pMT85 vector (HPA5_GR
1
); HPA5 transmutant strain with forward orientation 
tandem mCherry insert (HPA5_GRT
1
-F); HPA5 transformed clone with revers 
orientation tandem mCherry insert (HPA5_GRT
1
-R); HPA5 transmutant clone with one 
copy tandem mCherry insert cloned into the SpeI site of the vector (HPA5_GR-1Tn); 
HPA5 transmutant clone with two copies tandem mCherry insert (HPA5_GR-2Tn); 
HPA5 transmutant clone with half tandem mCherry insert (one copy mCherry  insert) 
(HPA5_GR- ½ Tn); HPA5 clone with two copies half tandem inserts (HPA5_GR- ½ Tn-
2); HPA5 transmutant clone with two copies of RFP with His-tag and SV1 MBA 
promoter (HPA5_U7); HPA5 transmutant clone with one copy optimized mCherry3  
(HPA5_GR-1m), HPA5 transmutant clone with two copies optimized mCherry3  
(HPA5_GR-2m), HPA5 transmutant clone with three copies optimized mCherry3  
(HPA5_GR-3m); HPA5 transmutant clone with one copy modified mRFP1 (Zimmerman 
fused protein) (HPA5_GRZ).   M: molecular mass marker. 
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Figure 6.8 Immunoblot of E. coli transmutant strains harbouring different constructs of 
mCherry. Total cell protein extract (10 µg) was separated by SDS-PAGE (12.5%) and 
blotted onto nitrocellulose. RFP was detected with anti-mCherry polyclonal antibody. 
Transmutant strains: GR (with empty pMT85), GRT (with tandem mCherry insert), GR-
1m (with one copy Opt-mCherry insert), GR-2m (with two copies Opt-mCherry insert) 
GR-3m (with three copies Opt-mCherry insert) and GRZ (with Zimmerman insert). RFP 
was expressed by all transmutant strains (approximately 25 kDa) compared to negative 
control (GR) and transmutant strain harbouring mCherry insert optimised for Ureaplasma 
(GRT). Lane M: molecular weight marker. 
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Figure 6.9 A graph showing the effect of the number of copies of the mCherry on 
expression by recombinant E. coli. RFP from three transmutant E. coli strains containing 
different copy number of mCherry: one (GR-1m), two (GR-2m) and three (GR-3m) was 
measured by fluorometer and compared to a transmutant strain carrying an empty pMT85 
vector (GR) as a negative control.  All transformants were grown overnight in L.B broth 
with gentamicin (15µg/ml) and the O.D at 600nm was adjusted to 1 before measurement 
of RFP.  Transmutants with more than one copy number of the gene show a higher level 
of expression. Note that there was a significant increase in expression in transmutant 
strains carrying two or three copies when compared to transmutant strain carrying only 
one copy *** = p<0.0001. Data are presented as a mean cellular fluorescence ± SEM of 
triplicate samples of each transmutant strain under investigation.  
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6.3 Discussion  
Ureaplasma spp. are among the smallest and simplest self-replicating and free-living 
bacteria known to date. The evolution of these tiny microbes has occurred through 
genomic reduction and reduction of G+C content from their ancestors that are believed to 
be Gram-positive bacteria (Dybvig, 1990). As a result of evolutionary process, many non-
essential genes were lost resulting in several genomic and biological changes such as an 
absolute reliance on their host for nutrient supply, unusual codon usage for tryptophan, 
and lack of classical cell wall. These features have made it difficult to investigate 
Ureaplasma using some of the powerful molecular genetic tools that are available for 
studying the biology and pathogenesis of many well-known microorganisms. The first 
report of foreign DNA delivery in Mollicutes was when DNA extracted from a 
Mycoplasma “virus” (L2) was introduced into A. laidlawii using a PEG-mediated 
transfection (Sladek and Maniloff, 1983). Taking the advantage of the first successful 
transformation in Ureaplasma, the pMT85 Tn4001-minitransposon vector, in this study, 
was used to introduce the red fluorescent gene, mCherry, as an exogenous gene into 
Ureaplasma cells and investigate its expression under the control of several factors that 
affect the level of expression.  Fluorescent proteins are widely used as labeling tools to 
investigate protein localization, protein-protein interactions, cell division, gene 
expression in many microorganisms (Chudakov et al., 2010). The first documented 
expression of recombinant fluorescent proteins in Mollicutes was achieved in M. 
pneumoniae, when a GFP gene (EGFP) was fused with the gene encoding for the 
cytadherence associated protein HMW2 to determine its subcellular localization (Balish 
et al., 2003) . In this work, the fusion protein construct was cloned into a modified 
pMT85 vector that was then used to transform the bacterial cells, and the results showed 
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that HMW2 protein is a part of the attachment organelle of M. pneumoniae. Afterwards, 
the subcellular localization of a number of other M. pneumoniae proteins including P65, 
HMW2, P41 and P24 were also identified by a similar labeling approach (Kenri et al., 
2004). In my study, expression of RFP was achieved by Ureaplasma in most cases, and 
the level of expression was varied and shown to be responsive to a number of parameters 
that are known to have a major impact on expression of foreign genes in other bacteria 
(Fakruddin et al., 2013; Glick and Whitney, 1987). 
 
The effect of transcriptional promoter on expression was one of the key parameters to be 
investigated in this study. I have selected and used three different promoters: 1) EF-Tu 
gene promoter (from SV3) that drives the expression of one of the most abundant 
bacterial proteins, EF-Tu protein, 2) the MBA gene promoter (from SV1) that drives the 
expression of a major surface lipoprotein of Ureaplasma spp., the MBA and 3) the EF-Tu 
gene promoter from the closely-related species M. pneumoniae.  Among these promoters, 
EF-Tu promoter of SV14 was found to be the strongest as all mCherry inserts under the 
control of this promoter were effectively expressed, and the MBA promoter was also a 
good promoter, but not as good as the EF-Tu promoter. On the other hand, the expression 
of the RFP fusion protein driven by the M. pneumoniae EF-Tu promoter failed, whether 
this failure was resulted from the promoter or other factors related to the gene construct is 
an issue that has not been defined in this study as the main target of this work is to get 
positive expression of RFP that can be examined. However, this construct was reported to 
efficiently express in M. pneumoniae by Zimmerman and Herrmann. The results of this 
work indicated that choosing a strong promoter is a key aspect for driving expression of 
mCherry in Ureaplasma. In other mollicutes, a variety of chosen promoters have been 
utilized. Of these, the S. citri spiralin gene promoter that drives the most abundant protein 
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of S. citri has been the most widely used promoter for expression of foreign genes. This 
promoter has been effectively used for driving expression of several exogenous genes, for 
example, antibiotic selection genes (tetM, cat, aacA-aphD) and reporter genes (lacZ and 
GFP) and was indicated to be a strong promoter (Duret et al., 2005; Duret et al., 2003). 
Many other strong promoters have also been used for controlling expression of foreign 
genes and proved to be useful such as the promoter of the P40 gene of M. agalactiae and 
the promoters of P65 adhesin and tuf genes of M. pneumoniae (Balish et al., 2003; 
Baranowski et al., 2010; Kenri et al., 2004). 
 
Another important factor that was shown to have a great effect on expression of foreign 
genes in Ureaplasma was the codon-usage of the gene. In fact, there are 61 different 
trinucleotide codons that encode for the 20 known amino acids, and a number of these 
codons can encode for the same amino acid. Variations in codon-usage preference have 
been reported among many prokaryotes, and the frequency of codon-usage by a particular 
microorganism is believed to be greatly influenced by the cognate tRNAs pool (Glick and 
Whitney, 1987).  Furthermore, and as indicated earlier, these species have a unique 
codon-usage for the amino acid tryptophan:  The UGA codon in all other bacteria 
encodes for the open-reading frame termination stop codon Opal, therefore it was 
important to take this in consideration when optimizing the codons used to encode the red 
fluorescent protein mCherry to get maximal gene product. All RFP inserts that were 
codon-usage optimized for Ureaplasma were positively expressed regardless the level of 
expression as detected by western blot analysis, whereas one RFP insert (OPT-mCherry) 
that was codon-usage manipulated to function in both Ureaplasma and E. coli showed 
low expression in Ureaplasma, but high expression in E. coli. This may indicate that 
changing the codon-usage away from those preferred by Ureaplasma may have adverse 
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effect on expression in E. coli. Furthermore, another insert that was successfully 
expressed in M. pneumoniae was not expressed in Ureaplasma. This insert contained two 
fusion genes (mRFP1 and MP200RNA) but neither of these genes was optimized for 
Ureaplasma and was used as constructed by the authors (Zimmerman and Herrmann, 
2005). This may explain why it did not express in Ureaplasma due to the importance of 
codon-optimization.  
 
The copy number of the exogenous gene, mCherry, was also evaluated in my study and 
found to improve the efficiency of RFP expression in Ureaplasma. Inserts with more 
copies of mCherry (e.g. tandem mCherry and 2 copies tandem mCherry) were showed to 
enhance the expression degree, with four copies (two tandem mCherry) being the best. 
Using more than one copy number of a gene on the same vector has been indicated to 
improve expression by stabilizing the cloned protein (Glick and Whitney, 1987).  
However, it should be noted that gene copy number is probably less important than use of 
a strong transcriptional promoter and codon-usage optimization. 
 
In summary, I have shown that introducing foreign genes into Ureaplasma using 
transposon-based approach is possible. This novel accomplishment will undoubtedly 
open doors for other researchers in this field to explore and understand Ureaplasma 
biology and pathogenicity in more detail. During this work, I also have tried to address 
and examine some of the key factors that play an important role in expression of 
exogenous gene in bacteria: the promoter, the codon-usage, and the gene copy number.  It 
should be noted that the level of expression achieved in this study is still low and did not 
achieve a level sufficient for use in intracellular or in vivo tracking during infection. 
Therefore, further investigations of expression optimization are needed to get the 
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maximal possible expression in these unusual microorganisms and create recombinant 
fluorescent Ureaplasma, which will indeed make it possible to visualizes and study these 
tiny microbes both in vivo and in vitro.  Some of the possible aspects that require more 
investigation are the stability of the foreign gene, the metabolic state of Ureaplasma cells, 
fusing RFP to Ureaplasma genes and/or using different vectors as well as other factors 
that could enhance foreign gene expression in bacteria. 
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7. General discussion 
7.1 Discussion  
In this study, I applied a range of powerful techniques and sought to enhance our 
knowledge about the strategies and mechanisms utilised by Ureaplasma to overcome the 
complement-mediated serum killing. The development of a new genetic tool (transposon 
mutagenesis) within this study was a novel and potentially important advance that has 
provided a powerful tool and opened doors for future work to investigate the biology and 
pathogenicity of Ureaplasma. Our understanding of Ureaplasma pathogenesis and its 
role in human diseases has been hampered by the lack of genetic tools that would identify 
and determine virulence factors responsible for differential pathogenicity among 
Ureaplasma (Waites et al., 2005). Now as this genetic method has become available, 
genes involved in virulence of Ureaplasma can be identified and studied. In other 
microbial pathogens, many powerful tools are available and have made it possible to 
reveal and study many virulence factors.  In fact, this has largely enhanced our 
understanding of the biology and pathogenesis of microorganisms as well as 
immunology. Of these techniques, genomic and proteomic approaches are amongst the 
most widely and most successfully used tools (Choi, 2009; Schmidt and Volker, 2011).  
The need for a genetic method that would allow investigation of Ureaplasma virulence 
genes, especially those that might be involved in mechanisms of serum resistance has 
driven me to seek a way to develop a transposon mutagenesis method that could be 
successfully applied to identify the mechanisms underlying serum resistance of these 
unique bacteria. In this project, serum resistance was highlighted and addressed and was 
found to be a common phenomenon among Ureaplasma serovars and clinical isolates that 
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could contribute to their role in human diseases. Therefore, it would be of great 
importance to define the underlying mechanisms by which Ureaplasma overcome this 
aspect of the host innate immunity. I developed PEG-mediated transformation protocol 
that was successfully applied to deliver a gentamicin resistance marker (6’-
aminoglycoside N-acetyltransferase) to a number of representative serovars of U. parvum 
as well as one clinical isolate of U. urealyticum (W11; SV12). Mapping transposon 
insertion and investigating the disrupted genes in some transmutant strains was also 
achieved. The findings showed that the insertion of transposon in the Ureaplasma 
genome occurred randomly with only one insertion of transposon in most cases resulting 
in disruption of non-essential genes. I also used this method successfully to deliver 
exogenous genes to U. parvum; the red fluorescent protein gene (mCherry) was 
introduced, as a measurable exogenous gene, into the genome of Ureaplasma. This 
allowed me to examine the ability of Ureaplasma to express foreign genes and determine 
the optimal promoter, codon usage and copy number to facilitate future expression and 
testing of any identified serum resistance genes.  Most importantly this method was also 
used for the first time in an attempt to investigate expression and physiological effect of a 
candidate gene (UU280) (the foremost candidate to encode the gene for the 41 kDa-
serum resistance associated protein identified by proteomics). However, a second 
candidate gene for the 41 kDa protein was identified through transposon gene disruption 
of the gene UUR10_0137 coincident with loss of serum resistance in U. urealyticum 
strain W11 (discussed in details in Chapters 4 and 5).   
As was the case for developing any new method, limitations exist and require further 
modification and optimization, especially when applied to challenging microorganisms 
such as Ureaplasma. In other mycoplasmas, the cultivation and growth conditions of 
these fastidious microbes have been proven to limit the transformation and genetic 
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manipulation (Dybvig and Voelker, 1996; Razin, 1985).  In my study, this was one of the 
major obstacles I faced during the early failed attempts of Ureaplasma transformation. 
Ureaplasma and Mycoplasma are different in their growth requirements: Ureaplasma 
needs urea as a main source of energy, whereas Mycoplasma requires arginine (Fiacco et 
al., 1984). These important supplements are added to the growth medium; however, in 
the case of Ureaplasma, hydrolysis of urea by the urease also produces ammonia, which 
is self-toxic for Ureaplasma (Ford and MacDonald, 1967). This dramatically affected the 
possibility of getting and selecting transformed cells as their numbers are usually very 
low and fail to thrive. I circumvented this barrier by repeated serial sub-culturing post-
transformation in the USM containing gentamicin to rescue the growing transmutant 
cells. Other factors that have generally made it difficult to develop genetic tools for 
manipulating mycoplasmas include the lack of natural plasmids for most mycoplasmas, 
the lack of suitable growth media with improved ingredients, the paucity of antibiotic 
resistance selection markers, and the unusual codon usage of UGA as tryptophan codon 
(Dybvig and Voelker, 1996). 
Although this method successfully transformed several representative serovars of U. 
parvum in this study, all attempts to introduce transposon Tn4001 into the ATCC 
prototype strains of U. urealyticum serovars were unsuccessful. This may indicate species 
variations in genetic manipulation among Ureaplasma.  Despite the large homology 
between the two species, there is a difference in the genome size of the two species; U. 
urealyticum (0.83 - 0.94 Mb) have a larger genome size than U. parvum (0.75 - 0.77 Mb). 
Further protocol refinement to achieve success both species of Ureaplasma is required.  
Similar challenges in introducing transposon Tn4001 into the genomes of some species of 
the genus Mycoplasma have been reported. For example, attempts to introduce the 
Tn4001 transposon to M. arthritidis and M. pulmonis have failed. The reason for 
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unsuccessful genetic manipulation was assumed to be functional failure of the antibiotic 
selection marker (the gentamicin resistance gene), as changing the gentamicin resistance 
gene by inserting the chloramphenicol acetyltransferase gene or the tetM tetracycline 
resistance gene into Tn4001 have resolved the problem in both species  (Dybvig et al., 
2000).  Another limitation of the method was also found to be the low degree of 
transformation efficiency, but this is a common transformation problem encountered with 
most mycoplasmas. The modified protocol in this study was based on a PEG mediated 
transformation protocol and the other methods of transformation using electroporation 
have not been attempted for Ureaplasma in my study. Therefore, the next set of 
experiments should utilise electroporation based methods to see if this overcomes 
transposon mutagenesis in U. urealyticum. Currently, electroporation protocols are 
widely used with the closely related species of Mycoplasma (Baranowski et al., 2014; 
Maglennon et al., 2013; Sharma et al., 2014; Shimizu et al., 2014). Other factors that 
affect the transformation and delivery of exogenous genes have been reported to be the 
presence of restriction and modification systems, which are commonly found in 
Mollicutes and restrict gene delivery (King and Dybvig, 1994; Voelker and Dybvig, 
1996). Such systems have also been hypothesised based on ORF homology in 
Ureaplasma spp., with U. urealyticum having more potential restriction modification 
enzyme genes than U. parvum (Dybvig and Voelker, 1996; Paralanov et al., 2012). 
Whether these systems are functional and restricted the transformation of U. urealyticum 
have not been addressed in this thesis. However, one clinical isolate of U. urealyticum, as 
mentioned above, was successfully transformed suggesting that these barriers are unlikely 
causes of transformation failure of the other serovars of U. urealyticum.  In the study by 
Lartigue and colleges (2009) for genome transplantation of  M. mycoides subsp. capri 
from yeast to M. capricolum, such barriers of genetic manipulation were overcome by 
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inactivation of the restriction enzyme in the recipient cells and protecting the genome of 
the donor cell via methylation using extracts of M. capricolum (Lartigue et al., 2009). 
 Regardless of all these limitations, genetic tools and protocols for studying these groups 
of bacteria have significantly been refined and improved. As a genetic tool, transposon 
mutagenesis has been improved dramatically and was successfully used to insert 
selectable markers in M. pulmonis, M. hyorhinis, and A. laidlawii (Dybvig and Alderete, 
1988; Dybvig and Cassell, 1987; Mahairas and Minion, 1989a, b). In addition, genetic 
approaches to study essential genes and the physiological effects of delivering exogenous 
genes continue to expand and be improved (Algire et al., 2009; Paralanov et al., 2012). 
As U. parvum are now amenable to genetic manipulation using the modified protocol of 
transposon mutagenesis work can begin on extensive definition of essential genes for this 
organism. 
Serum resistance of Ureaplasma was the main target of investigation in this study as it is 
known to be one of the determinants of pathogenicity in bacteria (Fierer et al., 1972). 
Susceptibility of U. parvum to complement-mediated serum killing has been recently 
investigated. In that study, it was found that sensitivity to complement killing by normal 
human sera from normal volunteers varied amongst serovars and even amongst strains 
from the same serovar (Beeton et al., 2012). These findings suggested differential 
pathogenicity factors (virulence factors) among serovars and clinical isolates that could 
allow them to evade the complement activity. In this study, I investigated the effect of 
complement on the other species of human Ureaplasma (U. urealyticum). My study 
demonstrated similar findings, as U. urealyticum also showed different susceptibility to 
serum killing ranging from high sensitivity to complement-mediated serum killing to 
absolute serum resistance, even in the presence of specific antibodies. As prevalence of 
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serum resistance was observed among Ureaplasma spp., it was important to try to define 
the underlying mechanisms that contributed to resistance. Achieving this goal would 
greatly increase our knowledge of Ureaplasma pathogenicity. In order to address this 
issue, I successfully created a number of serum-resistant strains from originally serum-
sensitive strains through repeated sublytic challenge with NHuS. These induced serum-
resistant strains were subjected to further investigation in an attempt to identify proteins 
that were induced, lost or had been otherwise altered associated with serum resistance. 
Identification of the deferentially expressed proteins and studying the role of some of 
these proteins in serum resistance were attempted using proteomic methods and the newly 
developed genetic method in this project.  
Upon investigation, I found that three immunogenic proteins were differentially 
expressed or altered following the repeated sublytic challenge and developing serum 
resistance: MBA, EF-tu and a novel protein (approximately 41kDa size) suspected to be 
UU280 (by proteomics) but later re-identified as the UUR10_0137 gene that encodes a 
hypothetical protein.  Altered expression of the MBA was not a new finding in my study, 
as many previous studies have reported both phase and size variations in this major 
surface antigen of Ureaplasma both in vivo and in vitro. And as a variable surface 
antigen, MBA has been proposed to be one of the virulence factors of Ureaplasma 
(Dando et al., 2012; Knox et al., 2010; Monecke et al., 2003; Robinson et al., 2013; Teng 
et al., 1994; Zheng et al., 1995; Zimmerman et al., 2009).  In M. pulmonis, a closely 
related species, the size of the variable surface protein (VsaA) of this bacterium was 
found to contribute to serum resistance.  Strains expressing long tandem repeats of VsaA 
(40 repeats) were shown to be more resistant to complement killing than those expressing 
short VsaA (5 or less tandem repeats) (Simmons et al., 2004; Simmons and Dybvig, 
2003). I also reported variations in the MBA size (in vitro and in vivo); therefore, I sought 
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to reveal the potential role of such antigenic variations of MBA in serum resistance. I 
examined the association between serum resistance and MBA type and size in 
Ureaplasma and found that such correlation did not exist among the species of 
Ureaplasma. As both serum-resistant and serum-sensitive Ureaplasma strains were 
shown to express a variety of MBA species that varied in size (small or large) and 
serovars (one or more variants) this does not appear to contribute to serum resistance. 
Furthermore, an induced serum-resistant strain (SR-HPA2) became resistant without any 
alterations in the MBA, while one isolate (SA-HPA5), which was subjected to repeated 
sublytic challenge with NHuS, had slight alteration in the MBA but did not develop 
serum resistant (as discussed in chapter 4). Although the results showed no relationship 
between the MBA and serum resistance in Ureaplasma, these findings do not exclude a 
role for MBA in Ureaplasma pathogenicity, which remains to be further investigated.     
In contrast, I found that the other two proteins (EF-Tu and the 41 kDa protein) were more 
likely to be involved in mechanisms of serum resistance as both of them were 
consistently altered in expression or isoform in all induced serum resistant strains. In my 
work, EF-Tu was shown to be immunogenic and had altered charge (seen as more acidic 
pI isoforms species), which is likely due to phosphorylation given the retention of 
molecular mass with the altered pI. EF-Tu is a multifunctional protein and has been 
proposed to play a role in bacterial pathogenesis (Dallo et al., 2002; Granato et al., 2004). 
EF-Tu in P. aeruginosa has been shown to play a role in complement evasion by 
mediating binding to FH and plasminogen (Kunert et al., 2007). Therefore, the possible 
involvement of EF-Tu in serum resistance of Ureaplasma, based on observations in my 
study, can be anticipated and needs further investigation to be confirmed.  
The 41 kDa immunogenic protein was a very interesting finding in this thesis. Using 
proteomic post-decay analysis of proteins separated by 1 dimensional SDS-PAGE, this 
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protein was identified as UU280 protein (endo-1,4-beta- glucanase). However, the role of 
this protein in serum resistance was ruled out after examination in serum resistant and 
sensitive strains as well as failure to alter phenotype after delivery by transposon 
mutagenesis (discussed in Chapter 4). Loss of this 41 kDa protein in one of the gene-
disrupted transmutant strains, W11 (SV12), coincided with loss of complement 
resistance. The only disrupted gene in this transmutant strain was identified as 
UUR_0137 gene; therefore, this gene is more likely to be the gene encoding for the 
candidate 41 kDa protein. The role of this gene as a virulence gene mediating serum 
resistance would be highly recommended for further investigation to elucidate its 
function and contribution to serum resistance. An example of such experiments would be 
by delivering this gene to a serum-sensitive strain and investigate its expression and 
ability to mediated serum resistance. Another alternative way is trying to knock out the 
gene responsible for the 41 protein expression in known induced serum-resistant strains 
(created in this study) via transposon mutagenesis and see if this can alter their 
complement susceptibility.  The additional experiment attempting to re-induce the 
expression of 41 kDa protein with recurrent complement challenge with examination of 
maintenance of gene disruption should also be performed.   
The acquisition of complement regulators to the surface of microbial pathogens is a 
common mechanism of evading complement killing (Blom et al., 2009; Kraiczy and 
Wurzner, 2006). This kind of mechanism has not been addressed in my study and is a 
potential future work.  Both EF-Tu and UUR_0137 gene product (the 41 kDa protein) 
could be surfaced expressed and either recruit complement regulators or directly regulate 
complement themselves as a mechanism of complement evasion in Ureaplasma. 
Therefore, induced serum-resistant strains, as well as inherently resistant strains, of 
Ureaplasma need to be investigated for their ability to bind regulators of the complement 
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activation such as FH, C4bP or other regulators. This will provide a new insight in 
possible tactics utilized by Ureaplasma to manipulate the host immune defences.   
It should be admitted that proteomic approaches used in this study to identify the 
candidate proteins were also another challenge.  Large scale culture of Ureaplasma 
growth was required to produce sufficient amounts of total cell protein lysate for analysis 
by proteomics.   In spite of that effort, the 2-DE-based proteomic method (2-DE in 
combination with MS) failed to identify the key proteins that were under investigated in 
this study, with exception of the EF-Tu. 2-DE is a powerful method for protein 
separation; however, it has some drawbacks such as inability to resolve hydrophobic, 
very basic or high molecular weight proteins. In addition, low-abundance proteins (e.g. 
regulatory proteins and receptors) cannot usually be visualised by conventional staining 
methods. They are often masked by other high-abundance proteins when analysing whole 
cell protein lysate. Moreover, membrane proteins are among those proteins that are 
difficult to visualise and analyse using 2-DE analysis, as reviewed in (Beranova-
Giorgianni, 2003). These limitations may have caused the failure of identification of 
some interesting proteins in my study. For example, although the MBA is a major surface 
antigen of Ureaplasma (membrane protein), it has not been identified in any of the 
protein spots analysed. In addition, I could not see any clear difference in protein 
expression at molecular mass sizes around 40 kDa, where the 41 kDa protein should be 
located on 2 DE gel, suggesting its low abundance among other cell proteins of 
Ureaplasma. Therefore, I chose an alternative method, which is 1-DE in combination 
with MS. This approach allowed a single band to be visualised and excised for 
identification by MS. Despite being able to identify the potential proteins (UU280 protein 
and MBA) using this approach, it seemed later that the 41 kDa protein was misidentified 
with another more prevalent protein present in the same excised band (UU280).  In fact, 
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1- D bands are believed to contain more than one protein at the same time (Huang et al., 
2002). As the 41 kDa protein is probably a low abundance protein, contamination with 
other high abundance proteins may cause failure in identification. 
7.2 Summary and conclusion: 
The work carried in this thesis was aimed to investigate mechanisms underlying serum 
resistance of Ureaplasma spp. by creating serum-resistant models of laboratory 
Ureaplasma strains and developing and using some powerful tools to study the role of 
potential factors. My original contribution to the knowledge in this work was the 
development of transposon mutagenesis method that can now be used to study virulence 
genes of Ureaplasma. The overall hypothesis of this study was that induced serum 
resistance of Ureaplasma sensitive strains would result in identifiable phenotypic and 
genotypic alterations that could be correlated to pathogenicity of Ureaplasma in future 
studies. Monitoring and investigating induced serum-resistant strains using proteomics 
and genetic tools revealed significant changes in two candidate proteins coincident with 
serum resistance. The first was the EF-tu protein that had altered pI isoforms, which is 
most likely to be as a result of phosphorylation even. The observed change in this protein 
was consistent in all serum-resistant strains, which suggests a possible contribution in 
mechanism of serum resistance, possibly as a mediator for binding complement 
regulators at the cell surface (Figure 7.1). The second candidate protein was a novel 41 
kDa protein that was uniquely expressed in all induced serum-resistant strains. 
Expression of this new protein in all resistant strains strongly indicated its involvement in 
mechanism(s) of serum resistance of Ureaplasma. The possible gene that encodes for this 
protein has putatively been identified as UUR10_0137 in the genome of U. urealyticum 
serovar 10 (ATCC 33699 strain); based on induced serum sensitivity coincident with 
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disruption in one transmutant strain using the new developed genetic method (transposon 
mutagenesis). Although the gene product of UUR10_0137 gene is not known 
(hypothetical protein), this protein is now identified and proposed to have a role in serum 
resistance of Ureaplasma (Figure 7.1). Whether this 41 kDa protein functions directly or 
indirectly as a regulator or inhibitor of complement activation needs to be determined. 
Confirmation of a gene that mediates complement resistance would dramatically increase 
our understanding of Ureaplasma pathogenicity and provide a target for future human 
studies with preterm birth and Ureaplasma infection.    
7.3 Future work and recommendations 
The findings presented in this study have answered some questions and provided an 
amount of new information that has added to our knowledge about mechanisms of serum 
resistance of Ureaplasma; however, many other questions are still unanswered and 
require further experiments. With regards to mechanisms underlying serum resistance of 
Ureaplasma, this study has paved the way towards identifying and understanding factors 
that could contribute to serum resistance.   
The next obvious investigations should determine if disruption of UUR_0137 blocks the 
ability to induce the 41 kDa protein and to deliver UUR_0137 under exogenous high-
level expression promoter control to a serum sensitive strain to determine if serum 
sensitivity phenotype is changed.  There is a general trend towards strains with low mass 
MBA to be very sensitive to non-immune human sera, therefore transposon mutagenesis 
delivery of a high mass MBA gene (with confirmation of expression by immunoblot) 
should be performed to confirm that this a single alteration determines overt serum 
sensitivity.  The ability of EF-Tu (total and more acidic pI isoforms) to be expressed on 
the bacterial cell surface needs to be investigated; however, the small (<200 nm on 
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average) size of the bacteria presents a significant difficultly in investigating this by any 
method other than immuno-electron microscopy or other technically challenging 
methods.  It is also possible to delivery phospho-mimetic EF-tu mutants by transposon 
mutagenesis if the pI is determined to be important to resistance or surface expression.  
The role of EF-tu surface expression on recruiting FH and C4bP can then be determined. 
Once the mechanisms have been clarified specifically characterised resistant and sensitive 
strains could be used to infect animal models to determine the importance of these 
alterations to pathogenicity of Ureaplasma. 
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Figure 7.1 Schematic illustration represents proposed mechanisms of complement 
evasion by Ureaplasma. Both Ureaplasma surface exposed immunogenic proteins, the 
EF-Tu and the novel 41 kDa protein (a possible product of the UUR10_0137 gene), may 
mediate recruitment and binding of the complement regulators FH (A) and/or C4BP (B) 
to Ureaplasma surface membrane. FH bound to Ureaplasma surface membrane functions 
as a cofactor for factor I mediating degradation of the C3 convertase (C3bBP), thus 
inhibiting the activation of complement via the alternative pathway (A). Whereas, 
binding C4BP to the surface membrane mediates the cleavage of C4b and degradation of 
the C3 convertase (C4b2a) leading to inhibition of complement activation by both the 
classical and lectin pathways (B). These proposed mechanisms might be ways used by 
Ureaplasma to avoid the complement-mediated serum killing. 
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Appendixes 
Appendix I: Sequence and detail of the pMT85 vector 
 
Legend: 
Inverted repeat 1 : 1-26 
Inverted repeat 2: 3412-3438 
Gentamicin resistance: 1036 - 2475 479 a.a. 
bifunctional AAC/APH (AAC(6'): 6'-aminoglycoside N-acetyltransferase and 
APH(2'): 2''-aminoglycoside phosphotransferase [synthetic Mycoplasma 
genitalium JCVI-1.0] 
Sequence ID: gi|166079093|gb|ABY79711.1|Length: 495 (100% match) 
transposase 3538-4710 390 a.a. 
IS256, transposase [Enterococcus faecalis V583] 
Sequence ID: gi|29374776|ref|NP_813928.1|Length: 390 (100% match) 
>pMT85gen 
GATAAAGTCCGTATAATTGTGTAAAAACCCATAGCTTTGGACACACACTAGTACGGA 
TCCACCCGCAATTACTGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTT 
TATACTTCCGGCTCGTATATTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGG 
AAACAGCTATGACCTTGATTACGGAATTCACGGCCGGGGGGGCCACCCCACCAATTG 
ACGCGGCCGCAACTCTAGAGGATTCATCGGCCGTCGTTGCCTGGTTTCCGGCACCAG 
AAGCGGTGCCGGAAAGCTGGCTGGAGTGCGATCTTCCTGAGGCCGATACTGTCGTCG 
TCCCCTCAAACTGGCAGATGCACGGTTACGATGCGCCCATCTACACCAACGTGACCT 
ATCCCATTACGGTCAATCCGCCGTTTGTTCCCACGGAGAATCCGACGGGTTGTTACT 
GCGCTCACATTTATATGCTGACTGAAAGCTGGCTACAGGAAGGCCAGACGCGAATTA 
TTTTTGATGGCTAGAAGCTTTAGGATGAATGGATTTATTCTTCAAGAAAATACATCA 
ATTTTGATAAGTAGAAATGGTAAAAACATTGTATAGCATTTTACACAGGAGTCTGGA 
CTTGACTGAGTTTATGGAAGAAGTTTTAATTGATGATAATATGGTTTTTGATATTGA 
TAATTTAAAAGGATTTCTTAATGATACCAGTTCAATTTGGGTTTATAGCTAAAGAAA 
ATAATAAAATTATAGGATTTGCATATTGCTATACACTTTTAAGACCTGATGGAAAAA 
CAATGTTTTATTTACACTCAATAGGAATGTTACCTAACTATCAAGACAAAGGTTATG 
GTTCAAAATTATTATCTTTTATTAAGGAATATTCTAAAGAGATTGGTTGTTCTGAAA 
TGTTTTTAATAACTGATAAAGGTAATCCTAGAGCTTGCCATGTATATGAAAAATTAG 
GTGGTAAAAATGATTATAAAGATGAAATAGTATATGTATATGATTATGAAAAAGGTA 
GATAAATAAATGAATATAGTTGAAAATGAAATATGTATAAGAACTTTAATAGATGAT 
GATTTTCCTTTGATGTTAAAATGGTTAACTGATGAAAGAGTATTAGAATTTTATGGT 
GGTAGAGATAAAAAATATACATTAGAATCATTAAAAAAACATTATACAGAGCCTTGG 
GAAGATGAAGTTTTTAGAGTAATTATTGAATATAACAATGTTCCTATTGGATATGGA 
CAAATATATAAAATGTATGATGAGTTATATACTGATTATCATTATCCAAAAACTGAT 
GAGATAGTCTATGGTATGGATCAATTTATAGGAGAGCCAAATTATTGGAGTAAAGGA 
ATTGGTACAAGATATATTAAATTGATTTTTGAATTTTTGAAAAAAGAAAGAAATGCT 
AATGCAGTTATTTTAGACCCTCATAAAAATAATCCAAGAGCAATAAGGGCATACCAA 
AAATCTGGTTTTAGAATTATTGAAGATTTGCCAGAACATGAATTACACGAGGGCAAA 
AAAGAAGATTGTTATTTAATGGAATATAGATATGATGATAATGCCACAAATGTTAAG 
GCAATGAAATATTTAATTGAGCATTACTTTGATAATTTCAAAGTAGATAGTATTGAA 
ATAATCGGTAGTGGTTATGATAGTGTGGCATATTTAGTTAATAATGAATACATTTTT 
AAAACAAAATTTAGTACTAATAAGAAAAAAGGTTATGCAAAAGAAAAAGCAATATAT 
AATTTTTTAAATACAAATTTAGAAACTAATGTAAAAATTCCTAATATTGAATATTCG 
TATATTAGTGATGAATTATCTATACTAGGTTATAAAGAAATTAAAGGAACTTTTTTA 
ACACCAGAAATTTATTCTACTATGTCAGAAGAAGAACAAAATTTGTTAAAACGAGAT 
ATTGCCAGTTTTTTAAGACAAATGCACGGTTTAGATTATACAGATATTAGTGAATGT 
ACTATTGATAATAAACAAAATGTATTAGAAGAGTATATATTGTTGCGTGAAACTATT 
TATAATGATTTAACTGATATAGAAAAAGATTATATAGAAAGTTTTATGGAAAGACTA 
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AATGCAACAACAGTTTTTGAGGGTAAAAAGTGTTTATGCCATAATGATTTTAGTTGT 
AATCATCTATTGTTAGATGGCAATAATAGATTAACTGGAATAATTGATTTTGGAGAT 
TCTGGAATTATAGATGAATATTGTGATTTTATATACTTACTTGAAGATAGTGAAGAA 
GAAATAGGAACAAATTTTGGAGAAGATATATTAAGAATGTATGGAAATATAGATATT 
GAGAAAGCAAAAGAATATCAAGATATAGTTGAAGAATATTATCCTATTGAAACTATT 
GTTTATGGAATTAAAAATATTAAACAGGAATTTATCGAAAATGGTAGAAAAGAAATT 
TATAAAAGGACTTATAAAGATTaATAAAGATCTACGAAGGCATGACCAAAATCCCTT 
AACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTT 
CTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGC 
TACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAA 
CTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAG 
GCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGT 
TACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGAC 
GATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGC 
CCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAG 
AAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGG 
TCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATA 
GTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAG 
GGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCT 
TTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATA 
ACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGC 
GCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCC 
CCGCGCGTTGGCCGATTCATTAATGCACGCTAGCATTTAAATGGTACCCTTTTACAC 
AATTATACGGACTTTATCCTGCAGGGGCCCAATTGTGTAAAAGTAAAAAGGCCATAT 
AACAGTCCTTTTACGGTACAATGTTTTTAACGACAAAAACATACCCAGGAGGACTTT 
TACATGACCCAAGTACATTTTACACTGAAAAGCGAAGAGATTCAAAGCATTATTGAA 
TATTCTGTAAAGGATGACGTTTCTAAAAATATTTTAACAACGGTATTTAATCAACTA 
ATGGAAAATCAACGAACAGAATATATTCAAGCAAAAGAATATGAACGAACAGAAAAC 
CGACAAAGTCAACGAAATGGCTATTATGAGCGCAGCTTTACGACACGTGTAGGCACG 
CTAGAATTAAAAGTACCCAGAACACGTGATGGCCATTTTTCACCCACAGTGTTTGAA 
CGTTATCAACGAAACGAAAAAGCCCTCATGGCTTCAATGTTGGAAATGTATGTATCA 
GGCGTTTCAACTCGTAAAGTATCAAAAATTGTGGAAGAACTTTGTGGTAAATCCGTC 
TCTAAGTCCTTCGTTTCTAGCTTAACAGAACAGCTAGAACCTATGGTTAACGAGTGA 
CAGAATCGTTTATTATCAGAAAAAAATTATCCTTACTTAATGACCGATGTACTCTAT 
ATAAAAGTACGAGAAGAAAATCGAGTACTCTCAAAAAGCTGTCATATAGCGATTGGA 
ATAACCAAAGATGGCGACCGTGAAATTATCGGCTTCATGATTCAAAGTGGCGAAAGC 
GAAGAGACCTGGACAACATTTTTTGAATACCTAAAAGAACGCGGTTTACAAGGTACG 
GAACTCGTTATTTCTGATGCGCACAAAGGATTAGTCTCTGCCATTAGAAAATCCTTC 
ACCAACGTAAGTTGGCAAAGATGCCAAGTTCACTTCCTAAGAAATATCTTTACCACC 
ATTCCTAAAAAAAATTCAAAATCTTTCAGAGAAGCTGTTAAAGGAATTTTTAAGTTC 
ACAGATATTAACTTAGCGCGTGAGGCTAAAAATCGATTGATTCATGATTATATCGAT 
CAACCAAAATATTCAAAAGCTTGCGCATCATTGGATGATGGATTCGAAGACGCCTTT 
CAATATACCGTACAAGGAAATTCCCACAATCGACTAAAGAGTACCAATCTAATTGAA 
CGACTGAATCAAGAAGTACGCAGAAGAGAAAAGATTATTCGCATCTTCCCCAATCAA 
ACATCAGCCAATCGCTTAATTGGAGCCGTTCTTATGGACCTACATGATGAATGGATT 
TATTCTTCAAGAAAATACATCAATTTTGATAAGTAGAAATGGTAAAAACATTGTATA 
GCATTTTACACAGGAGTCTGGACTTGACTCACTTCCTTTATTATTTTTCATTTTTTT 
GACCTCGAGGGGGGGCCCACCATACAGCTGA 
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Appendix II: Additional Figures 
 
  
Figure II-1 Validation of anti-UU280 polyclonal antibodies for Western blot. Dot blot 
analysis shows reactivity of UU280 synthetic peptide (23 aa -322-343) with two anti-
UU280 antisera (1:50) and seropositive serum. (A) and (B): anti-UU280 antisera detected 
strongly the UU280 peptide (in dilutions higher than 0. 25 µg). No reactivity was seen 
with seropositive serum (C) after a longer exposure. 
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Figure II-2 Growth of U. parvum transformed strains on USM agar plates with 128 mg/L 
gentamicin. Ureaplasma growth is shown as change in colour of the medium from yellow 
to red around the tiny colonies. Plate 1 shows no growth of untransformed strain, HPA5 
(negative control); plates 2-9 show growth of transmutant strains carrying the gentamicin 
resistant gene after successful transformation, HPA5 (SV3) (3-5) and others (O10(SV1), 
Urine6 (SV3), HPA56 (SV3), HPA58 (SV6)). 
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Appendix III: Talk and Poster Presentations from this work 
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